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Role of the cytokine of macrophage migration inhibitory factor (MIF) in 




Chair: Kate F. Barald  
 
Spiral ganglion neuron (SGN) loss, either dependent or independent of sensory 
hair cell (HC) loss, is a major cause of deafness, particularly in the ageing 
population.  Cochlear implants (CI) are presently the only known "cure" for many 
forms of deafness.  Nevertheless, successful function of a CI depends on the 
preservation of SGNs.  In the early developing inner ear, the otocyst secretes a 
factor called Otocyst Derived Factor (ODF).  ODF promotes directional neurite 
outgrowth and neuronal survival of the statoacoustic ganglion (SAG), the 
precursor of the auditory portion of the SAG that eventually forms the SG.  
Cytokine arrays and proteomic studies demonstrated that the bioactive 
components of ODF include Macrophage Migration Inhibitory Factor (MIF), which 
has been described as “pleiotropic” cytokine because of its multiple roles, 





regeneration.  Based on its known roles and our preliminary data, we 
hypothesized that MIF plays a key instructional role, acting as a neurotrophin, in 
inner ear development.  The goal of this dissertation project is to elucidate the 
role of MIF in inner ear neuronal development as well as the possibility of using 
this developmental information to study and to enhance inner ear neuronal 
regeneration.  We found that, at low concentrations (5 pg/ml and 5 ng/ml), 
recombinant MIF alone supports both mouse and chick SAG directional neurite 
outgrowth and neuronal survival, and evokes a neuronal phenotype from mouse 
embryonic stem cells (ESC); at higher concentrations (500 ng/ml), MIF inhibits 
these functions.  We also found that MIF is expressed in supporting cells (SC) of 
the inner ear and its receptor, CD74 is expressed on both SAG and SGN.  In the 
MIF knock-out (KO) mice, abnormal development of both SC and hair cells (HC) 
as well as a significant hearing impairment in the high frequency region of the 
cochlea are seen with concomitant loss of SGN in this region of the cochlea.  In 
addition, we observed that the neurites from SG explants extend directionally in 
culture toward the wild-type (WT) Organ of Corti (OC), but not in the isolated MIF 
KO OC.  Finally, we found that blockade of either MIF or its receptor with 
antibody or RNAi respectively suppresses SAG neurite outgrowth and survival.  
Our study indicates that MIF functions as an essential component of normal inner 
ear neuronal development and innervation and could potentially be used for SGN 
retention or re-growth as well as to potentiate the function of a cochlear implant 








More than 25 years ago, scientists and physicians interested in the 
intricacies of  inner ear development discovered that the developing inner ear, 
particularly cells in the region of the anterior ventral otocyst called the otic crest, 
produced a factor or factors, called the Otocyst Derived Factor (ODF) that served 
as a “neurotrophin” for the neurons of the developing statoacoustic ganglion 
(SAG) (Ard et al., 1985, Lefebvre et al., 1990, Bianchi and Cohan, 1991, Hemond 
and Morest, 1991, Bianchi and Cohan, 1993).   Neurotrophins, which are 
produced by target tissues, are responsible for causing directional outgrowth of 
the neurons that innervate them toward the source.  Neurotrophins also support 
the survival of such target-bound neurons.   In the intervening years, many 
groups, including ours, have sought to identify the molecular component(s) of 
ODF (Thompson et al., 2003, Germiller et al., 2004, Bianchi et al., 2005).  
Investigations into the identification of ODF were initially more useful for 
identifying which “classical” previously identified “neurotrophins” were either not 








ODF is not one of the previously identified neural growth factors  
Bianchi and Cohan (Bianchi and Cohan, 1991, 1993, Bianchi et al., 1998) 
investigated the role of classical neurotrophins in SAG development.  Very early 
stage SAG neurons do not survive or extend neurites when cultured in the 
presence of one or more of the identified neurotrophic growth factors including: 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), fibroblast growth factors 
(FGFs), transforming growth factors (TGFs) or ciliary neurotrophic factor (CNTF) 
(Bianchi and Cohan, 1993). The ODF is released at early stages corresponding 
to the period of initial neurite outgrowth (E4-6 in the chick, E11-14 in the mouse 
and rat; Bianchi and Cohan 1991, Bianchi and Cohan 1993a, Bianchi and Cohan 
1993b). Other tissues such as the limb bud, heart and liver do not release 
proteins that influence the outgrowth or survival of early stage SAG although they 
can influence the outgrowth and survival of other neural cell types (Bianchi and 
Cohan, 1991).  
At later stages of inner ear development, corresponding to the period of 
synaptogenesis, other growth factors such as the NT-3 and BDNF are necessary 
for maintaining the survival of cochlear and vestibular neurons, respectively 
(Bianchi et al., 1998, Wyatt et al., 1998).  However, these neurotrophins are not 
required at the early stage of initial neurite outgrowth (Bianchi and Cohan, 1993). 





factor (GDNF) has only limited positive effects on spiral ganglion neuron (SGN) 
regeneration (Altschuler et al., 1999). 
Combinations of various concentrations of these growth factors also failed 
to mimic the activity of ODF, which was produced by incubating 8 chick or mouse 
otocysts in 250 µl of serum-free medium for several days (Bianchi and Cohan, 
1991, 1993).  Furthermore, other tissues do not release factors that promote 
outgrowth of early embryonic SAG. These results suggested that the otocyst 
releases a novel growth factor or combination of factors to promote the initial 
outgrowth and survival of SAG.  
If ODF components are to have any potential therapeutic value in 
maintaining adult neuron survival, maintaining or re-growing axons, or in 
potentiating a cochlear implant (CI), three conditions must be met: 1) adult 
neurons must either retain or re-express embryonic receptors for these factors; 
2) ODF must support neuron survival and directional neurite re-growth in the 
adult; and 3) the surviving or re-grown neurites must be able to reconnect with 
their target tissues, or interact with the electrodes of a CI.   We have been able to 
document many of these criteria, and this thesis seeks to evaluate many of the 
others.    
Our recent surprising finding that ODF is a mixture of growth factors called 
cytokines or chemokines, known for their roles in both the immune system and in 
neuronal development and regeneration (Bajetto et al., 2002) has laid to rest only 
part of the mystery (the components of ODF).  This finding has raised a number 





We have identified 3 of these functionally significant components of ODF 
activity, through cytokine array and proteomic approaches: monocyte 
chemoattractant protein 1 (MCP1) (Bianchi et al., 2005), which is made by inner 
ear hair cells (HC) (Bianchi et al., 2005), macrophage migration inhibitory factor 
(MIF), which is made by supporting cells (SC) (see preliminary data; Table 2.1; 
Gerlach-Bank, Ebisu et al., in preparation), and RANTES (Bianchi et al., 2005), 
which is known to be a neurotrophic factor for dorsal root ganglion neurons (Bolin 
et al., 1998). 
The research in this thesis focuses on the role of the one of the identified 
cytokines, MIF, in the basic developmental mechanisms of inner ear formation 
and innervation as well as the possibility of using this developmental information 
to study inner ear regeneration.  
We hypothesize that the ODF cytokines play a key instructional role in the 
very earliest stages of inner ear development and demonstrate in the chapters in 
this thesis that adult neurons continue to express receptors for these critical 
components of the embryonic ODF, raising the possibility that a receptor-
expressing adult neuron in the spiral ganglion (SG) could respond therapeutically 
to one or more of the identified cytokines, which, if introduced at appropriate 
concentrations might be able to preserve remaining SG neurons and restore 
function, or at least potentiate the function of a cochlear prosthesis/implant.  It is 
known that the larger the number of functional SGNs remaining at the time of 
implant, the better the prognosis for a patient’s restoration of function (Pfingst 






The neuroimmunoaxis  
Discovering that cytokines play important roles in development of the inner 
ear is fully in accord with a major new focus in cytokine biology and 
neuroimmunology (Siemion et al., 2005, Wrona, 2006).  Although cytokines and 
chemokines (cytokines with known attractant properties) were initially identified 
and characterized for their critical roles in the immune system, particularly in 
mediating T cell function (Gonzalo et al., 1996), the roles of such molecules in 
the nervous system have been known for many years.  
Cytokines/chemokines are relatively small molecular weight proteins 
within a large super-family that are classified based on the relative location of the 
cysteine residues in the N-terminus of the molecule (Mantovani et al., 2003).  
Chemokines were initially identified for their ability to attract and activate immune 
cells by interacting with specific cytokine receptors (Coughlan et al., 2000).  
Recent studies have demonstrated that cytokines/chemokines are also present in 
developing and adult neural systems.  These proteins are now being 
implicated in a variety of roles including neuronal migration, outgrowth, and 
survival (Meng et al., 1999, Bajetto et al., 2001, Chalasani et al., 2003a, 
Chalasani et al., 2003b, Belmadani et al., 2005).  In some cases chemokines 
were found to regulate axonal outgrowth by inhibiting the repellent effects of 
other molecules such as semaphorins and slit-2 (Chalasani et al., 2003b).  Not 





Xenopus (Suzuki et al., 2004), they are also critical in neuronal repair processes 
after axotomy in both the peripheral and central nervous systems (Bajetto et al., 
2001, Koda et al., 2004).  
In order to set the experiments in this thesis in context, we will first discuss 
the major tenets of inner ear development and then the hypothesized role of the 
specific ODF cytokines in the process.  In this thesis the cytokine of interest is 
MIF, which we believe we have demonstrated is both necessary and sufficient to 
fulfill all the roles of the early neurotrophin in inner ear development. 
 
Physiological basis of hearing and balance in the vertebrate ear 
The ear consists of three functional parts; the external ear, the middle ear 
and the inner ear (Figure 1.1-A) (Friedman and Avraham, 2009).  The external 
ear, called the external pinna or auricle, captures and focuses sound into the 
external auditory meatus or ear canal, which ends at the tympanum, also called 
the tympanic membrane or eardrum.  The increases and decreases in air 
pressure that correspond to sound wave energy cause the tympanum to vibrate.  
These vibrations are conveyed across the air-filled middle ear by three tiny 
ossicles (bones), which in humans together are smaller than the size of a dime, 
called the malleus (the hammer), incus (anvil) and the stapes (stirrup) (Dror and 
Avraham, 2009).  Vibration of the stapes, which makes direct contact with the 
oval window, generates pressure waves in the fluids of the snail-shaped cochlea, 
which, in humans, houses the auditory organ of the inner ear.  Inner ear anatomy 





discussed in this dissertation where appropriate.   
The interior of the mammalian cochlea contains three co-spiraling fluid-
filled tubes within what is called the cochlear duct.  The duct is separated into 
three parts by membranes.  This is seen most easily in a cross section through 
the tube at right angles to its long axis.  The three tubes are the scala vestibule, 
the scala media (SM) and the scala tympani and are shown in Figure 1.1-B 
(Friedman and Avraham, 2009).  The organ of Corti (OC), which includes the 
sensory epithelium of the cochlea, is located on the “floor” of the SM, and 
contains a variety of cell types, which play both functional and structural 
supporting roles.  Two of the critical cell types in this organ are the non-sensory 
SC called Deiters cells (Spicer and Schulte, 1994b) and the mechanosensory 
receptor cells called hair cells (HC), which the underlying Deiters SC “support”, 
cupping the inner hair cells (IHC) physically.   HC acquired their name due to the 
hair-like stereocilia, which are really long actin-containing projections from the 
cell surface called microvilli, on the apical surface of these polarized epithelial 
cells (Figure 1.1-C) (Friedman and Avraham, 2009).  The HC and underlying SC 
are believed to be derived from a common progenitor cell (Fekete et al., 1998, 
Rivolta and Holley, 2002) and arranged in a precise, intricate and polarized 
cellular pattern, which is essential for proper mechanotransduction to occur.   
There are three rows of outer hair cells (OHC) and a single row of IHC, 
surrounded by SC that include Pillar cells, Hensen’s cells, and Claudius and 





cells are located lateral to the HC, and not directly underneath them.  They are 
also thought to be part of the supporting system of the OC (Spicer and Schulte, 
1994b, a).  Deiters cells, which have a very high metabolic capacity, are thought 
to provide more than just structural support (Spicer and Schulte, 1994b, a) 
although their exact role is still undefined.   
The Pillar cells, with their apposing cellular apices, structurally form the 
tunnel of Corti (Figure 1.1-D) (Audition Promenade ‘round the Cochlea).  The 
stereocilia on the outer HC are embedded in an overlying flexible structure called 
the tectorial membrane (TM) (Richardson et al., 2008).  Together the tiny bones 
of the middle ear and the tympanic membrane convert auditory signals to wave 
energy in the cochlear fluid (Rosowski et al., 1985). The basilar membrane, on 
which the HC and SC sit, moves in response to the fluid movement in the inner 
ear canals; HC also move up and down, in turn instigating movement in the 
stereocilia of the cochlear HC which causes ion channels on the stereocilia 
plasma membrane to open (Corey and Hudspeth, 1983b, a, Pickles and Corey, 
1992, Denk et al., 1995, Littlewood Evans and Muller, 2000, Gillespie, 2004, 
Vollrath et al., 2007, Grillet et al., 2009). Thus, the cochlear HC convert auditory-
derived mechanical stimuli (vibrations/waves) to electrical signals (Raphael and 
Altschuler, 2003).  The electrical signals are transmitted from the HC to cochlear 


















Figure 1.1: Schematic representations of the human ear. A: The ear is 
composed of three parts: the external, middle, and inner ear.  B: Cross section of 
the cochlear duct.  The three tubes, including the scala vestibule, the scala 
media (SM) and the scala tympani are shown.  The cochlear sensory epithelium 
is also illustrated, with the tectorial membrane (TM) situated above the HC in the 
SM.  C: Enlarged view of the sensory HC (green) and SC (blue) in the cochlear 
sensory epithelium-the OC.  Stereocilia (long microvilli) are seen on the apical 
surface of HCs (Friedman and Avraham, 2009).  D: The Pillar cells, with their 
apposing cellular apices, structurally form the tunnel of Corti (number 3) (From: 











Mammalian inner ear development 
Organogenesis: 
The mammalian inner ear is one of the most complex organs in the body 
and its formation is considered as one of the most remarkable and sophisticated 
events in vertebrate organogenesis (Barald and Kelley, 2004).  The development 
of this highly complex inner ear structure is the result of consecutive inductive 
signals emanating from neighboring tissues (the brain, the neural crest and the 
periotic mesenchyme are the best defined sources of signals) as well as the 
developing inner ear itself (Ohyama et al., 2007).  The developing inner ear is the 
source of ODF (see discussion above). 
 The earliest morphologically visible step of inner ear development is the 
formation of the otic placode, a thickened disc of ectoderm located adjacent to 
rhombomeres 5 and 6 of the hindbrain in the early embryo (Barald and Kelley, 
2004, Ohyama et al., 2007), typically seen once the first 5-10 pairs of somites 
have been generated (Ohyama et al., 2007).  As development proceeds, the otic 
placode invaginates in birds and mammals to produce a hollow open pit, called 
the otic pit, which post-invagination, closes to form an epithelial cystic vesicle 
referred to as the otocyst (Barald and Kelley, 2004, Kelley, 2006, Ohyama et al., 
2007).  The otocyst undergoes elaborate morphogenetic changes.  The part of 
the developing otocyst that originates in the dorsomedial region and extends 
towards the brain forms the endolymphatic duct and sac in the dorsal region 





otocyst extends to form the cochlear duct (Barald and Kelley, 2004, Kelley, 2006).  
Different regions of the developing inner ear continue to grow and differentiate 
and give rise to the different components of the inner ear.  These include the 
cochlea, the semicircular canals and their associated sensory organs called 
cristae, the organs of the vestibular system (utricle, saccule and, in the bird, the 
lagena) as well as the vestibulo-acoustic ganglion (Ohyama et al., 2007) or SAG.     
 
Neurogenesis: 
Soon after closure of the otocyst, which occurs at embryonic day 9 (E9) in 
the mouse, neuroblasts delaminate from the anteroventral surface of the otocyst, 
also called the “otic crest” and migrate, giving rise to the developing SAG [(Ard et 
al., 1985, Hemond and Morest, 1991); reviewed in (Barald and Kelley, 2004, 
Kelley, 2006, Ohyama et al., 2007)], also called the vestibuloacoustic ganglion 
(VAG) that transmits hearing and balance information to the brain during early 
development.  The SAG/VAG which is also termed the cochleovestibular 
ganglion (CVG) later gives rise to both the SG auditory ganglion (AG) that 
innervates the auditory organs and the vestibular ganglion (VG) that innervates 
the vestibular organs of the inner ear (Puligilla et al., Barald and Kelley, 2004, 








Spiral ganglion neurons (SGNs) 
As mentioned above, the SGNs are a mature form of the neurons in the 
part of the SAG destined to assume an auditory function.  The SG is defined as 
the collection of neuronal cell bodies that provide the afferent or sensory 
innervation to the OC (Spoendlin, 1985, Spoendlin and Schrott, 1988, Rusznak 
and Szucs, 2009, Shibata et al., 2010).  The central processes of these 
ganglionic neurons, which project toward the brain, comprise a major part of the 
acoustic nerve (Rusznak and Szucs, 2009).  The cell bodies of the SGNs 
themselves are located in a canal, called Rosenthal’s canal that spirals around 
the axis of the cochlea as shown in Figure 1.2-A.   
SGNs are of two different types, type I and type II, based on their 
morphology, the nature of their synaptic connections and their functions 
(Spoendlin, 1971, Morrison et al., 1975, Ota and Kimura, 1980, Spoendlin, 1981, 
Rusznak and Szucs, 2009) (Figure 1.2-B).  Type I SGNs have larger cell bodies 
than Type II and are responsible for the sensory innervation of the IHC.  IHC 
function as the primary sensory cells of the auditory system.  Activation of the 
IHC results in neurotransmitter release at the IHC type I SGN synapse.  The 
action potential firing of the acoustic nerve causes activation of the central 
auditory pathways (Rusznak and Szucs, 2009), which ascend from the cochlear 
nucleus to the auditory cortex via three main pathways, the dorsal acoustic stria, 
the intermediate acoustic stria and the trapezoid body.  The first binaural 
interactions take place in the superior olivary nucleus which receives input from 





nucleus are involved in the localization of sounds in space.  Postsynaptic axons 
from the superior olivary nucleus and axons from the cochlear nuclei extend to 
the inferior colliculus in the midbrain via the lateral lemniscus, which contains 
axons relaying input from both ears.  The axons in the colliculus project to the 
medial geniculate nucleus in the thalamus.  The geniculate axons terminate in 
the primary auditory cortex (Lee and Sherman, 2010).  Type II SGNs are smaller 
and provide the afferent innervation of the OHC (Spoendlin, 1969, 1971, 1972, 
Robertson et al., 1999).  Although the precise function of OHC has not been 
determined, there is a general consensus that activation of the OHC can adjust 
or modify some of the mechanical properties of the basilar membrane of the OC, 
and thus, may influence the level of activation of the IHC (Rusznak and Szucs, 

















Figure 1.2: Schematic view of the cochlea and SGNs.  A: The cell bodies of the 
SGNs are located in a canal, called Rosenthal’s canal, that spirals around the 
axis of the cochlea.  B: Two types of SGNs, type I and type II are present in the 
SG.  Type I SGNs have larger cell bodies than Type II and are responsible for 
the sensory innervation of the IHC, while Type II SGNs are generally smaller and 
provide the afferent innervation of the OHC. 
(A:http://biology.clc.uc.edu/fankhauser/Labs/Anatomy_&_Physiology/A&P202/Sp
ecial_Senses/Histology_Ear.htm) (B: Audition Promenade ‘round the Cochlea; 







Sensorineural hearing loss (SNHL) 
Hearing loss or deafness is among the leading disabilities in the United 
States (US); approximately 16.1% of the US population is affected by some form 
of hearing loss (Dinh and Van De Water, 2009).  This percentage increases with 
age and about 33% of individuals 70 years of age and older are hearing-impaired 
(Desai et al., 2001, Dinh and Van De Water, 2009).  Hearing impairment 
diminishes the quality of life of affected individuals by leading to social isolation 
and cognitive decline (Dinh and Van De Water, 2009). 
SNHL is the most common form of deafness in humans and derives, in 
most cases, from primary degeneration of the SGNs or from secondary 
degeneration of these neurons, which is seen after cochlear sensory HC loss 
(Martinez-Monedero et al., 2006, Friedman and Avraham, 2009).  Genetic 
predisposition as well as environmental factors, such as exposure to high-volume 
sound, infections, inadvertent ototoxic treatments including with aminoglycoside 
antibiotics and the anti-cancer drug cisplatin, contribute to SNHL (Cheng et al., 
2005, Beisel et al., 2008), and those insults are further exacerbated by age 
(Pichora-Fuller and Singh, 2006, Kricos, 2007).  While new HC production is 
quite common among cold-blooded vertebrates including fish, amphibia and 
reptiles as well as in birds after HC lesion (Corwin and Cotanche, 1988, Ryals 
and Rubel, 1988, Balak et al., 1990, Lombarte et al., 1993, Raphael et al., 2007, 





regenerate sensory auditory HC after birth (Matsui and Cotanche, 2004, Raphael 
et al., 2007, Stone and Cotanche, 2007, Beisel et al., 2008, Brignull et al., 2009). 
 
How HC loss leads secondarily to the loss of sensory neurons in the inner 
ear.  Why this causes deafness. 
As mentioned above, HC in the cochlea transduce acoustic energy into 
electrical signals that are transmitted to the central auditory system through the 
auditory nerves in normal ears.  SGNs provide the afferent innervation to the hair 
cells; type I SGNs are in synaptic contact with the inner HC and type II SGNs are 
responsible for the sensory innervation of the outer HC (Rusznak and Szucs, 
2009). 
Sensory HC in the OC provide neurotrophic support to SGNs (Fritzsch et 
al., 1997a).  Thus, loss of HC may lead to degeneration of nerve fibers from the 
sensory epithelium and eventually to degeneration of the SGNs due to a lack of 
this trophic support (Webster and Webster, 1981, Fritzsch et al., 1997a), 
although some studies argued that SC also secrete the neurotrophins necessary 
for SGN survival (Fritzsch et al., 1997a).  Since mammalian auditory HC and 
neurons do not spontaneously regenerate, the hearing impairment associated 
with these cells’ degeneration is permanent (Spoendlin, 1975).   
Among many neurotrophins, brain-derived neurotrophic factor (BDNF) is 
one of the most extensively studied neurotrophins in inner ear development and 
regeneration.  Expression of BDNF has been detected both in SC (Tan and 





BDNF binds with high affinity to tropomyosin-related kinase B receptor (TrkB) 
and TrkB expression has been found in SGNs.  One study found that adult 
mutant mice with severely reduced TrkB developed significant hearing loss 
(Schimmang et al., 2003).  The p75 neurotrophin receptor (NTR) is a member of 
the TNF receptor superfamily and has also been detected in SGNs (Gestwa et al., 
1999).  Both phosphoinositide 3-kinase and the mitogen-activated protein kinase 
(MAPK) signaling pathways mediate Trk-activated survival responses in neurons 
(Kaplan and Miller, 2000, Huang and Reichardt, 2003), whereas p75NTR has 
been shown to be aberrantly upregulated under both pathological and 
inflammatory conditions (Roux et al., 1999, Lee et al., 2001a).  Furthermore, 
some precursors of neurotrophins or pro-neurotrophins have been demonstrated 
to mediate cell apoptosis by their binding to p75NTR (Lee et al., 2001b, Nykjaer 
et al., 2004).   
Based on the fact that Trk receptors and p75NTR are often co-expressed 
in the same neuron, Tan and Shepherd examined the expression patterns of 
these receptors in SGNs after destroying both HC and SC by introducing 
aminoglycoside antibiotics.  The authors observed an augmentation of p75NTR 
and a reduced TrkB expression in degenerating SGNs, along with a decline in 
SGN density in Rosenthal’s canal where these molecular alternations occur.   
Coincidentally, the authors observed the upregulation of phosphorylated c-Jun, 
which is expressed in degenerating neurons and is a target of p75NTR-mediated 
pathway, whereas the downregulation of phosphorylated cyclic AMP response 





TrkB-mediated pathway (Tan and Shepherd, 2006).  In addition, they identified 
an increase in a truncated form of pro-BDNF and a decrease in mature BDNF in 
aminoglycoside-deafened cochleae, indicating that BDNF and its reception are 
altered under pathological conditions (Tan and Shepherd, 2006).  Together, 
these findings also demonstrated an antagonistic interplay of p75NTR and TrkB 
receptor signaling as an important event in SGN degeneration by modulating the 
signaling pathway.   
 
Why sensory neurons last longer than hair cells in the inner ear? 
It is well known that degradation of HC leads to subsequent loss of 
peripheral nerve fibers from the region of the OC due to a lack of electrical 
stimulation or to loss of the neurotrophin(s) normally provided by HC (Shibata 
and Raphael).  However, neuronal degradation, as a result of HC degeneration is 
a very slow process and spiral ganglion neurons can survival for many years 
after the loss of most or all HC (Bichler et al., 1983).   
Because of this reciprocity between neurons and HC, but with neuronal 
longevity far exceeding HC longevity, earlier studies focused on whether 
neuronal degeneration and loss depends only on the loss of sensory hair cells or 
whether there is also a correlation between the presence of supporting cells in 
the OC and the extent of neuronal degeneration (Bichler et al., 1983). 
Bichler et al. investigated the degeneration of SGNs after degeneration of 





that there was no significant difference in the extent of neuronal degeneration in 
the presence or absence of supporting cells.  In addition, the authors found that 
the most rapid reduction of the number of ganglion cells occurred within the first 
two months after the onset of the treatment and that degeneration progression 
slowed after that period.  About 90% of SGNs disappeared by 12 months; 
however, the remaining neurons could survive for many years, except for the 
natural degradation due to aging (Bichler et al., 1983).  Whether SC produce 
some trophic support for SGN was not examined or discussed in this report. 
In contrast, Otte et al. (1978) found that the degree of retrograde 
degeneration of SGNs was clearly dependent on the state of the supporting cells, 
particularly Deiters’ cells and pillar cells, rather than the state of sensory HC in 
humans (Otte et al., 1978).  These authors observed that even if the OC was 
devoid of hair cells, but if the pillar cells and Deiters’ cells remained, there was 
little or no SGN loss.  They also observed that some of the SGNs survived after 
SC injury, however, these surviving neurons frequently lacked a peripheral or 
dendritic fiber, a condition which may have affected the sensitivity or selectivity in 
response to electrical stimulation by cochlear electrodes in implants (Otte et al., 
1978). 
Neurotrophins are secreted from both sensory HC and SC (Fritzsch et al., 
1997a); thus, as long as SC still survive, SGNs may be able to receive the 





inhibitory factor (MIF), is indeed made by supporting cells of the OC (discussed 
in Chapter II, see Figure 2.9). 
 
How a cochlear implant works  
Cochlear implants (CI) (auditory prostheses) are surgically implanted 
devices that bypass a nonfunctional cochlea and function by directly stimulating 
the auditory nerves in the cochlea with patterns of electrical currents (Altschuler 
et al., 2008, Shibata et al., 2010) and the essential components in a CI system 
are shown in Figure 1.3 (Wilson and Dorman, 2008).  The external parts of the CI 
include a microphone, a speech processor and a transmitter, while the internal 
parts include a receiver and a stimulator and the electrodes.  The microphone 
picks up sound from the environment and the speech processor selectively filters 
sound to prioritize audible speech and sends the electrical sound signals to the 
transmitter.  The transmitter transmits the processed sound signals to the internal 
device by electromagnetic induction.  The implanted receiver and stimulator 
convert the signals into electric impulses and send them to electrodes through an 
internal cable.  The electrodes, which are inserted and wound through the 
cochlea, then send these impulses to the nerves followed by transmittal to the 
brain through the auditory nerve system.   
Since no HC regeneration occurs in mammals, cochlear prostheses are 





al., 2008, Shibata et al., 2010).  Cochlear prostheses provide an increasingly 
successful therapy to restore hearing, particularly speech recognition, for those 
suffering from profound deafness (Altschuler et al., 2008, Shibata et al., 2010).  
Nevertheless, the successful function of these cochlear prostheses depends on 
activation of auditory nerves, so the presence of these nerves and conserved 
functionality are essential for CI function (Altschuler et al., 2008, Serin et al., 
2009, Shibata et al., 2010).  Preserving SGN or finding a cellular replacement for 
lost or damaged SGN therefore is a priority if CI function is to be enhanced. 
 
Figure 1.3: Schematic view of the essential components in a cochlear implant 







Trophic factors on which each of the stages of neurons depends 
Various approaches to maintaining and activating the remaining SGNs 
and whole nerves have also been reported (Kong et al., Miller et al., 2002, 
Gillespie and Shepherd, 2005, Martinez-Monedero et al., 2007, Miller et al., 2007, 
Agterberg et al., 2008, Altschuler et al., 2008, Shibata et al., 2010).  Some 
investigators introduce exogenous intracochlear growth factors including BDNF 
(Kong et al., Miller et al., 2002, Miller et al., 2007, Agterberg et al., 2008, Shibata 
et al., 2010), GDNF (Ylikoski et al., 1998), a combination of GDNF with BDNF 
(Iguchi et al., 2003),  as well as such combinations of growth 
factors/neurotrophins combined with antioxidants such as ascorbic acid and 
Trolox (Maruyama et al., 2008) or a combination of growth factors with 
continuous electrical stimulation (Scheper et al., 2009).  The latter approach is 
based on the observation that secondary degeneration usually follows sensory 
epithelial degradation and neuronal cell death takes place due to a lack of trophic 
factors that could maintain the adult ganglion and nerve in functional condition 
(Fritzsch et al., 1997a, Martinez-Monedero et al., 2007, Shibata et al., 2010).  
Cells of the otocyst and later the cochlea secrete trophic factor(s) that support 
both the early development and growth of the developing neurons and later, the 
chemo-attraction, pathfinding and innervation of these neurons, which synapse 
on HC in the cochlea (Gillespie, 2003, Fekete and Campero, 2007) and still later, 
the continued maintenance of these neurons.  The trophic factors on which some 





presents what was known when we began the studies described in this thesis 
















SAG E12.5 (mouse) Vestibular neuron survival BDNF (Tessarollo et al., 2004) 
 E12.5 (mouse) 
 
Cochlear neuron survival NT-3 (Tessarollo et al., 2004) 
 E10.5 (mouse) Neuritogenesis and 
neuronal population 
NGF (Staecker et al., 1996b) 
 E11 (mouse)  
 
 
E3.5 (chick)  







(Hossain and Morest, 2000) 
 
 
(Brumwell et al., 2000) 
 Otic cup stage (E2 in 
chick) 
 
Cell survival, proliferation 
and neurogenesis 
IGF-1 (Leon et al., 1995, Frago et al., 2000, 
Camarero et al., 2003) 
SGN Early postnatal SGN development 
(maturation) and survival 
BDNF  (Malgrange et al., 1996, Staecker et al., 1996a, 
Marzella et al., 1999) 
 Early postnatal SGN development 
(maturation) and survival 
NT-3 (Malgrange et al., 1996, Staecker et al., 1996a, 
Marzella et al., 1999) 
 Neonatal and mature  SGN survival   
 
GDNF  (Ylikoski et al., 1998) 
 Early postnatal  SGN survival NT4/5 (Zheng et al., 1995, Zheng and Gao, 1996) 
 E11-P14 Establishment of cochlear 
innervations 
FGF-1 (Luo et al., 1993) 
 Postnatal mice SGN survival, 
differentiation and 
maturation  
IGF-1 (Camarero et al., 2001, Camarero et al., 2003) 
 Early postnatal rat 
(cell culture) 
SGN survival  TGF-β3 (Marzella et al., 1998, Marzella et al., 1999) 
 Early postnatal rat 
(cell culture) 
SGN survival TGF-β5 (Marzella et al., 1999) 
 




In the developing inner ear, the SAG contains neuroblasts/neurons, which 
are the precursors of both SGNs and vestibular ganglion (VG) neurons.  Several 
studies have reported that two neurotrophins, NT-3 and BDNF, play critical roles 
in inner ear neurite innervation and survival at a point in development when the 
SAG neurons ultimately separate into these distinct neuronal types.  Each of 
these neuronal populations begins to rely on specific, identified trophic factors 
(Fritzsch et al., 1997b).  Fritzsch et al. also demonstrated that the majority of 
mature SGNs relies on NT-3 for survival. Mice lacking either NT-3 or its 
associated receptor, TrkC, were found to have a dramatic loss of SGNs.   VG 
neurons, on the other hand, become dependent on BDNF and mice lacking 
either BDNF or its receptor, TrkB, showed a tremendous loss of VG neurons 
(Fritzsch et al., 1997b, Fritzsch et al., 1997c).   
However, prior to this stage, when afferent fibers initiate their extension 
towards the target cells in the otocyst in the periphery, these neurotrophins had 
little effect on outgrowth of SAG neurons (Bianchi and Cohan, 1991, 1993, 
Tessarollo et al., 2004).  Moreover, the biologically active components on which 
the earliest stage initiation of SAG neurite outgrowth depends were not fully 
characterized until our recent work identified a quartet of “inflammatory” cytokine 
factors, known to function in the immune system, but which behave as 
neurotrophins in early inner ear development.  More details about the most 
influential of these factors, MIF, in terms of being able to play both a necessary 
and sufficient role in SAG neurite outgrowth and survival will be presented in the 




At the SGN stage, several neurotrophins have been reported to play 
important roles in survival, maturation and maintenance in experimental animal 
models (Gillespie and Shepherd, 2005).  Early studies demonstrated that both 
BDNF and NT-3 promoted survival of dissociated neuronal cells in cultures of 
early postnatal rat SGNs (Malgrange et al., 1996, Marzella et al., 1999).  A 
synergic effect was seen when these neurotrophins were added together 
(Marzella et al., 1999).  Zheng et al. found that NT-4/5 also promoted SGN 
survival, and its effect on survival was equivalent to that of BDNF and stronger 
than that of NT-3 (Zheng et al., 1995).  In addition to their survival effects, each 
of  these factors (BDNF, NT-3 and NT-4/5) has been reported to protect the 
SGNs from ototoxic agents including therapeutic drugs such as salicylates 
(Zheng and Gao, 1996) and chemotherapeutic drugs used in cancer treatment, 
such as cisplatin (Zheng et al., 1995), suggesting that these neurotrophins might 
have therapeutic value in preventing hearing impairment caused by damage to 
primary auditory neurons.  In situ hybridization analysis detected the expression 
of GDNF in the inner ear HC of both the neonatal and mature rat cochlea, while 
its receptor, GDNF receptor-α, was found on the SGNs (Ylikoski et al., 1998).  
Several studies demonstrated that GDNF enhanced the survival in early 
postnatal rat SGNs both in vitro (Ylikoski et al., 1998, Qun et al., 1999) and in 
vivo following IHC lesions (Ylikoski et al., 1998).  
In addition to the neurotrophins, other families of growth factors, including 
cytokines, have demonstrated effects on SGN survival and maintenance.   Those 




Marzella et al. showed that both TGF-β3 and TGF-β5 promoted postnatal rat 
SGN survival in vitro (Marzella et al., 1999).  An effect of TGF- β5 on SGN 
survival was dose-dependent, with a significant increase in survival seen at 0.01 
ng/ml of exogenous TGF- β5 compared to control.  Maximum neuronal survival 
was observed with 1 ng/ml TGF- β5; however, higher concentrations didn’t show 
further survival.  The expression of FGF-1 at the mRNA level was detected in the 
rat cochlea from E16 to P14 and in the HC during the first postnatal week (Luo et 
al., 1993).  Based on its temporal expression patterns, the authors suggested its 
possible role in maintenance of SG neurons and the establishment of cochlear 
innervation (Luo et al., 1993).  Further studies demonstrated a role for FGF-1 in 
enhancement of SG neuron survival and maintenance in vitro (Dazert et al., 1998, 
Aletsee et al., 2000) as well as induction of SG neuronal branching in vitro 
(Aletsee et al., 2003).  The detection of IGF-1 expression has also been reported 
in both the developing inner ear and the postnatal cochlear as well as vestibular 
ganglia in chicks (Leon et al., 1995) and in mice (Varela-Nieto et al., 2004).   
Early studies of KO and transgenic (Tg) mouse models for the igf-1 gene 
have demonstrated an essential role for this cytokine in nervous system 
development (Powell-Braxton et al., 1993a, Powell-Braxton et al., 1993b).  The 
igf-1 null mice died shortly after birth, concomitantly showing growth retardation, 
drastically reduced brain size and loss of specific neuronal populations.  Similarly, 
the igf-1 deficient postnatal mice demonstrated reduction in the size of the 
cochlea, a highly immature tectorial membrane (TM) and SG neurons, and a 




(Camarero et al., 2001).  In addition, the authors demonstrated that a decrease in 
the number of SGNs found in mutants was due to an increase in caspase-3 
mediated apoptosis.  Furthermore, an abnormal synaptophysin expression 
pattern was observed in the somata of both SGNs and sensory HC in the 
mutants (Camarero et al., 2001).  An additional  study reported that the myelin 
sheaths were severely affected in these mutants (Camarero et al., 2003).  These 
results strongly suggest that IGF-1 plays an important role in inner ear neuronal 
and sensory cell maturation, and also in the survival and differentiation of the 
postnatal mouse inner ear. 
 
Otocyst derived factor(s) (ODF) enhance(s) directional neurite outgrowth 
and neuronal survival of the early stage SAG neurons 
Innervation target-derived or cellular pathway-derived growth and survival 
factors are essential for the normal development and survival of neurons (Ard et 
al., 1985, Lefebvre et al., 1990, Bianchi and Cohan, 1991, 1993, Bianchi et al., 
1998, Bianchi et al., 2005).  Early studies in both the rat and the chick (E4-6 in 
the chick, E11-14 in the mouse and rat) demonstrated that during the early 
stages of auditory development, cells in the anteroventral region of the otocyst 
secrete soluble and diffusible factor(s), which have been collectively termed 
Otocyst Derived Factor(s) (ODF), which influence both directional neurite 
outgrowth and survival of innervating SAG neurons of the eighth (VIII) cranial 
nerve in the nascent auditory-vestibular system (Bianchi and Cohan, 1991).  




provided by classical growth factors, including the neurotrophins (NGF, BDNF, 
NT-3 and NT-4) or CNTF, none of which was present at the time of early 
development, although the SAG comes to rely on these factors at later 
developmental stages (see discussion above).  Furthermore, these factors, 
exogenously applied “off the shelf”, either alone or in combination, had little or no 
effect on the survival and neurite outgrowth of early stages SAG neurons 
(Bianchi and Cohan, 1993).   
Moreover, ODF, produced from either early stage mouse or chick otocysts 
failed to promote neurite outgrowth from different types of placodally-derived or 
neural crest derived peripheral neurons, including trigeminal, ciliary, sympathetic, 
or dorsal root ganglion neurons, suggesting that ODF’s effects were specific to 
inner ear neuronal development (Bianchi and Cohan, 1993).  Additional 
experiments showed that antisera to nerve growth factors (e.g. NGF) were not 
able to block ODF activity (Bianchi and Cohan, 1993).  These results suggest 
that the classical neurotrophic factors are not the primary components of ODF 
and that ODF may have different molecular properties from other identified 
growth factors commonly thought to have effects in the nervous system.  Further 
study confirmed Bianchi and Cohan’s work by providing the precise 
spatiotemporal pattern of expression of NT-3 and BDNF during the process of 
inner ear innervation (Tessarollo et al., 2004).  This study was carried out with 
specific NT KO mice; wild-type (WT), mice null at the Bdnf locus (BDNF-/-), BDNF 




NT-3 with BDNF (NT-3tgBDNF-/-; BDNF-/- and NT-3tgBDNF+/-; BDNF-/-).  This elegant 
study characterized the spatiotemporal role of these factors in early otic 
development, prior to the time when embryonic lethality was notable.  The 
authors observed neuronal innervation patterns both in WT and all the mutant 
mice towards the appropriate regions of the otocyst at E11.5, indicating that both 
NT-3 and BDNF are not necessary for the initial outgrowth of SAG neuronal 
processes toward their targets.  On the contrary, the authors observed aberrant 
axonal branches and projections to the area, where BDNF was ectopically 
expressed in domains normally specific for NT-3 by E13.5.   
However, in contrast, other studies reported an important role for NGF, 
FGF-1 and FGF-2 and IGF-1 in initiation of SAG neurite outgrowth (Hossain et al., 
1996, Staecker et al., 1996a, Staecker et al., 1996b, Hossain et al., 1997, 
Hossain and Morest, 2000).  Staecker et al. detected the expression of NGF as 
early as E10.5 in the mouse otocyst and purported to demonstrate its essential 
role in inner ear development (Staecker et al., 1996b).  Their confocal 
microscopic analysis appear to demonstrate that downregulation of NGF in 
otocyst-SAG explants resulted in an inhibition of neuritogenesis as well as a 
reduction in the population of the SAG neurons compared to the control.   
Other studies demonstrated what the authors believe is an essential role 
for FGF-2 in initiating migration and neurite outgrowth of early stage SAG 
neurons (Hossain et al., 1996, Hossain et al., 1997), while BDNF was found to 
enhance the effect of FGF-2 in SAG neuronal development at later stages 




Brumwell et al., 2000) and in mice (Hossain and Morest, 2000).  In addition to 
FGF-2, a study showed that exogenous recombinant FGF-1 also enhanced early 
SAG migration and outgrowth in mice and the effect on migration and outgrowth 
was greater when combined it with FGF-2 than with either growth factor alone 
(Hossain and Morest, 2000).      
Both IGF-1 and its receptor, IGF-1R, are expressed during the otic cup 
stage in chick embryos (Leon et al., 1995, Camarero et al., 2003).  A central 
function of IGF-1 at the otic stage is to maintain cell survival and proliferation 
(Sanz et al., 1999, Frago et al., 2003).  Frago et al. demonstrated that exogenous 
IGF-1 protected otic vesicles/otocysts from cell death caused by pro-apoptotic 
stimuli such as serum deprivation (Frago et al., 2003), and its mechanism in cell 
proliferation was apparently due to activation of the mitogen-activated protein 
kinase (MAPK) cascade as well as to upregulation of the early genes, c-Jun, c-
Fos and proliferative cell nuclear antigen after IGF-1 binding to the IGF-1R (Leon 
et al., 1998, Sanz et al., 1999).  Recent work by Camarero et al. identified an 
additional role for IGF-1 in neurogenesis in chick embryos (Camarero et al., 
2003).  The authors demonstrated that IGF-1 promoted transition of neuroblasts 
into the post-mitotic stage of neuronal development using stage 19-20 (70-72 
hours) chick SAGs.  They observed that 1 nM IGF-1 alone enhanced chick SAG 
neurite outgrowth, along with high G4 immunoreactivity, the early neuronal 
marker.  Blockade of IGF-1 action with the receptor competitive antagonist, JB1, 





Proteomic studies demonstrate that the major components of ODF are 
immune system cytokines 
 
Our recent proteomic studies (included in Chapter 2) identified the 
bioactive components of ODF as immune system cytokines, including MIF 
(Gerlach-Bank, Ebisu et al., in preparation).   These studies also confirmed our 
earlier study that demonstrated a second immune system cytokine, MCP1 or 
JE/CCL2, was also a bioactive component of the ODF (Bianchi et al., 2005).   
This work will be discussed in detail in chapter 2.  
 
Development of immortalized mouse inner ear cell lines to characterize 
ODF 
 In order to analyze and characterize the cytokines in ODF, large 
quantities of material were and will still be required. ODF was originally 
generated by incubating 8 otocysts/ 250 µl of serum-free culture medium (Bianchi 
and (Bianchi and Cohan, 1991, 1993, Bianchi et al., 1998). Therefore, cultures of 
otocysts do not provide sufficient quantities of medium for biochemical or 
proteomic analysis. To overcome this limitation, other sources of ODF-like 
activity have been sought.  A number of years ago, we attempted to identify and 
isolate clones of cells that retained some plasticity and pluripotentiality by 
immortalizing early developing inner ear otocyst cells from the earliest stage of 
the otocyst that could be reliably isolated free of periotic mesenchyme and before 
emigration of the cells of the otic crest (Barald et al., 1997).    
Inner ear sensory HC and SCs as well as sensory neurons (SNs) are 




(Germiller et al., 2004).  However, cellular and molecular studies of the 
developing and adult inner ear in mammals have been hampered by the 
increasingly difficult access to developing sensory organs and especially to adult 
organs as the temporal bone, which houses these delicate structures, ossifies 
during inner ear maturation.   
Lack of appropriate organ and cell culture systems of the early inner ear 
also hindered more extensive molecular studies, due to the limited availability of 
the cellular material in the inner ear.  Thus, our laboratory (Barald et al., 1997) as 
well as others (Holley and Lawlor, 1997, Kalinec et al., 1999) developed 
conditionally immortalized cell lines from the embryonic mouse inner ear.  The 
cell lines in our lab were derived from the otocysts of 9.5-day embryos, the 
earliest stage at which the otocyst can easily be separated from surrounding 
mesenchymal, nervous system and neural crest cells (Germiller et al., 2004).  
Moreover, at this stage, many of the cells in the otocyst are still pluripotent, 
allowing us to identify uncommitted precursors as well as both HC and SN 
precursors.   
The H2kbtsA58 Tg, which carries a temperature sensitive variant of the 
SV40 large T antigen under the control of a gamma-interferon sensitive promoter, 
was used to isolate the otocyst cells that provided these IMO clonal cell lines 
(Barald et al., 1997, Barald and Kelley, 2004, Germiller et al., 2004).  
Conditionally IMO cells from this transgenic animal proliferate in the presence of 




expression, but they stop propagating and differentiate after a temperature shift 
to 37-39°C (the non-permissive temperature for the temperature-sensitive 
transgene expression) and removal of gamma-interferon from the media (Barald 
et al., 1997, Germiller et al., 2004).   
One notable difference between chicks and mice is that mature HCs in 
chicks express BMP4, while SCs do not.  The opposite is true in the mature 
mouse ear, where SCs but not HCs express BMP4 (Germiller et al., 2004).  In 
the chick, “new” HC arise from the SC population through transdifferentiation 
(Corwin and Cotanche, 1988, Balak et al., 1990, Corwin et al., 1991, Bhave et al., 
1995, Jones and Corwin, 1996, Stone et al., 1996, Warchol and Corwin, 1996, 
Molea et al., 1999, Stone and Rubel, 1999, 2000b, a, Bermingham-McDonogh et 
al., 2001, Stone and Cotanche, 2007, Ma et al., 2008, McCullar and Oesterle, 
2009).  These IMO cell lines provide a unique model system for studying early 
stages of inner ear development to determine the consequences of affecting key 
molecular events in their differentiation.  
At least 2 of the IMO cell lines (IMO-2B1, -2D2) that we have developed 
(Barald et al., 1997, Thompson et al., 2003, Germiller et al., 2004, Bianchi et al., 
2005) provide neurite-outgrowth and survival promoting activity for early stage 
SAG (Chapter 2). Because the IMO cells are grown in large numbers under 
serum-free conditions in larger volumes (10 ml per 100 mm culture dish), the 




characterization of the neurite-outgrowth promoting and survival factor(s) 
released by IMO cell lines.  
In this thesis, we have taken advantage of the IMO cells’ ability to produce 
an ODF-like bioactivity to use these cells to identify the composition of ODF 
(Bianchi et al., 2005). However, only by extending the information obtained from 
studies of IMO-generated ODF otocyst-derived ODF can we validate IMO cells 
as a model of inner ear development.  In the future, we will employ both gain and 
loss of function studies to examine the bioactivity of the cytokine components of 
ODF and the molecular rules that govern their potential synergy or antagonism.  
So far, we have used protein and nucleic acid probes to determine the 
expression patterns of the bioactive cytokine components in the developing and 
mature inner ear and eventually plan to extend these studies to determine if such 
factors could influence regeneration of neurons in a damaged or diseased inner 
ear. 
 
MIF, an inflammatory cytokine, plays the role of a “neurotrophin” in early 
inner ear development 
As discussed in the brief introductory paragraphs to this chapter, MIF has 
been found to be a major component (in terms of activity) in ODF.  MIF is a 
highly conserved cytokine with a molecular weight of 12.5 kilodaltons (kDa) 
(Weiser et al., 1989, Baugh and Bucala, 2002b), was originally described as an 
“activity” of cognate T cell supernatants that inhibited macrophage migration as 




yielding evidence that MIF is expressed in various cell types including 
monocytes/macrophages, endothelial cells, eosinophils, neurotrophils, epithelial 
cells, lymphocytes and smooth muscle cells under physiological conditions (El-
Turk et al., 2008, Cooke et al., 2009, Santos and Morand, 2009) and is secreted 
by the anterior pituitary gland in systemic stress responses or in response to low 
concentrations of glucocorticoids (El-Turk et al., 2008).  MIF is now described as 
a “pleiotropic” cytokine since it plays multiple roles including enzymatic activity, 
the pathogenesis and progression of both acute and chronic inflammatory, and 
autoimmune diseases including systemic and organ-specific autoimmune 
diseases (Bernhagen et al., 1993, Calandra and Roger, 2003, El-Turk et al., 
2008).  Further studies demonstrated that MIF is implicated in carcinogenesis, 
linking chronic inflammation and cancer (Lue et al., 2007). 
More recently, several studies found a vital additional role for MIF in the 
development and regeneration of peripheral nerves and skin after injury (Nishio 
et al., 1999, Abe et al., 2000, Nishio et al., 2002, Suzuki et al., 2004, Shimizu, 
2005, Dewor et al., 2007, Velnar et al., 2009) (discussed below).    
 
Enzymatic activity of MIF/MIF as a therapeutic target: 
Structural analysis of MIF by X-ray crystallographic and NMR studies 
demonstrate that MIF exists as a homo-trimer as shown in figure 1.4 (Sun et al., 
1996, Baugh and Bucala, 2002b, Leng and Bucala, 2006), and that is 
homologous to an enzyme called D-dopachrome-tautomerase (DDT) (Sugimoto 




and DDT, Rosengren et al. found that MIF has tautomerase activity and is able to 
convert D-dopachrome into 5,6-dihydroxyindole-2-carboxylic acid (DHICA) 
(Rosengren et al., 1996). Since D-dopachrome is not a naturally-occurring 
substrate, the authors were not able to determine what the actual biological effect 
of MIF is in the body that might be a consequence of this type of conversion.  
Nevertheless, the results could offer a potential approach for designing 
pharmacological inhibitors of MIF that might  modulate its potent immunological 
effects in vivo (Rosengren et al., 1996).  Further studies identified additional 
enzymatic activities of MIF, including its action as a phenylpyruvate tautomerase 
with thiol-protein oxidoreductase (Kleemann et al., 1998).  More recently, El-Turk 
et al. have demonstrated that inter-subunit interactions involving carboxy terminal 
residues 105-114 of MIF play critical roles in modulating tertiary structure 
stabilization, enzymatic activity and the thermodynamic stability of MIF, and 
suggested the possible use of strategies to develop novel inhibitors of MIF 
tautomerase activity (El-Turk et al., 2008), although the precise role for MIF 
enzymatic activity in either normal function or in clinical disease has not been 






Figure 1.4: Three-dimensional ribbon diagram of human MIF.  MIF exists as a 
homo-trimer; each molecule is represented in this diagram in a different color 
(green, red, blue) (Leng and Bucala, 2006). 
 
Since tautomerase activity is an evolutionarily ancient phenomenon and 
expendable, Al-Abed et al. developed a molecule called (S,R)-3-(4-
hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) that 
binds the catalytic site to inhibit MIF tautomerase activity (Al-Abed et al., 2005).  
In this study, the authors first treated mice with either lipopolysaccharide (LPS) or 
the cecal ligation and puncture (CLP) to induce endotoxemia, a condition that 
leads to rising levels of endotoxins in the blood, and which leads to septic shock, 
or to polymicrobial sepsis respectively.  Twenty four hours post injection, they 
treated mice with either ISO-1 or dimethyl sulfoxide (vehicle) to examine the 
effects of ISO-1 on MIF cytokine activity in vitro as well as tumor necrosis factor 




The authors observed that ISO-1 inhibited MIF cytokine activity and TNF release 
from macrophages isolated from LPS-treated mice (Al-Abed et al., 2005, Cooke 
et al., 2009).  They also observed that ISO-1 significantly enhanced survival in 
mice treated with LPS/CLP when compared to control.  These studies showed 
that MIF activity could be therapeutically regulated by a molecule specifically 
targeting its tautomerase-active site.  Moreover, they raise the possibility that the 
deleterious effects of MIF in disease is due to excess of MIF expression and that 
this may be abolished by treatments with ISO-1. 
More recently, Winner et al. identified an additional irreversible inhibitor of 
MIF, 4-iodo-6-phenylpyrimidine (4-IPP) that serves as a suicide substrate for MIF, 
resulting in the covalent modification of the catalytically active NH2 terminal 
proline (Winner et al., 2008).  The group demonstrated that 4-IPP is 5 to 10 times 
more potent in blocking MIF-dependent catalysis and lung adenocarcinoma cell 
invasion/migration and anchorage-independent tumor cell growth than ISO-1, 
although further studies are required to determine the antitumor efficacy of this 
novel compound. 
Our laboratory has begun studies of MIF-inhibition by 4-IPP, among other 
inhibitor assessments (Shen et al., submitted), to block MIF activity to determine 
its effects on inner ear development.  We have observed that zebrafish embryos 
treated with this small molecule had a curved body, slightly smaller head, eye 
and ears, which is to the phenotype of  mif morpholino antisense oligonucleotides 
(MOs)-treated embryos compared to the DMSO treated controls (Shen et al., in 




was observed in the 4-IPP treated embryos.  Furthermore, the saccular macula 
(the zebrafish hearing organ, which bears sensory HC) in these embryos was 
slightly smaller than the control embryos (Shen et al., in preparation).  The effect 
of 4-IPP on HC numbers is presently being evaluated. 
 
The pathogenesis and progression of acute inflammation in the body:  
The innate immune system provides host defense mechanisms against 
microbial pathogens in a non-specific manner (Calandra, 2003).  Macrophages 
play an essential role in the innate immune system by recognizing and 
eliminating invasive microbial pathogens (Aderem and Underhill, 1999, Roger et 
al., 2001).  When microbial products bind to pathogen-recognition receptors, 
macrophages are activated and release many kinds of cytokines, including MIF, 
to orchestrate the host’s innate immune response.  MIF has emerged as a pivotal 
mediator of acute inflammatory responses, such as those that occur during 
bacterial infections (Wiersinga et al., Geldhoff et al., 2009).  
 
Bacterial infection: Roger et al. demonstrated that MIF is an essential regulator 
of macrophage responses to endotoxin, such as those engendered by LPS, and 
gram-negative bacteria. They compared  NF- κB activity, which is involved in 
cellular responses to various stimuli, and pro-inflammatory cytokine production, 
including the production of  TNF-α and interleukin (IL)-6, in MIF-deficient mouse 
macrophages compared with WT macrophages (Roger et al., 2001).  The 




production in MIF-deficient macrophages, compared to WT macrophages.  The 
vital steps in the recognition of LPS or gram-negative bacteria by the host require 
interaction between LPS-binding protein (LBP) (Schumann et al., 1990), CD14, a 
ligand-binding GPI-anchored protein (Wright et al., 1990), and Toll-like receptor 4 
(TLR4) (Poltorak et al., 1998), the signal-transducing molecule of the LPS 
receptor complex required to activate NF-κB and proinflammatory cytokines 
(Roger et al., 2001).  LBP binds to LPS-containing particles and transfers them to 
a receptor complex composed of CD14 and TLR4.  Additional experiments 
performed by Schumann et al. (1990) demonstrated that the reduction of NF-κB 
activity and pro-inflammatory expression were due to the downregulation of 
TLR4, which is associated with decreased activity of PU.1, a transcription factor 
required for optimal expression of the Tlr4 gene in myeloid cells.  Their findings 
provided important information that MIF promotes both the recognition of LPS 
and gram-negative bacteria by immune cells and development of the host 
defensive system through upregulation of TLR4.  In addition, TLR4 upregulation 
mediated by MIF demonstrated a molecular basis for the increased resistance of 
MIF KO mice to LPS induced endotoxic shock.  Numerous studies have reported 
that neutralization of MIF either with anti-MIF antibodies (Calandra et al., 2000) 
or small molecule MIF inhibitors, including ISO-1 (Al-Abed et al., 2005), protected 
mice from various infections, including that resulting from CLP, which induced 
both peritonitis and sepsis, and which was previously described.  Recent studies 
showed that patients with the bacterial infections, such as melioidosis, had higher 




healthy controls.  Furthermore, elevation of MIF expression was associated with 
an adverse outcome for such patients (Wiersinga et al.), further suggesting MIF’s 
essential role in acute inflammation.  MIF is therefore a prime candidate target 
molecule for treatment of acute inflammation as well as many other diseases with 
inflammatory sequellae (Al-Abed et al., 2005).                        
 
The pathogenesis and progression of chronic inflammatory diseases 
(Autoimmune diseases): 
 
Autoimmunity results from either dysregulation of central tolerance in the 
thymus or the lack of appropriate peripheral tolerance (Stosic-Grujicic et al., 
2009).  Once the immune response is triggered, autoimmune diseases are 
sustained through a permanent activation of the inflammatory process, which 
usually protects the host against infection.  As a consequence of such an 
immune response, immune cells can induce cell death in the target tissue.  
Numerous studies have reported that pro-inflammatory cytokines such as IL-1β, 
TNF-α and IL-6 are involved in both systemic and organ-specific autoimmune 
diseases and that MIF is prominently located upstream of the events that lead to 
such autoimmune responses (Stosic-Grujicic et al., 2009).  Inhibition of MIF has 
proven beneficial in the treatment of autoimmune diseases in both animal and 
human studies (Mikulowska et al., 1997, Santos et al., 2001, Burger-Kentischer 





a. Systemic autoimmune diseases: Systemic lupus erythematosis (SLE) is a 
chronic multisystem immune disorder characterized by a loss of tolerance to host 
antigens.  It is associated with the development of pathogenic autoantibodies that 
can harm target organs, including the skin, joints, the brain and the kidney (Hoi et 
al., 2003, Santos and Morand, 2009).  Key immune response factors, which 
contribute to these disease states have been identified: TLRs, CD28-B7 family 
members, TNF-TNF receptor family members and inflammatory cytokines such 
as TNF, IL-6, IFN-α, IFN-γ and IL-10 (Santos and Morand, 2009).  Unlike other 
autoimmune diseases, cytokine-target therapy against the cytokines mentioned 
above is not applicable to SLE because of the strong possibility that they are 
required for the active maintenance of immune system tolerance.  An association 
of MIF with SLE severity was first reported by Rovenskey et al. over three 
decades ago (Rovensky et al., 1975).  More recent clinical studies have identified 
MIF as a therapeutic target in SLE.   The reasons for implicating MIF include: 
MIF is expressed in the cell cytoplasm of immune system and blood cells and is 
and released only on stimulation of these cells (Calandra et al., 1994).  Second, 
MIF directly affects key effector cells including macrophages and can generate 
other proinflammatory stimuli (Cunha et al., 1993, Calandra et al., 1994).  In 
addition, MIF can act as a chemokine and help facilitate the interaction between 
leukocytes and endothelial cells.  It can also inhibit apoptosis and promote cell 
proliferation.  These properties suggest that a blockade of MIF might have only 
partial effects once inflammation cascades had been triggered (Santos and 




in SLE using the lupus-prone MRL/lpr mice (Hoi et al., 2006). Found that renal 
MIF expression was significantly higher in MRL/lpr mice compared with control 
mice.  These findings also paralleled the markedly up-regulated MIF levels found 
in skin lesions of MRL/lpr mice.  In this study, the authors generated MRL/lpr 
mice with a targeted disruption of the MIF gene (MIF-/-MRL/lpr) to examine an 
effect of MIF on development of SLE.  They demonstrated that MIF-/-MRL/lpr 
mice exhibited significantly prolonged survival and a reduction of both the renal 
and skin effects of SLE compared with their unaffected littermates.  Furthermore, 
no major changes in T and B cell markers or alterations in autoantibody 
production were observed, suggesting that MIF is a critical effector of organ 
injury in SLE (Hoi et al., 2006). 
 
b. Organ-specific autoimmune diseases: MIF has been implicated in the 
pathogenesis of multiple organ-specific autoimmune diseases as well, including 
rheumatoid arthritis (RA) and multiple sclerosis (Stosic-Grujicic et al., 2009).  
b-1. Rheumatoid arthritis (RA): RA is characterized by chronic inflammatory 
destructive polyarthritis (Santos and Morand, 2009).  MIF is upregulated in RA 
synovial fluid and serum compared to its levels in healthy controls (Leech et al., 
1999, Onodera et al., 1999) and appears to contribute directly to the destructive 
progression of this disease (Onodera et al., 2000).  MIF stimulates macrophages 
to release other proinflammatory cytokines critical in RA, such as TNF, IL-1, IL-6 
and IL-8 (Onodera et al., 1999, Onodera et al., 2004, Santos et al., 2004).  In 




proinflammatory genes, including fibroblast-like synoviocytes (FLS) 
phospholipase A2, cyclooxygenase 2 (COX-2) and prostaglandin E2 (PGE2) 
(Sampey et al., 2001, Santos et al., 2004).  Antagonizing MIF delays onset and 
decreases the frequency of collagen-induced arthritis (Mikulowska et al., 1997) 
and murine antigen-induced arthritis (AIA) (Santos et al., 2001).  In the latter 
study, the authors first induced AIA by intra-articular injection of methylated 
bovine serum albumin in presensitized mice, followed by treatment of these mice 
with an anti-MIF antibody, recombinant MIF (rMIF) and/or dexamethasone 
(DEX).  The severity of arthritis was measured in a blinded study quantitating 
synovial cellularity by histological assessments.  They observed that that AIA 
was significantly inhibited by the anti-MIF antibody, whereas DEX treatment 
inhibited AIA in a dose-dependent manner.  Exogenous MIF treatment reversed 
the effect of therapeutic DEX on AIA.  Further studies confirmed that, in MIF KO 
mice, AIA severity was reduced (Leech et al., 2003, Santos et al., 2008).  This 
was also associated with an increased synovial p53 expression and apoptosis in 
fibroblasts (Leech et al., 2003) as well as decreased T-cell activation and the 
extracellular-signal regulated kinase (ERK) phosphorylation, which is also 
associated with cell proliferation in splenocytes (Santos et al., 2008).      
 
b-2. Atherosclerosis: Atherosclerosis is now recognized as not only a lipid 
disorder but also a chronic inflammatory disease of the arterial wall characterized 
by chemokine-mediated influx of immunocompetent mononuclear cells 




contributor to artherogenic progress through adverse effects on lipoprotein 
metabolism and the health and maintenance of the arterial wall.  Both the innate 
and acquired immune systems are involved in this process (Hansson and Libby, 
2006, Bernhagen et al., 2007).  Monocytes and T-cells migrate into the innermost 
arterial wall where they differentiate into macrophages (Kleemann et al., 2008).  
Monocyte-derived macrophages are found in large numbers during all stages of 
the disease process (Mangge et al., 2004, Hansson and Libby, 2006) and act as 
critical effectors through release of a series of proinflammatory molecules 
including cytokines (MIF, TNF-α, IFN-γ, etc.), chemokines and co-stimulatory 
factors (Nilsson and Hansson, 2008, Zernecke et al., 2008).  MIF has been 
demonstrated in all cell types present in atherosclerotic lesions and its 
expression is upregulated during the progression of atherosclerosis in humans 
(Burger-Kentischer et al., 2002) and in an animal (rabbit) model (Lin et al., 2000).  
An in vivo study confirmed an essential role for MIF in atherogenesis by 
examining the inflammation status, macrophage content and plaque areas in the 
aortas and in the heart.  The study compared apolipoprotein E deficient (ApoE-/-) 
mice treated with an anti-MIF antibody and the IgG treated controls (Burger-
Kentischer et al., 2006).  The authors observed that MIF expression was 
elevated in the aortic wall during atherogenesis by foam cells, a major source of 
atherosclerotic plaque formation in vessels.  Blockade of MIF showed a marked 
reduction of macrophages associated with the endothelial layer of the intima and 
a variety of inflammatory mediators associated with atherosclerosis, including 




fibrinogen and TNF.  Reduction of inflammation by anti-MIF antibody treatment 
was associated with a small but non-significant reduction in the aortic plaque 
area, suggesting the involvement of MIF in arthrosclerosis.   
 
Inflammation and cancer: 
Chronic inflammation is an essential component of tumor progression.  
Recent studies have raised a possible role for MIF in providing a critical link 
between chronic inflammation and carcinogenesis based on the observation of 
MIF overexpression in various tumors including those of the breast, colon, liver, 
lung, prostate  and in neuroblastoma (Cooke et al., 2009).  MIF influences tumor 
growth and development by inducing tumor associated angiogenesis, by 
promoting cell cycle progression in cells of the tumor, by inhibiting apoptosis in 
tumor cells through suppression of the p53 tumor suppressor gene and by 
inhibiting tumor cell lysis by natural killer (NK) cells (Bach et al., 2009).   
a. Tumor growth and tumor-associated angiogenesis: Tumors require neo-
vascularization (angiogenesis) to provide the innermost cells of the tumor with 
oxygen and nutrients for cell survival (Mitchell and Bucala, 2000).  Higher 
expression levels of MIF were observed in human melanoma cell lines than in 
normal cultured melanocytes and blockade of MIF with an antisense human MIF 
plasmid markedly suppressed the cells’ growth rates, implicating MIF in the 
mechanism of proliferation of melanoma cells (Shimizu et al., 1999).  These 
authors also examined the function of MIF in tumor cell migration and found that 




tumor cells in vivo significantly suppressed tumor-associated angiogenesis 
(Shimizu et al., 1999).  A different group compared tumor-induced angiogenesis 
in Tg mice carrying MIF cDNA driven by a cytomegalovirus enhancer and a β-
actin/β-globin promoter with non-Tg mice.  The mice were subcutaneously 
inoculated with cells of a murine sarcoma cell line, S-180 (Nishihira et al., 2003).  
The investigators found that tumor-induced angiogenesis was significantly 
enhanced in the MIF Tg mice compared to non-Tg mice.  They also found that 
tumor-induced angiogenesis was significantly suppressed by an anti-MIF 
antibody in the subcutaneous fascia that had been injected with the antibody.  
Taken together, these results indicate that MIF can stimulate both the growth and 
invasion of tumor cells and promote neo-vascularization of a growing tumor.  
b. Proliferation and cell cycle progression: Proper regulation of the cell cycle 
is essential for normal development and tumor prevention.  The earliest direct 
evidence suggesting a role of MIF in cell cycle activation was reported in studies 
of T lymphocyte activation (Bacher et al., 1996, Mitchell and Bucala, 2000).  
These authors demonstrated that immunoneutralization of MIF by antibodies 
during antigen or mitogenic challenge of T lymphocytes reduced the proliferative 
response by more than 80%.   Induction of both interleukin-2 and its receptor 
(Bacher et al., 1996) were also blocked.  These findings indicate that MIF could 
be an important factor acting in an autocrine manner to mediate upstream 
signaling required for activated T lymphocyte proliferation (Bacher et al., 1996, 
Mitchell and Bucala, 2000).  Other investigators have also examined in more 




expression and its effects in a colon carcinoma cell line (Takahashi et al., 1998).  
They observed that MIF expression was induced by several growth factors 
including TGF-β, basic-FGF (b-FGF) and platelet-derived growth factor (PDGF), 
in these cells.  Depleting endogenous MIF with an anti-sense MIF plasmid 
resulted in greater than a 40% reduction in tumor cell growth.  A molecular basis 
for these observations was provided by studies of serum-mediated growth in 
quiescent murine fibroblasts (Mitchell et al., 1999).  These experiments were 
designed to investigate the role of MIF in serum-induced cell cycle progression in 
the NIH/3T3 fibroblast cell line.  The studies showed that serum induced a rapid 
release of preformed MIF (about 6 ng/ml 4 hours post MIF plasmid 
administration) from the resting fibroblasts (about 2.5 ng/ml), while inhibition of 
secreted MIF by an antibody during serum-induced cell cycle progression 
resulted in a decrease of DNA synthesis by as much as 50% when compared to 
controls (Mitchell et al., 1999).  These studies showed that serum-deprived 
quiescent cells were stimulated to undergo cell cycle progression and DNA 
synthesis in response to exogenous MIF (Liao et al., 2003), further suggesting a 
role for MIF in cell proliferation by directly stimulating cell cycle progression.                             
c. Inhibition of apoptosis by suppressing p53 tumor suppressor gene: 
Proper cell proliferation and maintenance are critical for normal development and 
cancer prevention (Nemajerova et al., 2007).  Cells continuously experience DNA 
damage caused by base alternations due to reactive oxygen species (ROS)-
induced oxidative stress or genotoxic agents including ultraviolet and ionizing 




to various disorders including cancer (Whitcomb, 2004).  P53 has been classified 
as a tumor suppressor.  It plays a very important role in the regulation of cell 
proliferation and maintenance of genomic stability as well as in the suppression 
of cellular transformation and tumorigenesis.  The high frequencies of mutations 
in the p53 gene that are found in human tumors (Vogelstein et al., 2000) and the 
apparent correlation of p53 loss with tumor aggressiveness (Levine, 1997) 
emphasize the importance of p53 as a “gatekeeper’ in the development of 
neoplastic disease (Fingerle-Rowson et al., 2003).  Recent studies have 
suggested a possible broader role of MIF in growth regulation through its role in 
antagonizing p53-mediated gene activation and apoptosis (Hudson et al., 1999, 
Fingerle-Rowson et al., 2003, Honda et al., 2009).  By performing gene-targeting 
studies with embryonic fibroblasts from MIF KO mice (MIF-/-MEFs), Fingerle-
Rowson et al. observed p53-dependent premature growth arrest, and an 
increase in p53 transcriptional.  These parameters were associated with an 
observed resistance to ras-mediated transformation in the MIF-/-MEFs.  However, 
if the p53 gene was also deleted, these phenotypes were reversed (Fingerle-
Rowson et al., 2003).  Further, the authors demonstrated that benzo[α]-pyrene-
induced fibrosarcomas were smaller in size and had a lower mitotic index in MIF 
KO mice compared to their littermates in vivo.  More recently, Honda et al. found 
a higher incidence of tumors as well as a substantial decrease in the levels of 
p53, Bax and p21 proteins in Tg mice in which MIF was overexpressed (MIF Tg) 
than in WT mice after chronic UV irradiation (Honda et al., 2009), further 




d. Inhibition of tumor cell lysis by NK cells: Various cell types in the immune 
system collaborate in an orchestrated, multifactorial process to execute their 
cytotoxic functions (Chavez-Galan et al., 2009).  NK cells are among the major 
cytotoxic cell types since their most critical functions are to remove abnormal or 
infected cells from the body, preventing the development of malignancies and 
eliminating intracellular pathogens (Chavez-Galan et al., 2009).   Studies have 
demonstrated a functional link between MIF and NK cells, in that MIF inhibits the 
lysis of tumor cells by NK cells in at least one organ-- the eye (Apte and 
Niederkorn, 1996, Apte et al., 1998, Repp et al., 2000).  Apte et al. found that 
aqueous humor (AH), which bathes the anterior chamber of the eye bounded by 
the corneal endothelium, contains a protein that inhibits the NK mediated lysis of 
corneal endothelial cells (Apte et al., 1998).  Their amino acid sequence analysis 
showed that this protein shared more than 90% homology with MIF, was present 
in AH and can inhibit NK cell mediated cytolysis in vitro.  The same group 
showed that mouse rMIF produced a similar effect by inhibiting NK cell activity.  
Inhibition of MIF activity with goat anti-human MIF antibody neutralized the NK 
inhibitory effect of AH (Apte et al., 1998).   
 
Role of MIF in development:  
Cytokines are now being implicated in a variety of roles including neuronal 
migration, outgrowth and survival (Meng et al., 1999, Bajetto et al., 2001, 




them, MIF is the most extensively investigated cytokine in nervous system 
development and regeneration. 
a. MIF expression during embryogenesis: A number of studies demonstrated 
that MIF is ubiquitously expressed in various cell types and involved in both 
intracellular and extracellular events as mentioned previously (Abe et al., 2000, 
Yamaguchi et al., 2000, Shimizu et al., 2002a, Shimizu et al., 2002b).  Because 
MIF  is so ubiquitously expressed, and is also expressed at early times in regions 
of the body that undergo development before the immune system develops, it 
may have  additional role(s) beyond those in the immune system (Kobayashi et 
al., 1999, Suzuki et al., 2004).  Kobayashi et al. demonstrated the spatiotemporal 
expression of MIF during murine embryogenesis (Kobayashi et al., 1999).  MIF 
mRNA expression was apparent in the neural folds at E8.  By E8.5, its 
expression was detected in many tissues including the somites.  Somitogenesis 
is considered to commence at E8 and continues to E14, following a rostral to 
caudal gradient of differentiation.  An increase in the number of somites was 
observed along with more prominent MIF expression in the caudal region.  MIF 
expression was also observed in muscle cells, including cardiac muscle, both at 
the mRNA and protein levels at E9.5, and in smooth muscle of the arteries and in 
skeletal muscles at the protein level at E16.5.  In addition, the authors detected 
the expression of MIF mRNA in neural tissues, including the forebrain, midbrain, 
hindbrain, neural tube, in cranial ganglia, and dorsal root ganglia during all 
embryonic stages.  The expression of MIF was detected in optic and otic 




b. Role of MIF in neurulation: Based on the observations that MIF is expressed 
in many tissues during murine embryogenesis including neuronal cell types 
(Kobayashi et al., 1999), Suzuki et al. speculated that MIF plays a critical role in 
development, particularly in axis formation and neural development (Suzuki et al., 
2004).  These authors detected the expression of MIF in the developing central 
nervous system in the embryos of the African clawed frog Xenopus.  They 
conducted both loss- and gain-of- function experiments to determine the role of 
MIF in neurulation using the same model system.  They observed that an 
injection of MIF MOs into the one to eight cell stage frog embryo resulted in 
complete failure of neural axis formation and neural development (Figure 1.5) 
(Suzuki et al., 2004).  Co-injection of MIF capped RNA with the MIF MOs showed 
at least partial phenotypic rescue, indicating that MIF appears to be essential for 
neurulation in Xenopus embryogenesis.     Investigators in the Barald lab have 
performed similar studies in the zebrafish, which, due to a gene duplication, has 
2 mif genes and two mif receptors (Shen et al, in preparation).  Although 
blockage of the 2 zebrafish mif genes at the 1-8 cell stage in the zebrafish with 
either start-site MOs or splice junction MOs alone or in combination, did not block 
neurulation in the zebrafish, the size of both the CNS and the inner ear was 




   
Figure 1.5: MIF mRNA expression in the embryonic mouse (left) and 
Xenopus (right).  MIF mRNA in the otic vesicle/otocyst in the 9.5 day mouse 
embryo (left) (Kobayashi et al., 1999).     The expression of MIF mRNA and the 
role of MIF in neurulation are illustrated in developing Xenopus embryos (right) 
(Suzuki et al., 2004).  MOs were injected into the 1-8 cell frog embryo to block 
splicing.  Uninjected control (A and D).  Injection of MIF splice junction-blocking 
MOs  (MIF MOs) block neurulation (B and E). Co-injection of MIF capped RNA 
with the MIF MOs partially rescues phenotype (C and F).    
 
c. Role of MIF in inner ear development: Our laboratory has demonstrated a 
role of MIF inner ear development using zebrafish as model system (Thompson 
et al., in preparation; Shen et al., in preparation).  We have recently cloned two 
zebrafish MIF genes, mif and mif-like.  The sequences and expression patterns 
of both genes are highly similar to both the Xenopus and the mammalian MIF 
sequences (and they are also homologous to each other) and their expression 
patterns in the fish resemble those in the mammal and particularly resemble 
those in Xenopus.  Zebrafish mif has higher homology to the mammalian MIF 
gene, while mif-like has higher homology to a mammalian DDT gene.  Both 




are found among all MIF family genes in different species.  Shen et al. detected 
zebrafish mif expression in the neural keel, the developing eye, brain and inner 
ear as shown in Figure 1.6 (above).  Shen and colleagues then injected 3 types 
of antisense morpholino oligonucleotides (MOs): an antisense morpholino 
oligonucleotide (MO) that was complimentary to the start codon of zebrafish mif 
mRNA and two mif-like MOs to splice junctions. These injections were done at 
the one-cell stage in zebrafish, since SAG neurogenesis takes place before 18 
hours post fertilization (hpf) and MO effects last for 72 hours.  Shen et al. (in 
preparation) observed that the combination of these three MOs significantly 
reduced the number of the SAG neurons as well as other head ganglia, as well 
as reducing size of the head, as compared to the effect of the control MO (Figure 
1.6, middle on the bottom), while co-injection of mif MO or MOs with capped mif 
RNAs rescued neuronal development (Figure 1.6, right on the bottom), indicating 
that the zebrafish mif family genes are as important for neurogenesis in the fish 










Figure 1.6: Above: Zebrafish mif expression in the neural keel, the developing 
eyes, brain and inner ear of the zebrafish at 29 hpf and 31 hpf.   Bottom: ZN5, 
an antibody that stains neurons in the zebrafish, was used in the 48 hpf inner ear. 
(A) control; (B) mif morphant embryo in which MOs to both zebrafish mif genes 
were administered at the 1 cell stage; (C) mif morphant which was injected 
concomitantly with the 2 mif MOs and with capped mif RNAs.  The white line 
outlines the SAGs. The SAG is considerably smaller in the MOs-treated embryo.  
Note that other cranial ganglia (the tree-like green projections above the SAG, 
were also smaller in the mif morphants (B) than the control (A) or the “rescued” 
embryo (C). gAD: anterodorsal LL ganglia. Scale bar: 25 μm.  Control embryos 
(n=30), mif MOs (n=14), mif MOs+RNA (n=12) (from Shen et al., in preparation). 
 
Role of MIF in Regeneration: 
Tissue repair and wound healing are both continuously ongoing in the body 
and complex processes (Shimizu, 2005, Velnar et al., 2009).  They involve blood 
coagulation and hemostasis followed by inflammation, proliferation and wound 
remodeling with concomitant scar tissue formation (Velnar et al., 2009).  Recent 





process.  Thus, MIF has been a major target of research in association with 
wound healing (Abe et al., 2000, Dewor et al., 2007).   
a. Wound healing in the skin: The expression of MIF was detected in the 
human epidermis, particularly in the basal cell layers (Shimizu et al., 1996).  
Further studies identified a pathophysiological function for MIF in the skin (Abe et 
al., 2000, Zhao et al., 2005).  Abe et al. detected the temporal expression of MIF 
both at mRNA and protein levels following an excision wound by a punch biopsy 
instrument.  Maximum expression of MIF mRNA was observed 3 and 24 hours 
post-injury, while 12 hours post-injury maximum protein levels were seen in the 
whole epidermal lesion of the wound tissue.  In addition, they demonstrated that 
MIF has a chemotactic effect on freshly prepared keratinocytes from rat skin.  
Fibroblasts have been implicated as having a critical role in the wound healing 
process in the skin and keratinocytes, fibroblasts that synthesize extracellular 
martrix components, help to remodel the damaged tissue (Abe et al., 2000).  An 
effect of MIF on the wound healing process was further examined in mice by the 
same authors.  They introduced penetrating wounds through both epidermis and 
dermis using a punch biopsy instrument, followed by administration of either 
polyclonal anti-rat MIF antibodies that cross react with mouse MIF or non-
immune rabbit IgG every 2 days until wound healing was completed.   A delay in 
the healing process was seen in the mice injected with anti-MIF antibodies 
(which took 11-15 days for complete healing of the wound to be observed) 
compared to the control mice (which took 5-9 days for complete healing), 




Additional in vivo studies conducted by Zhao et al. support Abe and 
colleagues’ work, in which MIF also plays an important role in skin wound healing 
(Zhao et al., 2005).  In this study, the authors compared the time required for the 
complete healing of skin lesions in MIF KO mice with the time required in WT 
mice after the introduction of wounds to the skin in the same manner as Abe et al. 
(Abe et al., 2000).  Healing was significantly delayed in MIF KO mice (15 days on 
average) compared to WT mice (10 days on average).  They further examined 
whether exogenous MIF could accelerate the healing process by administrating 
various concentrations (1 to 6 µg/500 µl) of rMIF-impregnated hydrogel 
microbeads around the skin wounds in MIF KO mice.  Six days post-MIF 
microbead administration, more than 80% wound recovery was seen in the mice 
that received 6 µg/500 µl of rMIF, while about 60% recovery was observed in the 
mice that did not receive any rMIF.  The differences were considered to be 
significant.  Their work provides further evidence that MIF plays an essential role 
in skin wound healing.   
Given that fibroblast migration plays an important role in wound healing 
and that MIF has also been demonstrated to promote the migration of primary 
human neutrophils through its association with G-protein coupled receptors 
(Bernhagen et al., 2007), Dewor et al. further examined the role of MIF during the 
wound healing processes in scratch-wounded monolayers, or scrape wounds 
introduced into monolayers of cells in vitro (Dewor et al., 2007).  For this 
investigation, the authors used MEFs or human foreskin dermal fibroblasts 




MEFs) and from WT mice (MIF+/+ MEFs).  These cells were grown in monolayers 
and then scraped with a rubber policeman when they reached cell confluency, 
followed by an immediate addition of 50 ng/ml rMIF.  Two hours post-rMIF 
administration, the authors observed that both MIF-/- MEFs and MIF+/+ MEFs 
treated with exogenous MIF increased their motility significantly when compared 
to those without rMIF.  In contrast, prolonged exposure (24 hours) of the cells to 
the same concentration of rMIF showed a slight inhibitory effect in migration 
compared to the cells without rMIF.  The same experiments were conducted with 
HFDFs in the presence of mitomycin C, a proliferation blocking agent, and the 
same results were obtained as with MEFs, in which transient treatment (2 hours) 
of HFDFs with 50 ng/ml rMIF promoted migration, whereas prolonged MIF 
treatment had an inhibitory effect in HFDFs.  Immunostaining analysis of HFDFs 
with DAPI and anti-Ki67 showed that the rMIF-stimulated wound closure 
response in HFDFs was predicated upon its proliferative effect.  Besides CD74 
(see chapter 3), the best known receptor for MIF, two additional receptors, 
CXCR2 and CXCR4, were recently discovered; MIF acts as a non-cognate ligand 
for these receptors (Bernhagen et al., 2007), which will be discussed in more 
detail in the following section.  Binding of MIF to CXCR2 and CXCR4 promotes 
the chemotactic migration of leukocytes through a G-protein coupled receptor 
(GPCR)-mediated receptor pathway, in which both CD74 and calcium signaling 
are also involved (Bernhagen et al., 2007).  The authors detected the expression 
of both CD74 and CXCR4, but not CXCR2, in the fibroblasts in their study.  They 




calcium signaling.  They demonstrated that treatment of MIF-/- MEFs with rMIF 
induced a rapid calcium transient influx within a few seconds, while chronic 
exposure (2 hours) of the cells to rMIF down-regulated the calcium transient 
influx.  Additional studies have shown that CXCR4 also interacts with its cognate 
ligand, stromal cell-derived factor-1 (SDF-1); these interactions are implicated in 
both fibroblast migration and in dermal wound healing responses (Kucia et al., 
2004, Avniel et al., 2006), although there is no information yet available for the 
actual mechanism or interactions of MIF/CXCR4 in fibroblast migration and 
wound healing (Dewor et al., 2007).  Further studies need to be done in order to 
determine the precise contributions of these MIF receptors in MIF-mediated 
wound closure responses as well as in the effects of MIF on SAG neurite 
outgrowth and survival described in these studies (see chapters 2 and 3).        
b. Nerve regeneration: The processes of both nerve degeneration and 
regeneration seen after peripheral nerve injury (Nishio et al., 2002) are complex.  
During the process of degeneration, both the axon and its myelin sheath 
disintegrate and are digested by Schwann cells (and possibly macrophages 
drawn to the site of injury by release of MIF by SC) during a phagocytotic 
process, followed by extensive Schwann cell mitosis in the distal stump after 
peripheral nerve injury, indicating that axonal re-growth is dependent on the 
survival and proliferation of Schwann cells (Nishio et al., 1999, Nishio et al., 
2002).  Macrophages also play a pivotal role in the nerve degeneration-
regeneration processes by producing cytokines, stimulating Schwann cell 




role to concentrate macrophages at these inflammatory sites (Bloom and Bennett, 
1966, David, 1966).    
Nishio et al. detected an expression of MIF in the rat sciatic nerve at both 
the mRNA and protein levels (Nishio et al., 1999).  Immunohistochemical 
analysis demonstrated MIF expression in Schwann cells migrating into neuronal 
fibers, where the SC are also sources of MIF protein.  Further, the authors 
observed an elevation of MIF mRNA in both proximal and distal nerve segments 
12 hours post-nerve transection that remained elevated for 7 days (Nishio et al., 
1999).  Additional studies demonstrated that MIF plays an essential role in rat 
peripheral nerve regeneration (Nishio et al., 2002).  The authors conducted 
functional experiments with rat sciatic nerve.  Rats were treated either with anti-
MIF antibody or with non-immune rabbit IgG following sciatic nerve transection.  
A significantly shorter length of the regenerating nerve was observed in the anti-
MIF treated nerves compared to the controls (Nishio et al., 2002).  
Immunostaining demonstrated that this was apparently due to a pro-apoptotic 
effect in nerves treated with anti-MIF antibody.  The authors observed a 
decrease in the number of Ki-67 positive (a measure of cell proliferation) cells 
along with the upregulation of proapoptotic genes, such as p53 and Fas, in the 
nerves treated with anti-MIF antibody compared to the untreated controls.         





Mechanisms of MIF 
MIF was first identified in the early 1960s, in the cells and critical cellular 
processes in the immune system (Bloom and Bennett, 1966, David, 1966).  
However, it took some time to identify a possible receptor for MIF and to obtain 
information concerning the intracellular signaling cascades involved when MIF 
concentrations increase (Bach et al., 2009).  Expression cloning and functional 
analysis from Leng et al. contributed to the identification of CD74 as a MIF 
receptor (Leng et al., 2003).     
CD74, also called the MHC class II associated invariant chain (Ii), is a type 
II transmembrane glycoprotein.  In normal tissues, CD74 is expressed on HLA 
class II positive cells, such as B cells, monocytes, macrophages and thymic 
epithelial cells.  Under inflammatory conditions, its expression is observed on 
endothelial as well as some epithelial cells (Stein et al., 2007).  CD74 is been 
best known as an enzyme transporter, shuttling enzymes from the Golgi 
apparatus to the endoplasmic reticulum (Bach et al., 2009).  Given that CD74 is 
also abundant on the cell surface, it appears very likely that it also serves as a 
receptor for MIF (Bach et al., 2009).  Later studies found that the complex of MIF 
and CD74 binds to another cell-surface receptor, CD44, and that this binding is 
required to activate ERK½-MAPK signaling pathway (Shi et al., 2006).  This is 
mediated by Src kinase (Shi et al., 2006) and results in phosphorylation of the 
retinoblastoma (Rb) gene and subsequent cell proliferation as shown in Figure 





Figure 1.7: Intracellular mechanisms of MIF. MIF action is mediated in part by 
the CD74/CD44 receptor complex and leads to activation of ERK½-MAPK 
pathway. This is mediated by activation of Src tyrosine kinase and results in 
phosphorylation of the Rb gene and subsequently affects cell proliferation.  In 
addition, MIF interacts directly with the c-Jun activation domain–binding protein-1 
(Jab1).  Jab1 is necessary for ERK activation, while excess Jab1 expression 
inhibits its activation (Bach et al., 2009). 
 
 
In addition to interactions with CD74 and CD44, MIF has been shown to 
be a noncognate ligand for CXCR2 and CXCR4 by Berhagen and colleagues 
(Bernhagen et al., 2007).  The CXCR receptors are potential additional functional 
receptors for MIF.  Shen et al, in our laboratory, have also noted a potential 
interaction between the two mif receptors in the zebrafish with CXCR4 and with 
CXCR2.  In this context, MIF competes with the cognate ligands for these 
receptors, CXCL 1 and 8 for CXCR2 (Bernhagen et al., 2007, Schober et al., 
2008, Beswick and Reyes, 2009) and CXCR12 for CXCR4 (Schober et al., 2008).  
CXCR2 is commonly expressed on macrophages and functions in recruiting 




2009).  Besides its expression in the immune system, CXCR2 expression has 
also been detected in the nervous system (Horuk et al., 1997, Giovannelli et al., 
1998, Luan et al., 2001, Valles et al., 2006).  Developmental studies have shown 
that CXCR2 is expressed throughout the mouse brain during early development 
(Luan et al., 2001) and CXCR2-/- mice exhibited reduced numbers in 
oligodendrocyte lineages, myelination, and white matter in the vertebrate CNS 
(Padovani-Claudio et al., 2006).  CXCR4 is a G-protein coupled receptor for 
SDF-1/CXCL12 (Ganju et al., 1998, Vera et al., 2008), which is functionally 
expressed on the cell surface of various types of cancer cells, and also plays a 
role in cell proliferation and migration of these cells (Burger and Kipps, 2006) as 
previously discussed.  Colocalization and coimmunoprecipitation studies 
demonstrated that CXCR2 is colocalized and physically interacts with CD74 
(Bernhagen et al., 2007), while a different study reported that CXCR4 is 
associated with MIF in the rat bladder in the urothelium and this association 
increases in experimentally induced cystitis (Vera et al., 2008).  In the developing 
mouse CNS, CXCR4 expression is detected as early as E8.5 and its expression 
is also found in adulthood (McGrath et al., 1999, Tissir et al., 2004, Lieberam et 
al., 2005).  Abnormal development of the cerebellum (Zou et al., 1998), the 
hippocampal dentate gyrus (Lu et al., 2002) and uncontrolled initial motor axon 
trajectories (Lieberam et al., 2005) have been reported in CXCR4 KO mice.   
Besides MIF’s binding to those specific receptors, Kleemann and 
colleagues discovered an unconventional cellular function to account for the 




protein 1, Jab1, when the extracellular MIF concentrations are high (Kleemann et 
al., 2000).  In this case, MIF is taken up into target cells by endocytosis 
(Kleemann et al., 2000).  Jab1 functions in the activation of activation protein 1 
(AP-1), a transcription factor that activates pro-inflammatory genes, and in 
promoting the degradation of p27kip1, a protein that controls the cell cycle (Baugh 
and Bucala, 2002a).  The physical interaction of MIF with Jab1 modulates both 
the roles of Jab1 in the AP-1 pathway and in cell cycle progression (Kleemann et 
al., 2000, Lue et al., 2006).  Further studies demonstrated that the role of MIF in 
ERK signaling activation is a dose-dependent (Lue et al., 2006).  MIF can 
activate ERK phosphorylation at lower concentrations in the range of 50-100 
ng/ml in fibroblasts, which could physiologically occur in the inflammatory context, 
while exceedingly higher concentrations in the upper ng/ml to µg/ml range of MIF 
act as inhibitory in these cells (Lue et al., 2006).  According to the authors, MIF 
would act to impair a previously initiated signaling process and might possess a 
“switch-off” mechanism when MIF is present at high concentrations (Lue et al., 
2006).  In addition, the authors indicated that this feedback response may involve 
MIF endocytosis as well as a Jab1 mediated process based on their results that 
application of high concentrations of MIF to the fibroblasts for several hours could 
lead to increased p27 levels and cell cycle arrest.  Further, they demonstrated 
that Jab1, in fact, can exert a dual effect on MIF-induced ERK signaling (Lue et 
al., 2006).  They found that both the overexpression of Jab1 and a high 
concentrations of exogenous MIF led to an inhibition of ERK phosphorylation, 




ERK1/2 phosphorylation, indicating that Jab1 also appears to be necessary for 
the effects of MIF on transient ERK signaling activation (Figure 1.7) (Lue et al., 
2006).    Our laboratory is presently investigating the possible role of Jab1 in 
inner ear development and cell differentiation (Linn et al, in preparation) and has 
found that Jab1 is expressed in the inner ears of developing zebrafish as well as 
in the developing nervous system (Linn et al, in preparation).  Furthermore, Jab1 
was found in ODF in proteomic screen and was also found to interact with MIF in 
a yeast 2-hybrid screen for MIF interacting proteins (Thompson, Beck, Flynn and 
Barald, manuscript in preparation).  
All these intriguing roles of MIF in neurulation, neuronal development, 
pathfinding and cell migration and the discovery that MIF is a major component 
of the otocyst-generated ODF, prompted us to determine the role of MIF and its 
receptors and interacting proteins in inner ear development.  The following 
chapter details the role of MIF in the development of the mouse and chick inner 
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The cytokine, Macrophage Migration Inhibitory Factor (MIF), acts as a 
neurotrophin for neurons in the developing inner ear 
 
Abstract 
We have discovered that a key signaling factor in early inner ear neuronal 
development is an immune system “inflammatory” cytokine, macrophage 
migration inhibitory factor (MIF).  As this study demonstrates, MIF acts as a 
neurotrophic factor at the earliest stages of inner ear development.  MIF is a 
major bioactive component of the embryonic otocyst derived factor (ODF), which 
is produced by the otocyst (the primitive inner ear) for a brief time during its early 
development.  ODF promotes both neurite outgrowth in and neuronal survival of 
embryonic statoacoustic ganglion (SAG) neurons.  In the present study, MIF 
protein and bioactivity were detected in ODF generated from both the mouse and 
chick inner ear and in ODF generated from Immortalized Otocyst (IMO) cell lines 
derived from the 9.5 day Immortomouse otocyst.  IMO ODF mimicked the activity 
of otocyst-generated ODF in SAG neuronal cultures.  MIF protein also elicited a 
neuron-like morphology from mouse embryonic stem cells (mESC).  MIF was 




supporting cells (SC) of the mature inner ear, which underlie the sensory hair 
cells (HC). The MIF receptor, CD74, was detected on developing SAG neurons 
and on the mature form of these neurons, the spiral ganglion neurons (SGNs) 
that innervate the HC of the inner ear.   Evidence demonstrating a requirement 
for MIF in normal inner ear development was also found in MIF knock-out (KO) 
mice.  These mice are hearing-impaired with a corresponding reduction in SGN 
density as well as some SC and HC loss in the high frequency region of the 
cochlea (48kHz).  Neurites from spiral ganglion (SG) explants extend 
directionally in culture toward an excised wild-type (WT) Organ of Corti (OC), but 
not toward the isolated MIF KO OC, further demonstrating a role for this cytokine 
in neural development.   Together, these data demonstrate that MIF is a cytokine 
protein necessary for normal formation and innervation of the inner ear. 
 
Introduction 
New links between the neural and immune systems continue to be 
discovered, and in recent years, it has been demonstrated that the neural and 
immune systems interact to direct normal organismal development and function 
(Armstrong et al., 2003, Siemion et al., 2005, Wrona, 2006).  Our labs have been 
investigating the neurotrophic role of immune system chemokines and cytokines 
in the earliest stages of neuronal innervation (Bianchi et al., 2005), using the ear 
as a model system (Bianchi and Cohan, 1991, Barald et al., 1997, Germiller et al., 




macrophage migration inhibitory factor (MIF) acts as a neurotrophic factor for the 
developing inner ear. 
Previous studies indicated that cells in the otocyst secrete a factor or 
factors that support(s) the outgrowth and survival of the statoacoustic ganglion 
(SAG) neurons that innervate inner ear sensory cells (Bianchi and Cohan, 1991, 
1993).  The stages at which otocyst derived factor (ODF) is released correspond 
to the period of initial neurite outgrowth from the SAG [Embryonic day (E)4-6 in 
the chick, E11-14 in the mouse and rat (Bianchi and Cohan, 1991, 1993, Bianchi 
et al., 1998, Bianchi et al., 2000)].  Because so little ODF can be obtained from 
embryonic otocysts, we developed immortalized otocyst cell lines from the 
embryonic day 9.5 Immortomouse otocyst (IMO) cells (Barald et al., 1997), which 
secrete a functionally bioactive ODF equivalent (Thompson et al., 2003, 
Germiller et al., 2004, Bianchi et al., 2005).  This system initially allowed us to 
identify the cytokine monocyte chemotactic protein-1 (MCP-1) as an active, but 
not the sole, component of ODF (Bianchi et al., 2005).  We now demonstrate that 
MIF is the major bioactive component of ODF and plays a vital neurotrophic role 
in normal early inner ear development and innervation, promoting both the 
directional neurite outgrowth of statoacoustic ganglion neurons and neuronal 
survival.  It is both necessary and sufficient for these functions.  MIF is expressed 
in and released by the early stage inner ear (otocyst) in both the mouse and 




The absence of MIF in MIF knock-out (KO) mice caused hearing loss as 
well as structural abnormalities in the cochlea and loss of supporting cells (SC), 
hair cells (HC) and spiral ganglion neurons (SGNs).  Hearing impairment, HC 
and SGN loss are also seen in MCP1 KO mice, although MCP1 alone did not 
promote directional neurite outgrowth from excised SAG, although it contributes 
to the survival of dissociated SAG (Bianchi et al., 2005).  Together, these data 
demonstrate that the chemokines MIF and MCP1 play critical roles in cochlear 
development and innervation, directly demonstrating another important 
connection between the immune and neural systems. 
 
Materials and experimental methods 
Cell cultures and conditioned medium (CM) collection: Immortomouse 
otocyst (IMO) cells which had been generated from the H2kbtsA58 transgenic 
mouse as previously described (Barald et al., 1997, Thompson et al., 2003, 
Germiller et al., 2004) were cultured as described in those reports.  A subcloned 
cell line from one of these IMO cell lines, called 2B1DT cells (Germiller et al., 
2004), was initially grown at 32°C in Chick embryo fibroblast (CEF) medium 
containing 4 % fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) 
and 1 unit of γ-interferon (Chemicon International, Inc., Temecula, CA) on 100 
mm Primaria culture plates (Fisher Scientific, Pittsburgh, PA) to allow the cells to 
proliferate.   When cells reached approximately 70 % confluency, the medium 




incubated an additional 5 days at 32°C.  During the incubation and CM collection, 
1 unit of γ-interferon was replenished every other day in these cultures.  CM was 
collected on the fifth day in a siliconized falcon test tube (Fisher Scientific, 
Pittsburgh, PA) to minimize loss of active components that might stick to the 
surface of the tube.  The CM was stored at 4°C until use.  CM without γ-
interferon was similarly collected in parallel experiments.   
The D3 (NF11/1) mouse embryonic stem (mES) cell line (Doetschman et 
al., 1985) was also cultured as described by Roth et al. (Roth et al., 2007) to 
assess an effect of MIF bioactivity on differentiation.  In brief, D3 cells in ES 
proliferation medium  [81% Dulbecco's Modified Eagle (DME) medium without 
phenol red, 1% L-Glut, 1% Pen/Strep, 1% nonessential amino acids (Gibco, 
Carlsbad, CA), 15% FBS (Atlanta Biological, Nor-cross, GA), 1% sodium 
pyruvate (2% stock), 7 µL/L β-mercaptoethanol (Sigma, St. Louis, MO), 1,000 
U/mL ESGRO (Chemicon, Temecula, CA] were plated onto Primaria (Falcon) 
plates (Fisher Scientific, Pittsburgh, PA), incubated at 37°C and allowed to attach 
overnight.  The following day, cells were washed with phosphate buffered saline 
(PBS) once and placed in neuronal differentiation medium [95%F-12, 1% 
Pen/Strep, 1% N2, 2% B27 (Gibco), 2% sodium pyruvate (2% stock)].  Test 
media consisted of either 1 µg/L ciliary neurotrophic factor (CNTF) (R & D, 
Minneapolis, MN), 1 µg/L nerve growth factor (NGF) (Chemicon, Temecula, CA)], 
or various concentrations (1 to 500 pg/ml) of mouse/human recombinant MIF 




were fed with differentiation medium containing rMIF every other day during 
differentiation.   
In addition, dissociated inner ear cultures were prepared from E13/14 
mouse embryos as described in the previous reports (Bianchi et al., 2002, 
Bianchi et al., 2006) with minor modifications.  Briefly, the inner ears were 
dissected from E 13-14 CD-1 mouse embryos (Hilltop Labs, Scottdale, PA).  
After removal of the surrounding mesenchyme and SAG, the inner ears were 
transferred to a dish of DME medium, followed by the separation of cochlear 
regions from vestibular ones.  Pooled inner ear tissues (cochlear vs. vestibular) 
were rinsed three times with PBS, then incubated at 37°C in 0.1% trypsin in PBS 
for 10 minutes with DNase (80 U/ml) (Sigma, St. Louis, MO) added during the 
last 5 minutes of incubation.  The inner ears were rinsed in PBS, then incubated 
in 0.1% trypsin inhibitor for 10 minutes at 37°C.  The pooled cells were 
resuspended in the DME medium and further dissociated by trituration with fire 
polished pipets.  Once the cells were sufficiently dissociated, they were plated 
onto poly-D-lysine coated 48-well plates (Fisher Scientific, Pittsburgh, PA) in 
defined culture medium at a density of 700,000 cell/cm2.  If used in 
immunohistochemical assays, the cells were fixed for 10-20 minutes in 10% 
neutral buffered formalin after the designated culture period.   
Otocyst excision and otocyst CM collection: CM was also collected from 
chick otocysts at embryonic day 4-5 (E4-5) based on the method of Bianchi and 




otocysts from E4-5 chick were collected and incubated in a 250µl of either CEF 
medium without serum, γ-interferon or DME (serum free) medium (Fisher 
Scientific, Pittsburgh, PA) at 37°C for 3 days.  After centrifugation at 10,000 rpm 
at room temperature for 1 minute, the supernatant was transferred into a low 
protein binding microtest tube (DENVILLE Scientific INC, Metuchen, NJ) and 
stored at 4°C until use either for proteomic studies or in bioassays.        
Neurite outgrowth and survival of SAG neurons in vitro: To determine the 
effects of conditioned media obtained either from 2B1DT cells or otocysts on 
SAG neurite outgrowth and survival, bioassays were performed as in Bianchi et 
al., 2005 with minor modifications (Bianchi et al., 2005).  Briefly, whole SAGs 
were excised from chick embryos at E5 and placed on a poly-D-lysine (Fisher 
Scientific, Pittsburgh, PA) coated 96 well plate to evaluate SAG neurite outgrowth.  
The plate was then incubated at 37°C for 72 hours and the scoring mechanism in 
Bianchi et al., 2005 was applied to assess the extent of neurite outgrowth.  To 
examine SAG neuron survival, individual SAG neurons were prepared by pooling 
dissociated cells from 25-30 ganglia.  First, the isolated ganglia were washed 
with calcium-free PBS (3x) followed by centrifugation at 10,000 rpm for 1 minute 
and aspiration of supernatant.  Then, the ganglia were incubated with PBS 
containing 0.025 % trypsin (Invitrogen, Carlsbad, CA) at 37°C for 10 minutes with 
inversion or swirling.  After centrifugation and aspiration of trypsin-containing 
PBS, the cells were incubated with PBS containing 0.1 % trypsin inhibitor (Sigma, 
St. Louis, MO) at 37°C for 10 minutes.  Ganglia were rinsed once with either 




were resuspended in defined medium and dissociated by trituration with a fire-
polished glass pipet.    
The individual cells were plated on poly-D-lysine coated 96 well plates at a 
density of 10,000 cells per well (determined by haemocytometer counts).  Cells 
were incubated at 37°C until they became attached to the plate.  After cell 
attachment, the medium was replaced with CM or control medium (identical 
medium which had not had otocyst or cell contact, but which had been incubated 
for the identical number of days) +/- γ-interferon and incubated at 37°C for 48-72 
hours. 
SAG assays were also performed with either mouse/human rMIF (R&D, 
Minneapolis, MN) in basal media or in bio-inactive IMO conditioned medium 
(prepared from IMO cell lines that do not produce ODF) at concentration range of 
5 pg/ml – 500 ng/ml or 2 ng/ml -200 ng/ml respectively to determine if there was 
an effect on SAG neurite outgrowth and survival.  SAG neurite outgrowth was 
observed and scored after 24, 48 and 72 hours based on a standard scale of 0-5 
described by Bianchi et al. (2005) and the percentage of SAG neurons surviving 
was calculated after 48-72 hours following immunostaining.  For this assay, all 
samples were done in triplicate, but randomly assigned to wells on the plate (e.g. 
no triplicate conditions were next to one another).  Function-blocking anti-mouse 
MIF antibody (R&D, Minneapolis, MN) followed by protein G beads were added 





Organotypic co-cultures of postnatal OC with SGNs: Organotypic co-culture 
assays of the OC with SGNs were performed to assess neurite outgrowth from 
WT SAGs or SG toward the cochleae isolated from either WT (Balb/C) mice or 
MIF KO mice.  The inner ears were isolated from mice at postnatal day 3 (P3) as 
described by Chen et al. (Chen et al., 2009).  The cochlea were then carefully 
isolated and immersed in cold PBS.  After removal of the bone surrounding the 
cochlea, the lateral wall tissues, including the stria vascularis and spiral ligament, 
and the auditory nerve bundle were dissected away leaving the OC and SG, 
which were separated.  The freshly excised OC explants either from WT or MIF 
KO mice were then placed with the freshly excised SGNs from WT mice into 35 
mm culture dishes (Fisher Scientific, Pittsburgh, PA) coated with 15 µl of 
polymerized rat tail collagen solution (BD, Franklin Lakes, NJ) in 50 µl of DME 
medium.  The small amount of medium was added to prevent the tissues from 
drying.  The tissues were observed daily by light microscopy for the ensuing 7 
days.                
Preparation of sectioned cochlear epithelium: Mice were decapitated 
immediately after being euthanized with CO2.  Both temporal bones were then 
extracted and the cochleae were placed into 4% paraformaldehyde (PFA) (Sigma, 
St. Louis, MO) for fixation overnight at 4˚C on a Nutator (BD, Franklin Lakes, NJ) 
(Campos-Barros et al., 2000) with minor modifications.  The next day, the 
cochleae were rinsed in PBS, followed by decalcification by placing them in 5% 
ethylenediaminetetraacetic acid (EDTA) at 4˚C on a Nutator.  EDTA was 




Following decalcification, the cochleae were placed in 30% sucrose in 1x PBS 
solution until they sank in the solution.  After washing with fresh 30% sucrose 
solution, the cochleae were incubated in a 1:1 mixture of 30% sucrose solution 
and OCT until they sank.  The cochleae were then transferred to embedding 
molds containing 100% OCT and were frozen on dry ice with isopentane.  The 
frozen specimens were stored at -80˚C until cryosectioning.  The tissues were 
sectioned at 8 µm and placed onto two sets of Superfrost slides (One set serves 
as the experimental and the other serves as control for MIF and MCP1 [stained 
for IgG (Zymed, San Francisco, CA)].  Sectioned tissues were stored at -20˚C 
until staining with MIF and MCP1. 
Auditory brainstem response (ABR) assessment: Auditory brainstem 
responses (ABRs) were assessed for WT (Balb/C) (n=5) and MIF KO mice (n=4) 
at 4 weeks of age as described by Saul et al. (Saul et al., 2008).  Briefly, animals 
were anesthetized with an intraperitoneal injection of ketamin (65 mg/kg), 
xylazine (3.5 mg/kg) and acepromazine (2 mg/kg).  Body temperature was 
maintained with heating pads and heat lamps.  Subdermal needle electrodes 
were placed at the skull vertex (active) and pinnae of the test (reference) and 
contralateral (ground) ears.  ABRs were recorded in an electrically and 
acoustically shielded chamber (Acoustic Systems, Glendale Heights, IL) and 
Tucker-Davis Technologies (Alachua, FL) System II hardware and SigGen/Biosig 
software were used to present stimuli and record responses. Tones were 




(Beyerdynamic, Mt. Prospect, IL) and were delivered by a speculum placed just 
inside the tragus. Stimuli were presented as 15 millisecond tone bursts, with 1 
msec rise/fall times, and were repeated 10 times per second.  Responses were 
collected at 12, 24 and 48 kHz for a range of stimulus levels, separated by 10 dB 
steps at higher intensities and 5 dB steps near threshold. Thresholds were 
interpolated between the lowest stimulus intensity producing a response, and the 
highest stimulus where no response was observed (5 dB increments).  
SG neuronal density measurements: SG neuronal density measurements 
were performed by the Kresge Hearing Research Institute P30 core at the 
University of Michigan on WT (Balb/C, control), MIF-/-, and MCP1-/- KO mice at 4, 
8, and 12 weeks post-birth.  Balb/C 4wk (n=5), Balb/C 8wk (n=3), Balb/C 12wk 
(n=6), MIF-/- 4wk (n=5), MIF-/- 8wk (n=5), MIF-/- 12wk (n=3), MCP1-/- 4wk (n=3), 
MCP1-/- 8wk (n=6), MCP1-/- 12wk (n=3).  Briefly, mice were decapitated and their 
bullae were rapidly removed.  The cochleae were opened at the base and apex 
and 4% PFA was gently introduced through scala tympani.  Cochleae were then 
placed into fixative for 12-48 hours, followed by rinse in PBS.  Cochleae were 
decalcified in 5% EDTA in PBS at room temperature for 24 hours, dehydrated 
through a graded series of alcohols and then processed for embedding into JB-
4Plus, a glycol methacrylate plastic (Electron Microscopy Sciences, Hatfield, PA).  
Five micron plastic sections were cut in a paramodiolar plane and each section 
was picked up and put on a slide.  Slides were rehydrated, dipped in Paragon 
[200ml 30% ethanol (Fisher Scientific, Pittsburgh, PA), 1.46 g toluidine blue 




Pittsburgh, PA)] for 1 minute, dehydrated in graded strengths of ethanol, dipped 
in Xylene (Fisher Scientific, Pittsburgh, PA) and coverslipped with Permount 
mounting medium.  The twelve most mid-modiolar sections were selected and 
every other sections was used for quantitative assessment.  Each selected slide 
was placed in the microscope and digital images were acquired into the 
Metamorph Image Analysis workstation (Molecular Devices, Sunnyvale, CA) 
under bright field optics.  The most basal profile of the Rosenthal’s canal was 
acquired at a low (2.5-10x) magnification.  The outline of the profile of the 
Rosenthal canal was circles to determine the total area using the Metamorph 
Image Analysis software.  Magnification was then increased (16-25X) for SG Cell 
counting.  Every SG neuron within Rosenthals Canal was “clicked” and counted.  
SG Neuron density was then calculated by dividing the number of SG cells by the 
area measured.  Each of the remaining 2 more apical profiles was then assessed 
as above and binned separately, proceeding from base to apex. The next section 
for the “assessment area” was then counted, with a total of six sections for each 
animal assessed. 
RT-PCR assays for MIF and CD74: RT-PCR was carried out to detect the 
expression of MIF in the embryonic and adult inner ear using Jump Start Taq 
(Sigma, St. Louis, MO) following the manufacturer’s instruction.  Equal amounts 
of mRNA form each sample was used for this reaction.  PCR conditions included 
an initial denaturation at 95°C for 1 min, 94°C for 30 sec, 55°C for 30 s and 72°C 
for 30 s and 35 cycles and final extension at 72°C for 5 min and 4°C holding 




the embryonic SAG and adult SG neurons in the same manner, except using 
annealing temperature at 58°C.  The PCR products were separated on 2.0% 
agarose gels and visualized using ethidium bromide under UV light.  The primer 
sequences of MIF and CD74 are as follows: 
MIF-Forward (F) = CCAGAACCGCAACTACAGTAAGC  
MIF-Reverse (R) = TTGGCAGCGTTCATGTCGTAATAG 
 
CD74-F = GCTTCCGAAATCTGCCAAACC 
CD74-R = AAGAGCCACTGCTTCATCCAGC 
 
For the loading control, water was added instead of reverse transcriptase.   
2-D gel electrophoresis: 2-D gel electrophoretic analysis was performed to 
identify the factor(s) in bioactive 2B1DT cell conditioned medium when compared 
to a bio-inactive medium (either medium that had been incubated with IMO cell 
lines that do not produce ODF, or medium alone, without cell or otocyst 
exposure).  Conditioned media were collected in the same manner as described 
above.  Conditioned medium was also collected from otocysts of chick and 
mouse.  For the chick, eight otocysts from embryonic chick were isolated at E 
day 4-5.  These otocysts were placed in groups of 8 in 250 µl of serum-free 
medium under identical conditions to those under which the IMO CM was 
produced.  The samples were then sent to the Proteome Center at the University 




proteomic analysis and protein identification through sequencing of selected 
spots cut from the 2-D gels (http://www.proteomeconsortium.org/).     
Immunocytochemistry (ICC): ICC was performed with whole and dissociated 
SAG neurons, ES cells and dissociated inner ear cells (E13-14). In cultures of 
whole and dissociated SAG neurons, SAG neurites in the 96 well plates were 
fixed with 100 µl of 4 % PFA solution for 20 minutes followed by a careful 
washing of the plate three times with PBS.  After aspirating PBS, 100 µl of PBS 
containing 3 % hydrogen peroxide was applied and incubated for 10 minutes.  
The plate was then incubated with 100 µl of PBT [PBS containing 1 % Bovine 
Serum Albumin (BSA) (Sigma,  St. Louis, MO) and 0.5 % Tween 20] for 1 hour 
followed by blocking with 100 µl of PBT containing 5 % Normal Goat Serum 
(NGS) (Invitrogen, Carlsbad, CA) for 30 minutes.  Then, the plate was incubated 
with 100 µl of Monoclonal Antibody against Neuronal Class III β-Tubulin 
(Covance, Berkeley, CA) diluted with PBT containing 5 % NGS (1:500) at 4°C 
overnight.  Twenty-four hours later, the plate was incubated with 100 µl of PBT 
containing 5 % NGS for 30 minutes after washing the plate with PBT (3x).  Then, 
a secondary antibody, goat anti mouse, (BioRad, Hercules, CA) diluted with PBT 
(1:500) was applied and incubated for 3 hours.  The plate was washed with PBT 
(3x) followed by PBS (1x).  Plates were labeled with 20 µl of AEC substrate 
(Zymed, San Francisco, CA) for 5 minutes or until color developed.  The reaction 
was then stopped by adding 20 µl of MilliQ water.  Micrographs were taken using 




experiment was performed under the hood at room temperature, except for the 
incubation with primary antibody at 4°C. 
D3 mES cells (differentiated into neuron-like cells with MIF and undifferentiated) 
were immunostained in the same manner as SAG neurons, with a few 
modifications.  Rabbit anti-neurofilament polyclonal antibody (1:400) (Chemicon, 
Temecula, CA) and goat anti-rabbit-HRP (1:500) (Zymed, San Francisco, CA) 
were used as a primary antibody and a secondary antibody respectively.   
In cultures of the dissociated inner ear, ICC was performed in the same manner 
as described above and the cells were double labeled for myosin VI (a marker for 
sensory hair cells) (10 ug/ml, T. Hasson, University of California San Diego) and 
MIF (1:3000) (Santa Cruz biotechnology Inc., Santa Cruz, CA). For cytokeratin (a 
marker for supporting cells) (1:100) (Sigma, St. Louis, MO) and MIF as reported 
in the previous studies (Bianchi et al., 2002, Bianchi et al., 2006).  Alexa Flour 
488 goat anti-rabbit (1:2000) (Molecular Probes, Eugene, OR) and Alexa Flour 
594 rabbit anti-goat (1:2000) (Molecular Probes, Eugene, OR) were used as the 
secondary antibodies for detection of myosin VI and MIF, while Alexa Flour 488 
goat anti-rabbit (1:2000) (Molecular Probes, Eugene, OR) and Alexa Flour 555 
goat anti-mouse (1:2000) (Molecular Probes, Eugene, OR) were used as the 
secondary antibodies for detection of MIF and cytokeratin.  Confocal images 





Sandwich ELISA for MIF: Sandwich ELISA assays were performed (Abcam, 
http://www.abcam.com/ps/pdf/protocols/Sandwich_ELISA.pdf) to determine MIF 
levels in conditioned media secreted from E5 chick otocysts and 2B1DT IMO 
cells.  First, 100 µl of 2.0 µg/ml of an anti-human MIF IgG monoclonal antibody 
(R&D, Minneapolis, MN) was dissolved in diluent reagent (PBS containing 1 % 
BSA) and added to each well of a 96 well plate (Nalge Nunc International, 
Rochester, NY).  The plate was left at room temperature overnight.  Next 
morning, the plate was washed (3x) with 150 µl washing buffer (PBS containing 
0.05 % Tween 20).  Then, the plate was blocked with 200 µl of diluent reagent 
per well for 1 hour followed by washing with washing buffer in the same manner.  
Next, 100 µl of test sample per well, as well as 100 µl recombinant mouse MIF 
antigen per well at a concentration range of 0.125 – 1.75 ng/ml were incubated to 
determine a standard curve.  This incubation was allowed to proceed for 2 hours.  
After removal of antigen followed by washing, 100 µl of 400 ng/ml Biotinylated 
Anti-human MIF antibody (R&D, Minneapolis, MN) was added to each well and 
incubated for 2 hours. Then, the plate was incubated with100 µl Streptavidin-
horse radish peroxide (HRP) complex (1:1,000) per well for 2 hours after washing 
(3x).  The plate was covered with aluminum foil to avoid exposure of the light-
sensitive substrate.  After incubation, the plate was washed again with washing 
buffer.  Then, 100 µl of tetramethylbenzidine (TMB) (Promega, Madison, WI) was 
added to each well and incubated for 15 minutes.  During the incubation, the 
plate was kept covered with aluminum foil.  The reaction was stopped by adding 




was read at 450 nm using a Halogen BELLAPHOT plate reader (Fisher Scientific, 
Pittsburgh, PA).  The entire assay was performed at room temperature and all 
samples were done in triplicate. 
Immunohistochemistry: Embryonic sectioned inner ear tissues were labeled for 
MIF.  Tissues were incubated at a 1:1 ratio of ice cold acetone and methanol for 
1 minute followed by 5 minute air dry.  After washing with PBST for 2 minutes 
twice, a barrier was circumscribed around the tissue slice on the slide with a pap 
pen (Fisher Scientific, Pittsburgh, PA) to minimize the reagents used.  Then, the 
tissues were blocked against non-specific binding by the secondary antibody by 
incubation in 3% normal donkey serum for 30 minutes.  The tissues were 
incubated in rabbit anti-MIF antibody (1:3000) (Zymed, South San 
Francisco, CA) for 1 hour.  After rinsing with PBST three times, sections were 
incubated with goat anti-rabbit Alexa Flour 594 (1:200) (Molecular Probes, 
Eugene, OR) for 30 minutes.  After washing three times with PBS, the sections 
were coversliped in Prolong Gold Antifade reagents (Invitrogen, Carlsbad, CA), 
warmed to room temperature and observed with a fluorescence microscope.  
Negative controls lacked primary antibody.  All steps were done at room 
temperature in a humidified chamber.           
Adult sectioned cochleae (WT mice) were stained in the same manner as the 
embryonic specimens, with a few modifications.  Adult tissues were double-
labeled for MIF and MCP1.  After blocking with 3% normal donkey serum, the 




biotechnology Inc., Santa Cruz, CA) and goat anti-MCP1 antibody (1:100) (R&D, 
Minneapolis, MN) for 30 minutes followed by washing  (3x/ x min/wash) in PBST.  
Then, the tissues were incubated in donkey anti-rabbit Alexa Flour 555 (1:200) 
(Molecular Probes, Eugene, OR) and donkey anti-goat Alexa Flour 488 (1:200) 
(Molecular Probes, Eugene, OR) for 30 minutes. Photographs were taken 
sequentially using a Leica phase contrast microscope (Leica, Hicksville, NY).  
Statistical analysis: All data, except for the cytocochleogram analysis (OHC 
loss percentage), were analyzed by one-tail t-test.  Multiple comparisons Kruskal-
Wallis test with family alpha was used for the cytocochleogram analysis.  A 




Conditioned medium (CM) from IMO cells and embryonic chick otocysts 
enhanced SAG neurite outgrowth and survival. 
  Earlier studies demonstrated that CM or “otocyst-derived factor” (ODF) 
from chick, mouse and rat promoted directional neurite outgrowth and survival of 
early stage statoacoustic ganglion (SAG) neurons (Ard et al., 1985, Lefebvre et 
al., 1990, Bianchi and Cohan, 1991, 1993). SAG explants from E5 chick embryos 
were plated on poly-D-lysine-coated 96-well plates [as previously described; 




CM (otocyst-generated ODF), serum free IMO 2B1 CM (IMO-generated ODF +/- 
γ -interferon), or serum free basal medium.  After 48 hours in culture, SAG 
neurite outgrowth was scored using the scoring scale of 1 (no neurite outgrowth) 
to 5 (long, dense radial growth), developed by Bianchi et al. (Bianchi et al., 2005).  
Individual SAG explants treated with IMO-generated ODF or chick otocyst-
generated ODF showed robust neurite outgrowth, with mean scores of 4.1 in 
otocyst-generated ODF and 3.9 in IMO-generated ODF after normalization 
(Figure 2.1-B, C and G).  In contrast, the explants with basal medium or basal 
medium + γ -interferon showed little neurite outgrowth (Figure 2.1-A).  Statistical 
analysis demonstrated that both ODFs produced outgrowth significantly greater 
than basal medium (p < 0.05).    
 Dissociated neuron assays were performed with E5 chick SAGs to evaluate the 
effect of ODFs on neuronal survival.  Survival of SAG neurons was determined 
after 48-72 hours in culture after staining with anti-Tuj1 antibody (Figure 2.1-D, E, 
F and H).  After 48 hrs, 13% and 18% neurons respectively were Tuj-1 positive in 
the presence of otocyst-generated ODF and IMO-generated ODF after 
normalization (Figure 2.1-H).  Significant neuronal survival in ODFs was 
observed along with extended neuronal processes from individual cells 
compared to basal control medium, in which the cells were dead and no neurite 
outgrowth was observed (p < 0.05).  Together, these bioassays confirmed that 
both ODFs promote SAG neurite outgrowth and survival, but that we were able to 








Figure 2.1: (Top row): Chick SAG Neurite Extension: Neurites extend from E5 
chick SAG in the presence of conditioned medium from either otocyst-generated 
ODF (B) or IMO-generated ODF (C) compared to lack of neurite outgrowth in 
basal medium (A).  (Middle row): Survival of Dissociated SAG neurons: Neurons 
from E5 chick survive and extend neuronal processes in Otocyst-generated ODF 





extend neurites in basal medium (D).  (Bottom row): The quantification of extent 
of neurite outgrowth demonstrates that shows that both IMO- and otocyst-
generated ODFs significantly enhance SAG neurite outgrowth (G).  SAG 
neuronal survival in otocyst-generated or IMO-generated ODF is also 
significantly enhanced compared to control (H). (p < 0.05).  
 
MIF is a major bioactive protein component of the ODF.   
IMO-generated ODF identified in the previous assays as having bioactivity 
were then compared to inactive CM from IMO cells that do not produce ODF or 
to medium alone by 2D gel analysis and a subsequent proteomic screen in which 
components of the active fraction were identified on the gels, cut out, subjected 
to MALDI/TOF/TOF spectroscopy and sequenced by the University of Michigan 
Proteomics Core (http://www.med.umich.edu/mgpc/cores/ppc.htm#tdge).  MIF 
was found in all the biologically active, but not inactive, samples (Figure 2.2) from 
both IMO-generated and otocyst-generated ODF.  Proteomic analysis also 
confirmed the presence of MCP-1 (Figure 2.2), which we previously detected 
using a cytokine protein array (Bianchi et al., 2005).  The arrays we used in the 
2005 study did not include MIF.  A yeast 2-Hybrid screen was also performed 
(data not shown) that also confirmed that MIF and MCP1 are potentially 
interacting proteins.  This data will be reported elsewhere.  The proteomic 
comparisons were also conducted with chick otocyst-generated ODF and the 
same results were found (data not shown).  Following the identification of MIF 
and MCP-1 in ODFs, sandwich ELISA assays were performed to quantify both 




concentrations of MIF [1.14 ng/ml (n = 39)] and MCP-1 [1.27 ng/ml (n = 6)] in 
otocyst-generated ODF were similar to those found in IMO-generated ODF, 
where the concentration of MIF was 2.43 ng/ml (n = 6), while that of MCP-1 was 
1.22 ng/ml (n = 6).     
 
 
Figures 2.2: Proteomic analysis of bioactive ODF from IMO CM demonstrates 
that both MIF and MCP1 are expressed in bioactive CM prepared from IMO-
generated ODF.  Two-D gel comparison of Active (represented in pink) vs. 
Inactive (represented in green) CM from IMO 2B1 (active) and IMO 3C6 
(inactive) CM, determined in bioassays of E5 chick SAG neurite outgrowth and 
survival.  The spots represented in the active but not inactive CM were cut out 
and identified by the Protein sequencing/Proteomics facility at U of M.  Spot 25 is 
MCP1 and Spot 28 is MIF.  These proteomic comparisons have been repeated 






Cytokines Experimental approaches 








Cytokine array  
Proteomics 
IHC, ISH, Y2H 
 
Table 2.1: Summary of the two major cytokines found in ODF and the 
experimental approaches used to identify and verify these cytokines.  
IHC=Immunohistochemistry with an anti-MIF antibody and fluorescent secondary 
antibodies used to label the developing mouse inner ear between stages 11.5 
and 17.5; PCR: real time quantitative PCR (see methods); Y2H a yeast two 
hybrid analysis using each cytokine in turn as bait (MCP1 or MIF) was also 
performed (data not shown).  
  
Recombinant (r) MIF mimics the bioactivity of ODF in a dose-dependent 
manner. 
 
To characterize MIF’s role in neuronal extension and survival of SAG 
neurons in the developing inner ear, neuronal bioassays were conducted with 
various concentrations of either human or mouse recombinant (r) MIF.  MIF 
concentrations in a range of 5 pg/ml to 500 ng/ml were chosen based on the 
results of ELISA assays, which showed MIF concentration at 1.0 to 2.5 pg/ml in 
ODFs.  The concentration range chosen for testing was selected to be at least 
10x higher and lower.  Serum free basal medium and CM from E8-10 chick brain 




of rMIF on SAG neurite outgrowth and survival was dose-dependent (Figure 2.3).  
After 48 hours in culture, 5 pg/ml and 5 ng/ml of rMIF significantly enhanced SAG 
neurite outgrowth, while 50 pg/ml MIF promoted SAG neuron survival 
significantly compared to basal control (p < 0.05).  In contrast, higher 
concentrations (500 ng/ml) of rMIF either had no effect or inhibited both SAG 
neurite outgrowth and survival after 48 hours in culture (see discussion for 
proposed explanation).    
 
 
Figure 2.3: rMIF from either human (R&D, Mineneapolis, MN) or mouse (R&D, 
Mineneapolis, MN) enhances both SAG neurite ougrowth and survival in a dose-
dependent manner.  After 48 hours in culture, 5 pg/ml and 5 ng/ml of rMIF 
significantly enhanced SAG neurite outgrowth compared to control (p < 0.05) (left 
plot).  50 pg/ml of rMIF promoted SAG neuron survival significantly compared to 
basal control (p < 0.05) (right plot).  In contrast, higher concentrations (500 ng/ml) 
of rMIF have no effect or inhibited both SAG neurite outgrowth and survival after 
48 hours in culture.  Basal medium was used as the negative control and CM 
from E8-10 chick brain was used as the positive control. (p < 0.05), n= 20 




 Postnatal mouse SGNs were also examined for any effect of rMIF on 
neurite outgrowth/regrowth.  SGNs were isolated from the WT (Balb/C) mice at 
postnatal day 3 (P3) and cultured in serum free basal medium containing 5 ng/ml 
or 50 ng/ml rMIF.  As in assays of the embryonic SAG, serum free basal medium 
was used as the negative control and CM from E8-10 chick brains was used as 
the positive control in the assays.  After 48 hours in culture, SGNs in 50 ng/ml 
rMIF demonstrated significant neurite outgrowth compared to the negative 
control (p < 0.05) (Figure 2.4).  However, SG in 5 ng/ml rMIF also showed some 
degree of outgrowth, however, it was not statistically significant.  The results 
indicate that rMIF can promote neurite outgrowth not only from the embryonic 
SAG stage but also from postnatal SG.          
 
Figure 2.4: Mouse/human rMIF promoted WT (Balb/C) postnatal SG neurite 
outgrowth.  After 48 hours in culture, 50 ng/ml rMIF significantly enhanced SG 
neurite outgrowth (p < 0.05) compared to  the negative control (basal medium).  





MIF at as low a concentration as 1 pg/ml promotes the neuronal 
differentiation of mouse embryonic stem cells (mESC).   
 
To further explore the role of MIF in neuronal development, we examined 
the effect of MIF on neuronal development in the mouse D3 ES cell line 
(Doetschman et al., 1985).  Various concentrations (100 to 50 ng/ml illustrated in 
Figure 2.5) of rMIF were introduced to ES cells.  However, as low as 1 pg/ml of 
rMIF caused a subset of the ES cells, but not all, to become neuron-like after 48 
hours in culture.  The cells treated with rMIF developed long neurites that were 
neurofilament positive (Figure 2.5, D-I).  In contrast, the cells in the absence of 






Figure 2.5: Mouse D3 ES cells treated with MIF at the concentrations specified 
took on a neuron-like morphology within 48 hrs, elaborated long neurites and 
could be labeled with an antibody to neurofilament and a secondary HRP 
antibody.  Phase contrast (Leica) photograph (4x). Note that not all stem cells 
have become neuron neuron-like.  
 
Function-blocking antibodies to MIF inhibit ODF-induced SAG neurite 
outgrowth and prevent neuron survival. 
 
To determine whether MIF was an essential bioactive component of SAG 
neurite outgrowth and survival, functional-blocking assays were performed with 







protein G beads to remove MIF activity.  SAG explants treated with 10 ng/ml of 
rMIF produced neurite outgrowth with an average score of 4.1 (n=8), while the 
explants treated with MIF that had been pre-treated with the function-blocking 
anti-MIF antibody produced little if any  neurite outgrowth (n=7) as shown in 
Figure 2.6 (left).  In the assays of dissociated SAG neurons, measuring neuronal 
survival, IMO-generated ODF and 10 ng/ml rMIF demonstrated 67% (n=31) and 
77% (n=17) neuronal survival respectively (Figure 2.6, right). The antibody 
reduced dissociated SAG neuronal survival to background levels when used to 
treat rMIF (n=6), whereas some residual neuronal survival was seen after 
treatment of IMO-generated ODF with this function-blocking antibody (n=6) (see 
discussion).  Taken together, the results demonstrate that MIF is both necessary 









Figure 2.6: Function-blocking antibody-treated MIF, used in assays of SAG 
neurite outgrowth and survival.  10 ng/ml rMIF mimicked the bioactivity of IMO-
generated ODF.  Pre-treatment of MIF with a function-blocking anti-MIF antibody 
(R&D, Mineneapolis, MN) and protein G beads, substantially inhibited MIF’s 
neurite outgrowth-promoting activity.  Scoring of neurite outgrowth is according to 
Bianchi et al., 2005 (Left).  SAG neuronal survival was promoted by both IMO-
generated ODF and 10 ng/ml rMIF.  The same function-blocking antibody, which 
was used for the blockade of MIF’s ability to inhibit SAG neurite outgrowth was 
used to treat either rMIF or IMO-generated ODF.  The antibody reduces neuronal 
survival to background levels if used to treat rMIF, but some residual neuronal 
survival is seen after treatment of IMO-generated ODF with the function-blocking 
antibody and protein G beads (Right).  We hypothesize that this reflects the 
presence of additional bioactive cytokines such as MCP1 (see discussion). 
 
MIF is expressed in sensory epithelial regions of the developing and 
mature inner ear. 
 
Embryonic and adult mouse inner ears were examined for expression of 
MIF mRNA by RT-PCR and MIF protein by western blotting and 
immunohistochemistry.  Expression of MIF mRNA in the otic vesicle from E9.5 




MIF protein in IMO cells, isolated from E9.5 Immortomouse otocysts (discussed 
in Appendix).  Thus, our laboratory examined its expression at the mRNA level in 
the mouse E14 ear, during embryonic otic development and in adult inner ear 
tissues.  RT-PCR experiments demonstrated that MIF mRNA was expressed in 
both embryonic and adult inner ear tissues, including the cochlea (Figure 2.7) 
and ampullae (data not shown).    
 
 
Figure 2.7: MIF mRNA expression in cochlear tissues and SGNs.  Cochleae 
were removed from adult WT (Balb/c) mice. SG were separated from the 
remaining sensory epithelium.  RNA was isolated from the tissues and RT-PCR 
performed.  GAPDH expression, used as a control for loading, was seen in SGN 
(lane 2), sensory epithelium (lane 3), no GAPDH in the water control (lane 4), -
RT in SGN and sensory epithelium (lanes 5 and 6, respectively).  MIF expression 
is present in both the SG (lane 8) and sensory epithelium (Lane 9). Lanes 1 and 






The expression of MIF protein was examined in the E15.5 mouse inner 
ear.  Its expression was detected in the developing inner ear, including the 




Figure 2.8: MIF protein expression in the embryonic (E) day 15.5 mouse inner 
ear.  (A). Control: Secondary antibody alone.  No background labeling is seen.  
(B and C). MIF expression is detected in the developing inner ear, including the 
cochlea, utricle, saccule, lateral canal, lateral ampulla and the crux. (772 ms 
exposure; Image at 20x magnification). 
 
To determine the expression of MIF in the mature mouse inner ear, whole 
mount cochleae from 4 week (wk) old WT (Balb/c) mice (n=4) were 
immunostained.  As shown in Figure 2.9, MIF is expressed in supporting cells 
(SC) that cup the inner and outer HC (IHC and OHC, respectively).  Its 
expression was also detected in the stria vascularis (StV), spiral limbus (SL), and 
spiral ligament (SpL).  The cytokine MCP1 was expressed in the IHC and OHC of 
the Organ of Corti, as well as in the StV (Figure 2.9).  Overlapping staining 





Figure 2.9: Expression of MIF and MCP1 proteins in the cochlea of 4 week 
Balb/C mice.  Cryosections of Balb/c cochleae were labeled for MIF (green) and 
MCP1 (red).  MIF is expressed in SL, SpL, StV, SP and SC.  MCP1 expression is 
found in IHC and OHC as well as in StV and basement membranes.  The region 
of yellow overlap indicates the portion of the SC that directly contact and cup the 
IHC and OHC. Reisners membrane (RM), scala media (SM), scala vestibuli (SV), 









Expression of MIF in Cultured Inner Ear “Domes” from 13/14 day Mouse 
Embryos 
 
To examine the differential expression of MIF in inner ear cells in more 
detail, cultures of inner ear cells, which are dissociated and subsequently form 
inner ear “domes” were analyzed as previously described (Bianchi et al., 2002, 
Bianchi et al., 2006).  As in our previous studies, domes formed with a central 
mass of HC resting upon a SC layer.  Cytokeratin labeled the outer borders of 
SC (Figure 2.10-A, red), whereas myosin 7A labeled HC in the centrally located 
region above the plane of the SC (Figure 2.10-B, green).  In contrast, MIF was 
co-localized to the SC layer of the dome, with cytokeratin localized to the cellular 
borders (Figure 2.10-B, red) and MIF appearing in the cytoplasm (Figure 2.10-B, 
green).  The central regions of the domes (above the focal plane), that contain 








Figure 2.10: Ear domes (made as in Bianchi et al., 2002, 2006) were produced 
and cultured from E13-14 mouse embryos.   (A). Double-labeled fluorescent 
immunocytochemistry shows myosin 7A positive hair cells primarily in the central 
region of the domes (green), whereas MIF (red) is detected in the surrounding 
(and underlying) SC layer (20x).  (B). Double labeled fluorescent 
immunocytochemistry with anti-cytokeratin and anti-MIF (20x).  SC are labeled 
with cytokeratin (red) in the underlying layer of the domes, while MIF expression 
is detected in the cytoplasmic region of these same cells.  In domes, the upper 
layer of HC is not immunoreactive in these preparations.  Note: MIF signal is 












CD74, a MIF receptor, is expressed in developing SAG and postnatal SG 
neurons at the mRNA level. 
 
 RT-PCR was conducted to examine the expression of mRNA for CD74, a 
MIF receptor, on E14 mouse SAG neurons, adult mouse SG neurons and the 
mouse sensory epithelium (Figure 2.11).  CD74 mRNA was expressed both in 
the embryonic SAG (Figure 2.11-A) and the adult SG neurons as well as the 




Figure 2.11: Expression of CD74 in embryonic and adult inner ear at the mRNA 
level.  Expression of CD74 mRNA is present in the E14.5 WT (Balb/C) mouse 
SAG (lane1) (A).  Expression of CD74 is present in the adult SGNs (lane 1) and 
the sensory epithelium (lane 2), but not in the water control (lane 3). Lane 








Characterization of the MIF Knock-out (MIF KO) Mouse 
Hearing: Auditory Brain Stem Response (ABRs) Recordings from MIF KO 
and WT Mice 
 
 Auditory brain stem response (ABR) testing was performed to determine 
whether loss of MIF affects hearing in the MIF KO mice.  Hearing loss began as 
early as 4 weeks in MIF KO mice (Table 2.2).  The most dramatic hearing loss 
was noted at 48kHz.  MIF KO mice had statistically elevated thresholds at this 
frequency compared to WT mice.  A statistically significant difference was seen 
at 24kHz as well.  Furthermore, the MIF thresholds at 48 kHz remained elevated, 
but constant as the KO mice aged through 12 weeks. Balb/c mice, which served 
as the control mice in this experiment, are known to have age related hearing 












Frequency  Genotype  Mean dB SPL + SD 
12 kHz      WT (n=5)   28 + 3 
   MIF KO (n=4)  36 + 2 
24 kHz   WT (n=5)  24 + 2 
   MIF KO (n=4)  43 + 2 
48 kHz   WT (n=5)  29 + 14 
   MIF KO (n=4)  58 + 2   
 
Table 2.2: ABR Thresholds in WT and MIF KO mice at 4 weeks.  The most 
dramatic hearing loss is seen at 48kHz, the high-frequency detecting basal 
region of the cochlea.  MIF KO mice have statistically elevated thresholds 
compared to WT mice in the 48 kHz region.   
 
Morphological changes in MIF KO mouse inner ears 
 To determine if hearing loss was a result of altered innervation patterns, 
missing neurons or obvious phenotypic changes in the SG, spiral ganglion 
neuron counts were performed on Balb/c (control) and on MIF and MCP1 KO 
mice at 4, 8 and 12 weeks of age.  The density of neurons was determined by 
cochlear turn, and is shown in Figure 2.12.  At 4 wks, MIF KO mice had lower cell 
densities than Balb/c mice in the P1 (12 kHz) and P3 (48kHz) turns.  In addition, 
immunostaining assays were performed: In MIF KO mice, in the basal turn of the 
cochlea (organ of Corti) in the 48 kHz range, cochleograms showed that both 
OHC and IHC were missing, although small numbers of supporting cells 






Figure 2.12: Density of spiral ganglion neurons in WT, MIF and MCP1 KO mice 
at 4 weeks of age.  MIF KO mice demonstrate statistically lower average cell 















Figure 2.13: A. MIF KO mouse basal turn of the OC in the 48 KHz range (same 
region as in WT mice as shown in Figure 2.9) shows missing OHC and IHC, 
although SC are still present.  B. Similar findings are seen in the MCP1 KO 
animals.  In cochleograms, 7 out of 9 animals at 4 weeks of age show this loss of 
HC at 48 kHz.  C. Control OC at 8 weeks.  
 
Expression of neurofilament and myosin 7a in whole mount vestibular 
tissue and cochlea in WT and MIF KO mice 
 
 Whole mount vestibular and cochlear tissues from 4wk old WT (Balb/c) 
mice were analyzed by epifluorescence for normal innervation patterns and the 
presence of HC, using antibodies to neurofilament and myosin 7a, respectively.  
Figure 2.14 shows analysis of neurofilament and myosin 7a expression in the 
cochlear epithelium of WT and MIF KO mice in basal high frequency region.  The 













the apex (data not shown) and hook (basal) regions of the OC in WT mice.  
However, in the comparable sections from a MIF KO mouse, there was an 
absence of OHC in some regions of the OC (Figure 2.15).  These missing OHC 
were seen in the entire regions of the cochlea in MIF KO mice, with most loss in 
the apical low frequency region (P1) (mean % loss, 7.10 ± 1.19%), suggesting 





Figure 2.14: Epifluorescence of OC for neurofilament (a neuronal marker, red) 
and myosin 7a (a HC marker, green) in WT (Balb/C) (A) and MIF KO (B-D) mice.  
(A): Both IHC and OHC in the cochlea are phenotypically normal in both the apex 
and hook regions of the OC in WT mice.  (B-D): There are lower neuron density 










Figure 2.15: Mean OHC loss percentage in MIF KO mice compared to WT mice 
at 4 weeks of age.  Mean % loss of OHC is 7.10 ± 1.19 in P1, 1.33 ± 1.13 in P2 
and 0.49 ± 1.46 in P3.  (p<0.05), n = 4. 
 
Neurites from spiral ganglion explants extend directionally toward the WT 
OC, but not toward the MIF KO OC. 
 
To further determine if MIF affects inner ear neuronal development or 
maturation at post-natal stages, co-culture assays of the cochlea with SGNs 
were conducted.  Freshly excised OC from WT and MIF KO mice at P3 were 
cultured with freshly excised SG from P3 WT mice.  After 5 days of culturing in 
basal medium, directional SG neurite outgrowth was observed toward the WT 
OC, while only random neurite extension that did not reach the OC was seen in 
MIF KO OC as shown in Figure 2.16.  The results present further evidence that 




embryonic SAG, but also postnatal SG.  Immunostaining of the SG explants from 
WT P4 and the neurite outgrowth for Tuj1 confirmed that both were neurons 

















Figure 2.16: Co-culture assays of OC with SG.  Freshly excised OC from P3 WT 
(A) and P3 MIF KO mice (B) are cultured with freshly excised SG from P3 WT 
mice.  Directional SG neurite outgrowth is seen toward the WT mouse cochlea 
(A).  Only random neurite extension that does not reach the OC is observed in 
cultures of WTSG and cochleae from MIF KO mice (B).  The SG explants from 
WT P4 mouse are stained for Tuj1 (C).  The explants show SG neurite outgrowth 









Discussion   
 The role of classic “neurotrophic factors”, in the development of the inner 
ear has been studied extensively (Malgrange et al., 1996, Staecker et al., 1996, 
Marzella et al., 1997, Ylikoski et al., 1998, Tessarollo et al., 2004).  Nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF) (Malgrange et al., 1996, 
Staecker et al., 1996, Tessarollo et al., 2004) and glial cell line-derived 
neurotrophic factor (GDNF) (Ylikoski et al., 1998) in the development and 
maintenance of the SAG has been a focal point of the research in many 
laboratories interested in both ganglionic neuronal development and regeneration. 
However, there is mounting evidence from a great many laboratories, including 
ours, that these factors have little to do with the very early stages of SAG 
development. Our research has identified the major bioactive components of 
ODF, which provides the earliest trophic cues to developing SAG neurons.  
These components are immune system cytokines, rather than “classical” 
neurotrophins.  These cytokines are crucial for directional neurite outgrowth and 
neuron survival in the early inner ear (see also Bianchi et al., 2005).  MIF and 
MCP1 are produced in otic crest cells of the developing otocyst (data not shown).  
As the otic epithelium matures, MIF begins to be produced by SC and MCP1 by 
the sensory HC of the inner ear (Figure 2.9).   
The receptors for both of these cytokines [CD74 for MIF and CCR2 for 
MCP1 (Bianchi et al., 2005)] are expressed on the neuroblast on neurons of the 




 We have additional evidence that MIF can also direct the development of 
mouse embryonic stem cells into neurons, a finding that could be used in repair 
processes when these neurons are lost or damaged.  Furthermore, MIF is 
involved in sensory HC development, probably through its influence on SC 
development. We and others (Fekete et al., 1998), hypothesize that SC and HC 
come from a common precursor during development.  What is even more 
important is that the findings of this study—that “inflammatory” cytokines act as 
neurotrophins in the developing nervous system—are not only relevant to an 
understanding of SAG development in the inner ear, but are of general relevance 
to the development of all neural and sensory systems (Barald and Bianchi, in 
preparation).  
MIF is the most extensively investigated of the ODF cytokines in nervous 
system development and regeneration.   MIF is expressed in the developing 
nervous system, eye and inner ear of Xenopus (Suzuki et al., 2004), mouse 
(Kobayashi et al., 1999) and zebrafish (Ito et al., 2008).  MIF mRNA is expressed 
in the mouse developing inner ear at embryonic day 9.5, just prior to neural 
innervation (Kobayashi et al., 1999), and we have found that it is expressed in 
SC in the adult mouse (Figure 2.9).  
Exposing isolated SAGs to exogenous recombinant MIF (from either a 
mouse or a human source) promotes neurite outgrowth and survival comparable 
to that observed with active ODF fractions.  Addition of function-blocking MIF 




together, these results suggest that cytokines/ chemokines play an important role 
in otic innervation.  However, concentrations of MIF that have positive effects on 
the survival of dissociated neurons of the SAG are different from those that affect 
neurite outgrowth from whole ganglia (Figure 2.3).  In the dissociated cell assays 
of survival, the amount of MIF in the culture equally reaches each cell.  Therefore, 
lower concentrations of MIF have adverse effects on cell survival.  In the cultures 
of the whole ganglia, however, cells are clustered together and other cell types, 
including glial cells are present in the undissociated ganglia.  Not only does the 
full effect of the MIF in the medium not reach every cell, but because other cell 
types are present, several explanations for both the effects and the variability can 
be offered.  First, the effects on the neurons in the whole explant cultures could 
be mediated through effects of cytokines on the glial cells.  The effects on the 
neurons could be both primary (direct effects of MIF) and secondary effects 
(through the effects of MIF on the glial cells and glial cell production of factors.  
Second, Schwann cells themselves produce MIF (Huang et al., 2002a, Huang et 
al., 2002b, Nishio et al., 2002), of unknown concentration, so that the final 
concentration of MIF in the cultures could be quite different from that which is 
exogenously added.  Although the effects of MIF on neurite outgrowth in “whole” 
ganglia, appear to be biphasic, (Figure 2.3a), increasing concentrations of MIF 
have increasingly inhibitory effects on dissociated neuronal survival (Figure 2.3b). 
We also found this to be true of MCP1; increasing concentrations of rMCP1 had 
similarly inhibitory effects on SAG neuronal survival (Bianchi et al., 2005).  We 




the only cytokine made by Schwann cells/glial cells.  MCP1 is also found in ODF 
and is made by Schwann cells/Glial cells (Vincent et al., 2005).  
Such cytokines are potentially interactive, even synergistic at specific 
concentrations (Wu and Bradshaw, 1996, Kavanaugh, 2002).  We have not yet 
explored this relationship between, for example, MIF (made by SC) and MCP1 
(made by HC) in any detail.  If it proves to be the case, as we and others 
speculate that SC and HC are derived from a common precursor cell, the 
expression patterns of cytokines in the postulated precursor cells and the 
differentiating “daughters” could become a focus of future work.  In addition, the 
MIF KO mouse appears to form a relatively “normal” inner ear (Figure 2.14).   A 
careful developmental study of the developing inner ear of these animals must be 
done, particularly in tracing the expression patterns of other cytokines known to 
be present in ODF (in addition to MCP1, RANTES and TNFα are present in ODF; 
Bianchi et al, 2005).  These cytokines are both (Chow et al., 2001)binders to 
other cytokine receptors (Chow et al., 2001, Budagian et al., 2005) and can have 
synergistic effects (Kadokami et al., 2001, Telekes et al., 2005, Hirano et al., 
2007); the absence of MIF could well be compensated for by the presence of 
these additional cytokines.  Cytokines are well known to have “knife-edge” 
differences between concentrations that have positive and negative effects.  This 
is true of their effects on neuronal regeneration (Liefner et al., 1998) and in the 
immune system (Kleemann et al., 2000).   The variability we saw in the neurite 
outgrowth assays (Figure 2.3) could be due to cytokine accessibility issues in 




explanted ganglion (and how many of these neurons are affected/exposed) 
differs appreciably from ganglion to ganglion.  Correlating ganglionic dimensions 
with outgrowth could possibly clarify some of these issues, since presumably the 
larger the diameter of the explanted ganglion, the greater the surface area and 
the greater the accessibility of neurons on the outside to the cytokine in the 
medium.  Cytokines are also notoriously “sticky” and adhere to plastic, substrates 
(natural and artificial).   
If MIF and MCP1 specifically regulate SC and HC innervation respectively, 
one would expect to find MIF expression in SC and MCP1 in HC, as we do.  In 
addition, their receptors should be present on the immature SAG neurons and 
the possibly the mature SG. Immunohistochemistry demonstrates that MIF is 
expressed in SC and MCP1 in the inner and outer HC of 4wk old WT mice.    RT-
PCR shows the presence of a MIF receptor, CD74, and the MCP1 receptor 
CCR2 in the developing SAG (data not shown), suggesting a capability of HC 
and SC to secrete, and the SAG to detect and migrate toward, the source of 
these chemokines, the otic crest in the otocyst and the HC/SC in the maturing 
inner ear.  Adult SGNs also express these receptors, opening a promising 
avenue for auditory system regeneration and possibly cochlear 
prostehsis/implant potentiation.  
It is highly likely that other chemokines and their receptors are involved 
with cochlear innervation as well.  The receptors for cytokines identified in ODF, 




(CXCR4/CXCR2) (Bernhagen et al., 2007) and TNF-α (TNFR1/TNFR2) (Zou et 
al., 2005), are all expressed in developing and adult otic tissue.  Determining the 
interactions among these chemokines and their receptors will be crucial to 
determining the exact mechanisms by which these factors direct cochlear 
innervation. 
Not only are these chemokines expressed in the ear and the ganglion, but 
the absence of these factors results in profound hearing loss in KO mice.  ABR 
testing done on 4wk, 8wk, and 12 wk old MIF, MCP1, CCR2 (MCP1 receptor) KO 
and WT mice indicated a profound hearing loss at the high frequency region of 
the cochlea at 48kHz as early as 4wks in all the KO mice tested (both cytokine 
[MIF and MCP1] and cytokine R [CCR1, CCR5, CCR2] KO mice). After ABR 
testing, analysis of the innervation and cochlear structure of MIF and MCP1 KO 
mice demonstrated abnormal auditory nerve structure as well as some missing 
IHC and OHC.  Rosenthal’s canal was frequently disorganized when compared 
to Balb/c control tissues.  The absence of functional MIF and/or MCP1 proteins 
during development produces structural and physiological abnormalities, 
supporting the hypothesis that these chemokines play a crucial role in recruiting 
SG neurons to allow for proper innervation of HC, at least in the high frequency 
basal turn of the cochlea.  This research provides the first direct link between 
chemokine secretion and innervation of the inner ear.  Discovering that cytokines 
play important roles in development of the inner ear is fully in accord with a major 
new focus in cytokine biology and neuroimmunology (Siemion et al., 2005, 




properties) were initially identified and characterized for their critical roles in the 
immune system, particularly in mediating T cell function (Gonzalo et al., 1996). 
Cytokines/chemokines are relatively small molecular weight proteins initially 
identified for their ability to attract and activate immune cells by interacting with 
specific cytokine receptors (Coughlan et al., 2000). Recent studies have 
demonstrated that cytokines/chemokines are also present in developing and 
adult neural systems.  These proteins are now being implicated in a variety of 
roles including neuronal migration, outgrowth, and survival (Meng et al., 1999, 
Bajetto et al., 2001, Chalasani et al., 2003, Belmadani et al., 2005).  In some 
cases, chemokines were found to regulate axonal outgrowth by inhibiting the 
repellent effects of other molecules such as semaphorins and slit-2 (Chalasani et 
al., 2003).  Not only are cytokines/chemokines absolutely required for neuronal 
development (Suzuki et al., 2004), they are also critical in neuronal repair 
processes after axotomy in both the peripheral and central nervous systems 
(Bajetto et al., 2001, Koda et al., 2004). Our finding that immune system 
“inflammatory” cytokines behave as neurotrophins in the early developing 
nervous system indicates that, evolutionarily and developmentally, such 
cytokines are multifaceted and pleiotrophic. 
 In the future, exogenous MIF or MCP1 expression in the adult cochlea 
could be used to reinnervate damaged cochleae and restore hearing. Neuron 
loss is a significant contributing factor in hearing loss and is notable in ageing 
human populations. Cochlear implants, presently the only treatment for many 




The larger the numbers of functional SGNs remaining at the time of cochlear 
implant the greater the probability of success in restoring function (Altschuler et 
al., 2008).  MIF could therefore play a significant role in SGN maintenance or 
regeneration in therapeutic efforts to maintain or restore hearing function.  
 It is possible that other chemokines in secreted ODF are required for 
innervation in the regions of the cochlea required for low and mid-frequency 
hearing.  One can envision a tonotopic map that correlates individual chemokine 
and/or neurotrophin expression with defined frequency intervals.  If such a 
patterning mechanism exists, it would provide a very detailed mechanism for 
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Conclusions and future work 
Sensorineural hearing loss (SNHL) is the most common form of deafness 
in humans and derives, in most cases, either from primary degeneration of the 
spiral ganglion neurons (SGNs) or from secondary degeneration of these 
neurons, due to the loss of cochlear sensory hair cell (Martinez-Monedero et al., 
2006, Friedman and Avraham, 2009).  Cochlear implants (CI) are currently the 
only treatment for SNHL (Roehm and Hansen, 2005, Altschuler et al., 2008, 
Shibata et al., 2010).  CI provide an increasingly successful therapy to restore 
hearing, particularly speech recognition, for those suffering from profound 
deafness (Altschuler et al., 2008, Shibata et al., 2010).  Nevertheless, the 
efficacy of these cochlear prostheses is dependent upon the functionality of 
residual neurons and the ability of the CI to stimulate those neurons, so that the 
presence of some conserved nerve functionality is essential for CI functionality 
(Altschuler et al., 2008, Serin et al., 2009, Shibata et al., 2010).  Preserving SGN 
or finding a cellular replacement for lost or damaged SGN therefore is a priority if 
CI function is to be enhanced.  Ultimately, inducing restoration of hearing function 
through regeneration of hair cells (HC), neurons or both would be a more 
satisfactory way to resolve this problem.  Nevertheless, despite a great deal of 




mammalian inner ear to replace lost cell population has been unsuccessful.  
Such a population/source could be used to induce regeneration, either through 
transdifferentiation of supporting cells (SC) or other cell types into HC or by 
replacing lost or damaged cell populations with appropriately differentiated stem 
cells (Hernandez et al., 2007, Hori et al., 2007, Diensthuber et al., 2009, Oshima 
et al., 2009).    
Innervation target-derived or cellular pathway-derived growth and survival 
factors are essential for the normal development and survival of neurons (Ard et 
al., 1985, Lefebvre et al., 1990, Bianchi and Cohan, 1991, 1993, Bianchi et al., 
1998, Bianchi et al., 2005).  In the developing inner ear, the otocyst is the 
precursor of the inner ear sensory organs as well as the innervations of the 
sensory organs (Barald and Kelley, 2004).  Early studies in both the rat 
(embryonic day (E)11-14) and the chick (E4-6) demonstrated that during the 
early stages of auditory development, cells in the antero-ventral region of the 
otocyst secrete soluble and diffusible factor(s), which have been collectively 
termed Otocyst Derived Factor(s) (ODF), which influence both directional neurite 
outgrowth and survival (the definition of a “neurotrophin”) of neurons, which are 
the precursor to both the auditory ganglion and the vestibular ganglion in the 
embryonic statoacoustic ganglion (SAG)  (Bianchi and Cohan, 1991, 1993).  The 
identity/identities of the biologically active components of ODF had not been fully 
characterized until our recent proteomic studies identified the bioactive 




migration inhibitory factor (MIF) (Gerlach-Bank, Ebisu et al, in preparation), 
Monocyte chemoattractant protein 1 (MCP-1, also called JE or CCL2) (Bianchi et 
al., 2005), gamma interferon, TNF-alpha and RANTES.  However, of all of these 
cytokine components found in ODF, only MIF acts as a sufficient and necessary 
molecule that promotes both SAG neurite outgrowth and the survival of 
dissociated SAG neurons (Gerlach-Bank, Ebisu et al, in preparation). 
MIF is a ubiquitously expressed “pleiotropic” cytokine since it plays 
multiple roles including in the immune system and the pathogenesis and 
progression of inflammatory diseases (Bernhagen et al., 1993, Calandra and 
Roger, 2003, El-Turk et al., 2008).  Studies demonstrated that MIF is implicated 
in carcinogenesis and demonstrate a link between chronic inflammation and 
various types of cancers (Lue et al., 2007).  More recently, several studies found 
vital additional roles for MIF in the early development (neurulation) as well as 
repair mechanisms of peripheral nerves and skin after injury by enhancing cell 
proliferation and migration (Nishio et al., 1999, Abe et al., 2000, Nishio et al., 
2002, Suzuki et al., 2004, Shimizu, 2005, Dewor et al., 2007, Velnar et al., 2009).   
Based on all of the intriguing roles that MIF plays in neurulation, neuronal 
development, pathfinding and cell migration as well as the discovery that MIF is a 
major component of the otocyst-generated ODF, we hypothesized that MIF plays 
a key instructional role in inner ear neuronal and sensory cell development.  The 




ear neuronal and sensory cell development using chicks and mice as model 
systems both in vitro and in vivo.   
As mentioned previously, the otocyst secretes ODF that supports the 
neurite outgrowth and survival of SAG neurons.  Because so little ODF can be 
obtained from the embryonic otocyst, our laboratory developed immortalized 
otocyst cell lines from the E9.5 Immortomouse otocyst (IMO) cells (Barald et al., 
1997).  These early studies found that IMO cells secrete a functionally bioactive 
ODF equivalent (Thompson et al., 2003, Germiller et al., 2004, Bianchi et al., 
2005).  Neuronal culture bioassays with SAG explants in the presence of IMO-
generated ODF, conditioned medium (CM) from IMO cells cultured in basal 
medium (serum-free without γ-interferon), and  otocyst-generated ODF, CM 
produced by incubating E 4 or E5 chick otocysts in the same basal medium, 
demonstrated that both ODFs promoted the extension of neurites from ganglionic 
explants and the survival of dissociated SAG neurons significantly compared to 
control (basal medium), confirming that IMO-generated ODF is “bioequivalent” to 
otocyst-generated ODF.  Moreover, these results demonstrate that IMO-
generated ODF can be used for further experiments to characterize ODF 
bioactivity.  The identified active IMO-generated ODF and inactive CM from IMO 
cell lines without ODF activity were subjected to proteomic analysis.  MIF was 
found in the bioactive ODF samples from both mouse and chick otocysts (data 
not shown), as well as MCP1 (Bianchi et al., 2005).  Following the identification 
of MIF and MCP1, we quantified the concentrations of MIF and MCP1 both in 




MCP1 were very similar in both ODFs, in a range of 1.0 to 2.5 ng/ml.  This is 
similar to the concentration of MIF produced by the rat spinal cord neurons 
(Chalimoniuk et al., 2006).   
In the neuronal bioassays with mouse or human recombinant MIF (rMIF), 
we found that rMIF mimics the bioactivity of ODF in a dose-dependent manner.  
Concentrations of rMIF at 5 pg/ml and 5 ng/ml significantly enhanced chick SAG 
neurite outgrowth, while 50 pg/ml of rMIF also significantly promoted SAG 
neuronal survival.  In contrast, higher concentrations (e.g.500 ng/ml) of rMIF had 
no effect or inhibited both SAG neurite outgrowth and survival.  Lue et al. 
demonstrated the dose-dependent rMIF bioactivity in ERK signaling activation, 
where rMIF activated ERK phosphorylation in fibroblast at lower concentrations 
in the range of 50-100 ng/ml, while higher concentrations exceeding 1000 ng/ml 
were inhibitory in these cells (Lue et al., 2006), supporting our findings that too 
high a concentration is inhibitory and injurious.  This finding presents a caveat to 
any proposed MIF-inducible regenerative attempts to restore functional 
connections in the adult mammalian inner ear using MIF, since rather small 
increases in MIF could prove deleterious and induce an inflammatory response 
that could do irreparable damage to the neuronal cells in the spiral ganglion (SG) 
that continue to carry CD74 receptors on their cell surfaces into adulthood 
(Gerlach-Bank, Ebisu et al., in preparation).  We observed significant SG neurite 
outgrowth in the presence of 50 ng/ml of rMIF compared to control, indicating 
that rMIF at this range can still promote neurite outgrowth not only in the 




In addition, we examined MIF’s bioactive effect on cultures of mouse 
embryonic stem (mES) cells.  We found that concentrations as low as 1 pg/ml of 
rMIF induced a subset of the cells to become neurofilament positive cells with a 
neuron-like morphology, further demonstrating a role for this cytokine in neuronal 
development.  Studies to examine how closely these MIF-induced ES-derived 
neurons resemble early or mature inner ear neurons both chemically and 
physiologically are underway (Ramamurthy et al, in preparation).  To further 
explore the role of MIF in neuronal development, we performed functional-
blocking assays using anti-MIF antibodies on SAG neurons.  Blockade of MIF 
activity reduced MIF-induced SAG neurite outgrowth to background levels.  The 
antibody also reduced MIF-induced SAG neuronal survival to basal levels, 
whereas some residual neuronal survival was seen after treatment of IMO-
generated ODF with this function-blocking antibody, indicating that additional 
factor(s), which we speculate to be MCP1,  in the ODF also play a role in inner 
ear neuronal development.  Together, we demonstrated that MIF appears to be 
both necessary and sufficient to promote outgrowth and survival of inner ear 
neurons, from early to late stages. 
We detected the expression of MIF in the mouse inner ear at both the 
mRNA and protein levels in sensory epithelial regions of both the developing and 
mature inner ear.  A group detected MIF mRNA expression in the otic 
vesicle/otocyst at E9.5 (Kobayashi et al., 1999).  We detected MIF protein 
expression in IMO cells, which were isolated from E9.5 Immortomouse otocysts.   




tissues.  We also found MIF mRNA in the adult inner ear tissues, including the 
cochlea.  Immunostaining assays with adult inner ear tissues demonstrated the 
expression of MIF and MCP1 proteins in the SC and HC respectively.  It has 
been suggested that hair cells possess a migratory mechanism to help achieve 
their final position in the organ of Corti (Bianchi et al., 2002, Bianchi et al., 2006).  
An in vitro assay in which dissociated embryonic inner ear otocyst cells 
reaggregate in culture to form structures called “ear domes” (Bianchi et al., 2006) 
demonstrated that MIF activity segregated with the cytokeratin-labeled 
supporting cells and that MCP1 labeling segregated with the Myosin 7a-
expressing HC .  Our previous study demonstrated the co-expression of MCP1 
with myosin 7A, a HC marker, in dissociated embryonic inner ear cells, as well as 
in “domes”.   The directional chemotactic activity of MCP1 towards isolated 
human blood monocytes and the ability of IMO-generated ODF to mimic this 
activity were also demonstrated in the earlier study (Bianchi et al., 2005).  In the 
studies described in this dissertation, we used immunohistochemistry to localize 
cytokeratin, a SC marker, to the outer border of SC, while myosin 7A labeled HC 
in the centrally located region above the plane of the SC.  MIF was co-localized 
to the cytoplasm in the SC of the dome, with cytokeratin forming the cellular 
borders.  In contrast, the central regions of the domes, that contain HC, were not 
labeled with MIF antibodies.  These results provide further evidence for cell 
specific expression patterns of MIF in SC and MCP1 in HC, as well as an ability 




reaggregation and sorting in a tissue culture dish (Bianchi et al, 2006; Bianchi et 
al, 2005; Gerlach-Bank, Ebisu et al, in preparation).   
In characterization of MIF knock-out (KO) mice, we found that MIF KO 
mice developed hearing impairment at 4 weeks of age, with the most profound 
hearing loss at 48 kHz.  The lower average density of SG neurons was also 
observed in the P1 (12 kHz) and P3 (48 kHz) turns of the cochlea in MIF KO 
mice compared to wild-type (WT) mice at 4 weeks of age.  Immunostaining 
assays showed that both inner hair cells (IHC) and outer hair cells (OHC), as well 
as SC were missing some, but not all, in MIF KO mice at 4 weeks of age.  
Cochleograms and an anatomical analysis demonstrated that MIF KO mice 
exhibited disorganized auditory nerve structure, with some OHC and IHC missing, 
suggesting the requirement of MIF expression for normal development and 
patterning of HC and SC, as well as normal neuronal development.  Furthermore, 
co-culture assays of post-natal organ of Corti explants, which expressed MIF, 
with SGN explants compared with the same WT explants and organ of Corti from 
MIF KO animals demonstrated an ongoing role of MIF in the directional neurite 
outgrowth of mature inner ear neurons toward the cochlea.  Taken together, 
these results suggest that normal expression of MIF is essential for normal 
physiological and morphological inner ear development and innervation. 
Future studies will focus on the effects of MCP1 and its possible synergy 
with MIF in MIF-induced SAG/SG neurite outgrowth and survival.  Our previous 




(Bianchi et al., 2005).  However, blockade of MCP1 bioactivity in IMO-generated 
ODF reduced ODF-induced SAG neurite outgrowth and the addition of 
recombinant MCP1 (rMCP1, 20 ng/ml) significantly remedied the inhibition of the 
outgrowth; however, too much rMCP1 (200 ng/ml) had reduced effects on neurite 
outgrowth (Bianchi et al., 2005).  In the current study, we found that MIF alone 
enhanced SAG neurite outgrowth, however, the maximum lengths of neurite 
outgrowth induced by rMIF was less than that induced by ODFs.  Furthermore, 
blockade of MIF activity in ODF failed to completely block ODF-induced SAG 
neurite outgrowth.  These results suggest that another component of ODF, likely 
MCP1, is capable of interacting with MIF to promote/synergize in SAG outgrowth.  
We will examine this possibility by performing neuronal outgrowth and survival 
assays in the presence of rMIF and rMCP1.  We will then perform function 
blocking assay with IMO- and otocyst-generated ODF pretreated with anti-MIF 
and anti-MCP1 antibodies or RNAi constructs to mouse MIF and MCP1.  We 
have recently found that siRNA against mouse MIF (0.25 µg/ul) significantly 
reduced MIF expression in IMO cells.   
Based on our observation on that MIF KO mice developed hearing 
impairment at 4 weeks of age, with the most profound hearing loss in the 48 kHz 
region along with lower SG neuronal density at this region, additional future 
studies include determining whether there is any potential involvement of MIF in 
the establishment of the tonotopic map, a sound detection gradient, by immune-
labeling of the cochlea for MIF.  We detected MIF expression both in the 




development in WT mice, while abnormal HC development in MIF KO mice, 
suggesting its involvement in HC development/maturation probably through 
effects on SC.  We will perform loss-of-function assays using RNAi knock-down 
techniques to determine MIFs role in both neuronal and SC/HC 
development/maturation.   
In addition, we will examine the downstream signal pathway of MIF.  We 
observed a dose-dependent bioactivity of rMIF.  The lower concentrations of 
rMIF promoted both SAG neurite outgrowth and survival, while higher 
concentration was inhibitory.  A group found that lower concentrations of MIF 
activated ERK phosphorylation, while higher concentration inhibited it (Lue et al., 
2006).  The expression of phosphorylated ERK will be examined after the 
treatment of inner ear neurons with various concentrations of rMIF.  In addition to 
ERK, Kleemann et al. discovered the direct interaction of MIF with Jab1 when the 
extracellular MIF concentrations are high (Kleemann et al., 2000).  As mentioned 
previously, Jab1 functions in the activation of AP-1, a transcription factor that 
activates pro-inflammatory genes, and in promoting the degradation of p27kip1, a 
protein that controls the cell cycle.  Many studies (Chen and Segil, 1999, Chen et 
al., 2003, McKenzie et al., 2004) have implicated p27kip1 in inner ear development.  
We will investigate whether MIF plays a role in p27kip1 regulation via Jab1.  It is 
known that the physical interaction of MIF with Jab1 modulates the role of Jab1.  
Immunostaining assays will be performed to examine whether MIF and Jab1 are 
co-localized in the presence of high concentrations of rMIF.  As mentioned above, 




dependent phenomenon in MCP1 needs to be investigated in much more detail 
as well. 
Based on the limited observations discussed above, the possible 
developmental scenario of the ear in the MIF KO mouse that results in the 
majority SC being missing in the adult high frequency detecting cochlear regions 
suggests that they are abnormally developed in the MIF KO mouse.  SC and HC 
are hypothesized to come from the same precursors (Fekete et al., 1998, Rivolta 
and Holley, 2002), therefore, few or no HC are developed in this region either.  
The neurotrophins and/or cytokines responsible for neuronal development and 
for maintenance of neuronal connections are secreted by HC and SC, as 
described previously.  Since some SC are still present in the MIF KO mouse, 
different neurotrophins(s) must also be secreted from SC in the MIF KO mouse 
to maintain at least some neuronal survival.  However, since there is also HC 
loss, the auditory nerves, which are known to carry receptors for other 
neurotrophins and cytokines (Gerlach-Bank, Ebisu et al, in preparation) might not 
be able to project toward HC to innervate them or the connections, if made, might 
not be maintained.  The consequence is that the MIF KO mouse develops 
hearing impairment in a specific cochlear region (high frequency).  It is certainly 
possible to speculate that different cytokine/neurotrophin combinations are 
responsible for establishing and maintaining the tonotopic map.  It is possible that 
different combinations are responsible for the different frequency-detecting 




overlapping to some extent.  Only careful examination and experimentation will 
discern whether this is the case.   
In this dissertation, we also examined a role of CD74, the most 
characterized receptor for MIF, in inner ear neuronal development.  We detected 
its expression both in the embryonic SAG neurons and the adult SG neurons in 
mice at the mRNA level.  Blockade of its activity with RNAi significantly, but not 
completely, reduced chick SAG neurite outgrowth and survival, suggesting that 
CD74 is required at least for chick embryonic SAG neurite outgrowth and survival. 
Further studies will be performed to determine its effect on SAG/SG 
neurite outgrowth and survival in mice.  A recent study identified additional 
receptors for MIF, CXCR2 and CXCR4 (Bernhagen et al., 2007).  The failure of 
complete blockade of neurite outgrowth and survival with CD74 siRNA suggests 
the possible involvement of additional receptors and the CXCR receptors are 
potentially good candidates for this interaction.  We will clarify this possibility by 
assessing their expression both in the embryonic SAG and postnatal/adult SG 
neurons both in the mouse and the chick. Similar studies are being done in the 
zebrafish by others in the lab (Shen et al., in preparation).  If we detect their 
expression in SAG/SG, we will then examine their role in inner ear neuronal 
development and maintenance by functionally blocking their activity using RNAi 
techniques.  Additionally, we will investigate whether damaged SG neurons still 




performing immunoassays after the treatment of SG neurons with ototoxic 
drug(s).   
The significance of this project is that these approaches could provide new 
therapeutic avenues to treat hearing loss.  If damaged SG neurons retain or are 
capable of re-expressing cytokine receptors responsible for SGN survival and 
outgrowth during development, MIF could be used to maintain SGN survival or 
potentiate integration of remaining sensory HC with a CI.    
Nevertheless, there are a few things that one must include consideration 
when introducing rMIF and other cytokines.   
First, carefully controlled concentrations of cytokines, particularly MIF and 
MCP1 that do not produce an inflammatory response must be introduced as we 
observed that the low concentrations of the cytokines have effects on the 
auditory system, while the high concentrations of those have deleterious effects.  
Tumor necrosis factor-α (TNF-α), another proinflammatory cytokine, which is 
known to be released by SC (Satoh et al., 2003), is apparently involved in a 
positive feedback mechanism with other inflammation-associated cytokines to 
promote hair cell damage caused by inflammatory cytokines, including some of 
the IGF factors.  However, we believe that those effects are undoubtedly seen at 
higher concentrations of TNF-alpha and other "inflammatory" cytokines, than the 
very low concentrations of such cytokines that produce the positive neurotrophic 
and neurite-outgrowth stimulating effects seen at lower cytokine concentrations.  
The additional studies by different group support our ideas.  One group 




with mixed connective tissue disease (MCTD) with SNHL and compared these 
levels with MCTD patients without SNHL (Hajas et al., 2009).  The authors found 
that serum levels of TNF- α and γ -interferon increased in MCTD patients with 
SNHL compared to those without SNHL (Hajas et al., 2009).   Another group 
demonstrated that blockade of TNF-α with a TNF-α antibody reduced the extent 
of cochlear injury and hearing loss associated with Streptococcus pneumoniae 
meningitis in Mongolian gerbils (Aminpour et al., 2005).   
Second, these studies also highlight the remarkable similarities and 
molecular interactions between the developing immune and nervous systems 
and also underscore the fact that molecules like MIF, which play vital roles in 
development can also play a role in both disease (e.g. multiple sclerosis) and 
carcinogenesis (Shimizu et al., 1999, Fingerle-Rowson et al., 2003, Nishihira et 
al., 2003, Honda et al., 2009).  Since many therapies for auto-immune diseases, 
multiple sclerosis and other inflammatory disorders like arthritis depend on the 
potential use of anti-MIF function blocking antibodies, these strategies, too must 
be carefully considered, especially if such treatments or strategies adversely 
affect adult neuronal populations that respond to MIF or if MIF in low 
concentrations are needed to maintain a functioning auditory and possibly 
vestibular system.  Anti-cancer drugs like cisplatin and anti-bacterial 
aminoglycoside antibiotics have severe consequences for hearing; it is possible 
that anti-MIF therapeutics could have similar deleterious effects.   
The additional issue of cytokines and their receptors is their redundancy 




of them have overlapping functions (Leonard, 1994, Ozaki and Leonard, 2002).  
Cytokine pleiotropy and redundancy can be explained by the ability of certain 
cytokines to signal via more than one type of receptor complex and by an 
individual receptor component being shared by more than one cytokine (Ozaki 
and Leonard, 2002).  As mentioned above, in the case of MIF, it has a high 
affinity for CD74 and its binding to CD74 activates the ERK-MAP kinase signaling 
pathway for cell proliferation.  The additional receptors for MIF are CXCR2/4, 
which MIF acts as a noncognate ligand of these receptors in inflammatory and 
artherogenic cell recruitment (Bernhagen et al., 2007).  The authors observed 
that blockade of MIF, but not of the canonical ligands of CXCR2 or CXCR4, in 
mice with advanced atherosclerosis led to plaque regression and reduced 
monocyte and T-cell content in plaques (Bernhagen et al., 2007).  We are 
presently investigating the role of the CXCR receptors in mif signaling cascades 
in the zebrafish (Shen et al., in preparation).  An additional example of cytokine 
receptors’ promiscuous binding includes IL-10R2 (Hinck, 2010).  IL-10R2 is a 
shared cell surface receptor required for the activation of class II cytokines, such 
as IL-10, IL-22, IL-26, IL-28 and IL-29, which play critical roles in host defense 
(Yoon et al., 2010).  Yoon et al. (2010) identified IL-10R2 residues and the 
ligand-specific- ternary complexes with two cytokines, IL-22 and cmvIL-10.  
There is a key structural determinants shared with class I cytokines, yet 
promiscuity in binding is seen with the class II cytokines, IL-22 and cmvIL-10.  
Binding of IL-22 to ligand specific receptor, IL-10R1, and the common receptor, 




contrast, binding of cmvIL-10 to the ligand specific receptor, IL-22, and the 
common receptor, IL-10R2, results in acute-phase response and innate immunity.     
Finally, how could one introduce rMIF into a diseased or damaged inner 
ear?  Such introduction would be dependent on the condition of SGNs.  If many 
of SGNs survive or are in good condition, one could introduce exogenous MIF 
into either a gel coating a CI or by “coating” a CI with MIF-producing cells (such 
as Schwann cells, which produce MIF) to potentiate neuronal contact with the CI.  
If most of SGNs are lost, it is possible that stem cells induced to become neuron-
like through exposure to the “right” concentrations of MIF could be transplanted 
into the inner ear to potentiate a CI.  In such a scenario, the stem cells would be 
induced pluripotent stem cells, derived from the patient and to be efficacious, 
these neuron-like cells must a) not become tumors and b) must have the same 
physiological and molecular properties as the neurons that they might replace.  
These experiments, determining how inner ear neuron-like the MIF-induced ES 
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Suppression of the expression of CD74, a receptor for macrophage 
migration inhibitory factor (MIF), inhibits inner ear statoacoustic ganglion 
(SAG) neurite outgrowth and SAG neuronal survival in vitro  
 
Abstract  
CD74 is one of the known receptors for Macrophage Migration Inhibitory Factor 
(MIF), an important immune system cytokine.  MIF has now been identified as 
the major “neurotrophic” molecule on which the earliest stages of inner ear 
development depends. We have shown that MIF is produced by the embryonic 
otocyst and secreted as part of the otocyst derived factor (ODF) and that it is 
both necessary and sufficient to promote directional neurite outgrowth from 
nascent statoacoustic ganglion neurons (SAG) and to serve as a survival factor 
for these neurons (Gerlach-Bank, Ebisu et al., in preparation and Chapter 2).  We 
also demonstrated that MIF is produced by both the embryonic otocyst during 
SAG neuritogenesis and innervation and by the Supporting Cells (SC) of the 
mature inner ear.   Both embryonic SAG neurons and mature Spiral Ganglion 
neurons (SGNs), the mature form of these cells, express CD74 receptors and 




(SG) explants and survival of both these dissociated neuronal populations is 
highly MIF concentration-dependent.  Low concentrations have positive effects: 
higher concentrations are inhibitory.  Here we demonstrate that blocking 
expression of the CD74 receptor with siRNA inhibits both neurite outgrowth and 
neuronal survival of SAG. These results demonstrate that both MIF and its CD74 
receptor play critical roles in the establishment of connections between the SAG 
and the inner ear.   
 
Introduction 
Release of neurotrophic factors by target tissues is essential for the 
neuronal populations that innervate these tissues and organs to initiate 
directional neurite outgrowth toward the targets (Ard et al., 1985, Lefebvre et al., 
1990, Bianchi and Cohan, 1991, 1993).  In the early developing inner ear, cells in 
the otic crest region of the otocyst secrete a factor called Otocyst Derived Factor 
(ODF) (Ard et al., 1985, Lefebvre et al., 1990, Bianchi and Cohan, 1991, 1993).  
ODF has been implicated as a promoter of both directional neurite outgrowth and 
survival of early stage statoacoustic ganglion (SAG) neurons, which at earlier 
stages, had migrated away from the otic crest region and then send out 
processes to innervate the nascent inner ear.  In a previous study, we reported 
that Macrophage Migration Inhibitory Factor (MIF), an immune system cytokine, 
is a major component of ODF and also acts as a major directional neurite 




we have demonstrated that MIF functions as an essential component of normal 
inner ear neuronal development and innervation.   We also found MIF expression 
both in cells of the developing otocyst and in supporting cells (SC) of the adult 
cochlea.  One known receptor for MIF found in mammals is CD74 (Leng et al., 
2003).  In the zebrafish, the CD74 homolog is called Major Histocompatibility 
Complex (MHC) class II invariant chain, of which there are two variants, iclp 1 
and 2 in the zebrafish.  Binding of MIF to CD74 is known to be necessary for 
activation of MIF-mediated ERK phosphorylation via a Ras-Raf-MEK dependent 
pathway, for cell proliferation in cell populations that express CD74, and for both 
immune system and neuronal cells’ differentiation and gene induction.  CD74 is 
also expressed both on embryonic SAG and on adult spiral ganglion (SG) 
neurons.  In the current study, we asked whether a role could be demonstrated 
for CD74 in inner ear neuronal development.  We hypothesized that CD74 is 
necessary for initiation of MIF-induced SAG neurite outgrowth.  We have now 
demonstrated that knockdown of CD74 with specific RNAi inhibited ODF-induced 
SAG neurite outgrowth and survival significantly, indicating a critical role for 
CD74 in inner ear neuronal development.  In addition, we detected MIF 
expression in an Immortomouse otocyst (IMO) cell line obtained from a 
transgenic mouse at embryonic day 9.5, which is a critical period for inner ear 
morphogenesis and neurogenesis and MIF siRNA also successfully knocked 




Sensorineural hearing loss (SNHL) is the most common form of deafness 
in humans and derives, in most cases, either from primary degeneration of spiral 
ganglion neurons (SGNs) or from secondary degeneration of these neurons, 
which is seen after cochlear sensory hair cell (HC) loss (Martinez-Monedero et 
al., 2006, Friedman and Avraham, 2009).  Although new HC production is quite 
common in cold-blooded vertebrates and birds (Corwin and Cotanche, 1988, 
Ryals and Rubel, 1988, Balak et al., 1990, Lombarte et al., 1993, Raphael et al., 
2007, Brignull et al., 2009), the mammalian cochlea has no ability to 
spontaneously regenerate sensory auditory HC after birth (Matsui and Cotanche, 
2004, Raphael et al., 2007, Stone and Cotanche, 2007, Beisel et al., 2008, 
Brignull et al., 2009).  Cochlear implants (CI) are surgically implanted devices 
that bypass a nonfunctional cochlea and improve hearing function by directly 
electrically stimulating any remaining auditory nerves that project toward the 
cochlea (Altschuler et al., 2008, Shibata et al., 2010).  Since no HC regeneration 
occurs in mammals, CI are currently the only treatment for SNHL (Roehm and 
Hansen, 2005, Altschuler et al., 2008, Shibata et al., 2010).  Nevertheless, the 
successful function of a CI depends on activation of auditory nerves, so the 
presence of these nerves and conserved functionality are essential for CI 
function (Altschuler et al., 2008, Serin et al., 2009, Shibata et al., 2010). 
In the developing inner ear, the otocyst is a precursor of all inner ear 
organs, including sensory HC and neurons of the auditory and vestibular systems, 




neuroblasts delaminate from the anteroventral region of the otocyst called the 
otic crest (Hemond and Morest, 1991) and coalesce to form the developing SAG 
neurons, a precursor of the SG and the vestibular ganglion (VG), which provide 
the sensory innervation for the auditory system and vestibular structures 
respectively (Barald and Kelley, 2004).  Early studies found that directional 
neurite outgrowth of SAG neurons toward the otocyst was mediated by ODF, 
which is secreted by cells in the otocyst (Ard et al., 1985, Lefebvre et al., 1990, 
Bianchi and Cohan, 1991, 1993).  We previously found that among the bioactive 
components of ODF, MIF is a major component (Gerlach-Bank, Ebisu et al., in 
preparation, Chapter 2).  Immunohistochemical and functional assays have 
demonstrated that MIF is expressed in both the developing and the 
postnatal/adult inner ear and functions as an essential factor for morphogenesis 
and neurogenesis in the auditory system (Gerlach-Bank, Ebisu et al., in 
preparation, Chapter 2).   
CD74 is one of the functional receptors reported for MIF and has been 
shown to be necessary for activation of the extracellular signal regulated 
kinase1/2 MAP kinase (ERK1/2-MAPK) cascade as well as for cell proliferation 
(Leng et al., 2003).  We have found that CD74 is expressed on both developing 
SAG and adult SG neurons in mice and chicks (Gerlach-Bank, Ebisu et al., in 
preparation, Chapter 2) and its homologues iclp1 and 2 are expressed on SAG 




Based on our data and that of others (Leng et al., 2003), we hypothesized 
that CD74 is required for neuronal development (and possibly maintenance) in 
the inner ear. We used RNAi techniques to knock-down CD74 expression in 
cultured avian embryonic SAG explants and measured neurite outgrowth and 
survival in the presence of either CD74 siRNA or the missense control.  We 
report here that CD74 siRNA exposure for 48 hrs resulted in significant 
suppression of CD74 expression and concomitantly reduced SAG neurite 
outgrowth and survival significantly.  Additionally, we found that MIF is produced 
by some clones of IMO cell lines (Barald et al., 1997), which we obtained from 
H2kbtsA58 transgenic mice (Barald et al., 1997, Holley et al., 1997) at embryonic 
day (E) 9.5, which is an appropriate time for it to play a role in inner ear 
morphogenesis and neurogenesis.  This result indicates that MIF is expressed at 
least as early as E9.5 in mice and provides further evidence that MIF plays an 
essential role of in inner ear development.  We also demonstrated that mouse 
MIF siRNA constructs successfully suppressed MIF expression in IMO cells, one 
source of ODF, which can be used in future experiments to further characterize 
the role of MIF in inner ear development and maintenance.        
 
Materials and Methods 
Design of siRNAs: RNA interference techniques were used to knock down the 
expression of mouse MIF protein and avian CD74 protein by introducing a 




and complimentary dsRNA for mouse MIF mRNA and avian CD74 mRNAs were 
as follows:  
Mouse MIF siRNA duplex: 5'-CCGCAACUACAGUAAGCUGdTdT-3' and 5'-
CAGCUUACUGUAGUUGCGGdTdT- 3'.  
A control RNA duplex: 5'-GCGCGCUUUGUAGGAUUCGdTdT-3' and 5'-
CGAAUCCUACAAAGCGCGCdTdT-3'.  
  
Avian CD74 siRNA duplex: 5’-GCAACAAGACUGAGGAUCAAATdTd-3’ and 5’-
UUUGAUCCUCAGUCUUGUUGCTdTd-3’.   
A control RNA duplex: 5’- GCAAGAAGACAGAGGUUCAAATdTd-3’ and 5’- 
UUUGAACCUCUGUCUUGUUGCTdTd-3’. 
All constructs were confirmed by enzymatic digestion (Hind III) and DNA 
sequence analysis (DNA sequencing core, University of Michigan).   
Cell Culture of cells for siRNA transfection: IMO 2B1DT cells that express 
MIF and the chick brain cells that express CD74 receptor (Bryan et al., 2008) 
were used to titrate the siRNA concentrations necessary to achieve maximal 
inhibition of MIF and CD74 protein, as determined by western blotting.   
IMO 2B1DT cells: The IMO cell line, IMO 2B1DT was cultured as previously 
described (Barald et al., 1997, Thompson et al., 2003, Germiller et al., 2004) with 
minor modifications to accommodate the transfection process.  Transfection of 




western blotting assays to examine the effects on MIF levels.  1-3 × 105 cells/well 
of 2B1DT cells were grown in chick embryo fibroblast (CEF) medium containing 
15 % fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1 
unit of γ-interferon (Chemicon International, Inc., Temecula, CA) on 6-well culture 
plates (Fisher Scientific, Pittsburgh, PA) overnight at 37°C prior to transfection.   
Chick brain cells: Primary cultures of chick brain cells were also cultured in 
Dulbecco’s modified Eagle's (DME) medium (Invitrogen, Carlsbad, CA) 
containing 15% FBS and 1 unit of γ-interferon for the transfection of avian CD74 
siRNA and its missense control followed by western blotting assays to examine 
the effects on CD74 levels.  The brain cells were excised from E5-8 chick 
embryos.  The cells were then treated with 1 ml trypsin solution [100 µl trypsin 
(Invitrogen, Carlsbad, CA) and 900 µl of Phosphate Buffered Saline (PBS) 
(Invitrogen, Carlsbad, CA)] for 10 minutes at 37°C, followed by repetitive 
pipetting to dissociate the cells.  After washing the dissociated cells with PBS, the 
cells were resuspended in the DME medium.  About 1-3 × 105 cells/well were 
placed on the 6-well plates coated with poly-d-lysine (BD, Franklin Lakes, NJ).  
The cells were incubated for 24 hours at 37°C prior to transfection.   
Transfection of siRNA: IMO 2B1DT cells were transfected either with mouse 
MIF siRNA or its missense control and the chick brain cells were transfected 
either with avian CD74 siRNA or its missense control using a transfection 
reagent (Mirus, Madison, WI) according to the manufacturer’s protocol.  Twenty 




2B1DT cells and chick brain cells to examine any effect of these siRNAs on MIF 
and CD74 levels respectively.     
Western blotting assay: Western blotting assays were performed as described 
by Takakura et al. (Takakura et al., 2008) with minor modifications.  Protein 
samples were prepared by lysing IMO 2B1DT cells or chick brain cells in lysis 
buffer containing complete protease inhibitor cocktail (Roche Diagnostics 
Corporation, Indianapolis, IN).  After addition of sample buffer followed by boiling, 
gel electrophoresis was performed using 12% precast SDS-polyacrylamide gels 
(BioRad, Hercules, CA).  Proteins were transferred onto a nitrocellulose 
membrane (Millipore, Billerica, MA) at 100 voltages for 1 hour.  After blocking 
with 2% non-fat Milk (Nestle, Solon, OH), membranes were probed with the 
following antibodies.  For the detection of mouse MIF expression, anti-MIF 
antibody (1:3,000) (Zymed, South San Francisco, CA) was followed by anti-rabbit 
IgG peroxidase conjugate secondary antibody (1:40,000) (Zymed, South San 
Francisco, CA).  For the detection of avian CD74 expression, anti-avian CD74 
antibody (1:200) (Santa Cruz, La Jolla, CA) was followed by goat anti-mouse 
HRP-conjugated secondary antibody (1:10,000) (BioRad, Hercules, CA).  
Membranes were also probed with anti-GAPDH antibody (1:10,000) (Millipore, 
Billerica, MA) followed by goat anti-mouse HRP-conjugated secondary antibody 
(1:10,000) (BioRad, Hercules, CA) to assess protein loading.  Membranes were 
then developed by enhanced chemiluminescence (ECL) (Amersham Life Science 
Ltd, Bucks., UK) followed by exposure to photographic film (Kodak, Fisher  




experiment was repeated three times.  Quantification of bands was done with 
Scion Image software (Frederick, MD) and normalized to GAPDH.   
Otocyst excision and otocyst conditioned medium (also called otocyst-
generated ODF) collection: To produce otocyst-generated ODF, conditioned 
medium (CM) was collected from chick otocysts at E4 based on the method of 
Bianchi et al. (Bianchi and Cohan, 1993, Bianchi et al., 1998) with minor 
modifications.  Briefly, eight otocysts from E4 chick were collected and incubated 
in 250µl of serum and γ-interferon free DME medium (basal medium) at 37°C for 
3 days.  After centrifugation at 10,000 rpm at room temperature for 3 minutes, the 
supernatant was transferred into a low protein binding microtest tube (DENVILLE 
Scientific INC, Metuchen, NJ) and stored at 4°C until used.   
Neuronal cell culture-based bioassays for neurite outgrowth and survival in 
the presence of avian CD74 siRNA or its missense control: SAG bioassays 
were performed as in Bianchi et al. (Bianchi et al., 2005) with minor modifications 
to determine whether there was an effect of CD74 siRNA on ODF-induced SAG 
neurite outgrowth and survival.  For SAG neurite outgrowth, whole SAGs were 
excised from chick embryos at E5 and placed on a poly-D-lysine coated 96 well 
plate.  For the assays, SAG neurite outgrowth in basal medium was used as the 
negative control and that in the otocyst-generated ODF was used as the positive 
control.  After 2-3 hours, SAGs that had been cultured in the otocyst-generated 
ODF were transfected either with avian CD74 siRNA (2.0 µg/µl) or its missense 
control (2.0 µg/µl).  Forty-eight hours post-transfection, SAG neurite outgrowth in 




previously published standard scale of 0-5 (Bianchi et al., 2005).  To examine 
SAG neuron survival, individual SAG neurons were prepared by pooling 
dissociated cells from 25-30 ganglia.  First, the isolated ganglia were washed 
with calcium-free PBS (3x) followed by centrifugation at 10,000 rpm for 1 minute 
and aspiration of supernatant.  Then, the ganglia were incubated with PBS 
containing 0.025 % trypsin (Invitrogen, Carlsbad, CA) at 37°C for 10 minutes.  
After centrifugation and aspiration of trypsin-containing PBS, the cells were 
incubated with PBS containing 0.1 % trypsin inhibitor (Sigma, St. Louis, MO) at 
37°C for 10 minutes.  Ganglia were rinsed once with basal medium followed by 
centrifugation and aspiration.  Finally, the ganglia were resuspended in basal 
medium and dissociated by trituration with a fire-polished glass pipet.  The 
individual cells were plated on poly-D-lysine coated 96 well plates at a density of 
10,000 cells per well (determined by haemocytometer counts).  Cells were 
incubated at 37°C until they became attached to the plate.  After cell attachment, 
the medium was replaced with otocyst-generated ODF or basal medium.  A 
subset of the wells containing cells cultured in otocyst-generated ODF were 
transfected either with avian CD74 siRNA (2.0 µg/µl) or its missense control (2.0 
µg/µl) and incubated at 37°C for 48-72 hours.  All samples were assessed in 
triplicate in three separate experiments.    
Immunocytochemistry (ICC): ICC was performed with dissociated SAG 
neurons.  Dissociated SAG neurons in the 96 well plates were fixed with 100 µl of 
4 % paraformaldehyde (PFA) solution for 20 minutes followed by careful washing 




3 % hydrogen peroxide was applied and incubated for 10 minutes.  The plate 
was then incubated with 100 µl of PBT [PBS containing 1 % Bovine Serum 
Albumin (BSA) (Sigma, St. Louis, MO) and 0.5 % Tween 20] for 1 hour followed 
by blocking with 100 µl PBT containing 5 % Normal Goat Serum (NGS) 
(Invitrogen, Carlsbad, CA) for 30 minutes.  Then, the plate was incubated with 
100 µl of Monoclonal Antibody against Neuronal Class III β-Tubulin (Covance, 
Berkeley, CA) diluted with PBT containing 5 % NGS (1:500) at 4°C overnight.  
Twenty-four hours later, the plate was incubated with 100 µl of PBT containing 
5 % NGS for 30 minutes after washing the plate with PBT (3x).  Then, a 
secondary antibody, goat anti mouse, (BioRad, Hercules, CA) diluted with PBT 
(1:500) was applied and incubated for 3 hours.  The plate was washed with PBT 
(3x) followed by PBS (1x).  Plates were labeled with 20 µl of AEC substrate 
(Zymed, San Francisco, CA) for 5 minutes or until color developed.  The reaction 
was then stopped by adding 20 µl of MilliQ water.  Micrographs were taken using 
Nikon ACT-1 software on a Leitz (Leica) Diavert inverted microscope.  The entire 
experiment was performed under the hood at room temperature, except for the 
incubation with primary antibody at 4°C. 
Statistical analysis: The data were analyzed by one-tail t-test.  A statistical 







siRNA to mouse MIF reduced the expression of MIF in IMO 2B1DT cells 
 IMO 2B1DT cells are a subcloned cell line isolated from E9.5 murine 
otocysts of the H2kbtsA58 transgenic mouse, which we have used to study 
certain aspects of sensory cell development in the inner ear (Barald et al., 1997, 
Thompson et al., 2003, Germiller et al., 2004).  They also serve as a source of a 
bioequivalent ODF, which contains MIF (Bianchi et al., 2005; Gerlach-Bank, 
Ebisu et al., in preparation, Chapter 2).  Earlier studies in many labs have 
demonstrated that cells in the otocyst secrete a factor called ODF, which 
enhances both directional neurite outgrowth and survival of early stage SAG 
neurons (Ard et al., 1985, Lefebvre et al., 1990, Bianchi and Cohan, 1991, 1993).  
We had previously demonstrated that CM obtained from the IMO 2B1DT cells 
(IMO-generated ODF) has a bioequivalent ODF effect to that of ODF obtained 
from E4 chick otocysts (otocyst-generated ODF) on both SAG neurite outgrowth 
and survival (Bianchi et al., 2005; Gerlach-Bank, Ebisu et al., in preparation, 
Chapter 2).  Both IMO- and otocyst-generated ODFs contain MIF (Gerlach-Bank, 
Ebisu et al., in preparation, Chapter 2).  In the current study, we examined the 
expression of MIF in 2B1DT cells with western blotting assays, followed by 
measuring the effect of the mouse MIF siRNA constructs on 2B1DT cells’ 
production of MIF by introducing varying concentrations (0.25 to 1.5 µg/µl) of the 
siRNA constructs 24 hours after plating the cells.  We found that the optimal 




significantly (by about 30%) when compared to the missense control was 0.25 
µg/µl (Figure A.1), indicating that siRNA techniques will be helpful for further 





















1. No transfection 
2. GFP, 1.0 µg/µl 
3. siRNA to mouse MIF, 0.25 µg/µl 
4. siRNA to mouse MIF, 0.5 µg/µl 
5. siRNA to mouse MIF, 1.0 µg/µl 
6. siRNA to mouse MIF, 1.5 µg/µl 
7. Missense, 0.25 µg/µl 
8. Missense, 0.5 µg/µl 
9. Missense, 1.0 µg/µl 
10. Missense, 1.5 µg/µl 
 
Figure A.1: Western blots were performed after cultured IMO cells, which exude 
MIF into conditioned serum-free medium, were treated with various 
concentrations of siRNA to mouse MIF or with its missense control for 24 hours 
in culture.   
siRNA/missense, 0.25 µg/µl 0.72
siRNA/missense, 0.5 µg/µl 1.02
siRNA/missense, 1.0 µg/µl 0.89
siRNA/missense, 1.5 µg/µl 3.06
 
Table A.1: The ratio of siRNA/missense at various concentrations.  0.25 µg/µl of 
siRNA produced the most effective reduction in the expression of MIF compared 
to its missense control. 
MIF 
GAPDH 




Exposure to CD74 siRNA for 48 hours significantly reduced ODF-induced 
SAG neurite outgrowth and survival 
CD74 has been implicated as a surface receptor for MIF (Leng et al., 
2003).  Binding of MIF to CD74 is necessary for the activation of the MIF-
mediated ERK1/2-MAPK signaling pathway, cell proliferation and gene induction 
in mouse embryonic fibroblasts.  We constructed avian CD74 siRNA and its 
missense control and examined their effects on CD74 expression levels using 
the chick brain, since it expresses CD74 (Bryan et al., 2008) and we are able to 
obtain enough cells to perform Western blotting assays.  The western blotting 
assays demonstrated that avian CD74 siRNA constructs at concentrations from 
0.5 µg/µl to 2.0 µg/µl almost equally reduced CD74 expression when compared 
to its missense control as shown in Figure A.2 (16-27% reduction).  We then 
performed neuronal bioassays with chick SAG explants to determine an optimal 
concentration of the siRNA on SAG neurite outgrowth using the same 
concentration range (from 0.5 µg/µl to 2.0 µg/µl).  We decided to use the 
concentration at 2.0 µg/µl for the following experiments.    
To determine whether CD74 is necessary for chick SAG neurite outgrowth 
in response to ODF, we performed neuronal cell culture assays either with avian 
CD74 siRNA or missense control in otocyst-generated ODF.  We excised SAGs 
from E5 chick embryos and cultured them in otocyst-generated ODF for a few 
hours or until the explants attached to the plate at 37°C.  Basal medium and 
otocyst-generated ODF without added siRNA were used as the negative control 




we introduced either 2.0 µg/µl avian CD74 siRNA or 2.0 µg/µl of its missense 
control into the cultured SAG explants in ODF.  The SAGs were cultured for an 
additional 48 hours at 37°C.  We then observed and scored SAG neurite 
outgrowth using scoring criteria reported earlier (Bianchi et al., 2005).  We 
observed that the SAG explants exposed to 2.0 µg/µl avian CD74 siRNA had 
significantly reduced SAG neurite outgrowth, with an average neurite outgrowth 
score of 1.0 ± 1.32 (Figure A.3-A), compared to those explants exposed to the 
same concentration of the missense control, which had average neurite 
outgrowth scores of 3.11± 1.27 (about 70% reduction, Figure A.3-B), after 48 
hours exposure to the siRNA.  SAG explants in otocyst-generated ODF (positive 
control) produced neurite outgrowth, with average scores of 1.67 ± 1.22, while 
the explants in basal medium (negative control) produced little or no neurite 
outgrowth (average scores = 0).  Statistical analysis of this data showed that 
SAG explants treated with siRNA to CD74 significantly reduced the outgrowth 
compared to the positive control (about 40% reduction).  
The SAG neuronal survival assays were performed in the same manner 
as the SAG neurite outgrowth assays with a few modifications.  Dissociated SAG 
neurons were used for the survival assays and after 48 hours exposure to siRNA 
or its missense, both vital cells and total cells were counted to obtain the 
percentage of cell survival.  We observed that the SAG neurons exposed to 2.0 
µg/µl avian CD74 siRNA for 48 hours had significantly lower survival (5.1 ± 
21.81% neuronal survival on average, Figure A.3-C) compared to those treated 




80% reduction) (Figure A.3-D).  Statistical analysis also demonstrated that cells 
treated with the siRNA (2.0 µg/µl) significantly reduced neuronal cell survival 
compared to the positive control (average cell survival of 32.4 ± 13.66%, about 
85% reduction).  These results suggest that CD74 is involved in both chick SAG 




















1. No transfection 
2. siRNA to avian CD74, 0.5 ug/ul  
3. siRNA to avian CD74, 1.0 ug/ul  
4. siRNA to avian CD74, 1.5 ug/ul  
5. siRNA to avian CD74, 2.0 ug/ul  
6. Missense, 0.5 ug/ul  
7. Missense, 1.0 ug/ul  
8. Missense, 1.5 ug/ul  
9. Missense, 2.0 ug/ul 
Figure A.2: Western blots were performed after cultured dissociated E5-8 chick 
brain cells that express CD74, a receptor for MIF, to examine the effect of avian 
CD74 siRNA and its missense on expression.  The brain cells were treated with 
various concentrations of siRNA to avian CD74 or with its missense control for 24 
hours in culture.   
0.5 ug/ul siRNA/control 0.27
1.0 ug/ul siRNA/control 0.19
1.5 ug/ul siRNA/control 0.16
2.0 ug/ul siRNA/control 0.23
 
Table A.2: The ratio of siRNA/missense at various concentrations.  All 
concentrations of siRNA to avian CD74 almost equally reduced the expression of 
Avian CD74 expression compared to the missense control.     
CD74 
GAPDH








Figure A.3: Avian CD74 siRNA reduced SAG neurite outgrowth and 
survival: Neuronal bioassays using E5 chick whole SAGs and dissociated SAGs 
from the same stage embryos were exposed to conditioned medium generated 
from chick otocysts (called otocyst-generated ODF) at E4 to determine the effect 








in the presence of 2.0 µg/µl avian CD74 siRNA show little SAG neurite outgrowth 
(A).  In contrast, SAG explants treated with otocyst-generated ODF in the 
presence of 2.0 µg/µl of the missense control show robust SAG neurite 
outgrowth (B).  Dissociated SAG neurons treated with otocyst-generated ODF in 
the presence of 2.0 µg/µl avian CD74 siRNA demonstrate lower cell survival (C).  
In contrast, dissociated SAG neurons treated with otocyst-generated ODF in the 
presence of 2.0 µg/µl missense control show higher neuronal survival (D).    
Statistical analysis demonstrates that 2 µg/µl of siRNA significantly reduced both 
SAG neurite outgrowth (E) and survival (F) compared to its missense control (P< 
0.05).  Serum and γ-interferon free basal medium is used as negative control and 
otocyst-generated ODF is used as positive control.  n=9 (SAG neurite outgrowth).  
n=12 (dissociated SAG neuronal survival).   
 
Discussion  
MIF is a ubiquitously expressed pleiotropic cytokine (Nishihira, 2000, 
Bifulco et al., 2008, Rendon et al., 2009), which plays multiple roles in many 
different cell types, including a prominent role in T cell development and 
maturation in the immune system (Bernhagen et al., 1993, Bacher et al., 1996, 
Bernhagen et al., 1996, Bozza et al., 1999, Roger et al., 2001, Santos et al., 
2008, Tohyama et al., 2008).  MIF has also been shown to play a vital role in 
neuronal development (Suzuki et al., 2004) and in peripheral nerve regeneration 
(Nishio et al., 2002).  A receptor for MIF, discovered by Leng et al. (2003) was 
found to be a type II transmembrane protein also called MHC class II invariant 
chain, CD74 (Leng et al., 2003).  These authors determined that MIF binds to 
CD74 with high affinity, and the expression of CD74 is necessary for MIF-
mediated activation of the ERK1/2-MAPK cascade, for cell proliferation and 
differentiation in mouse embryonic fibroblasts.  We have characterized two 




zebrafish (Shen et al, in preparation).  Inhibition of iclp1 and 2 with antisense 
oligonucleotide morpholinos leads to the reduction in size of the SAG in the 
zebrafish (Shen et al, in preparation).  
Target-derived growth and survival factors that act as neurotrophins are 
essential for the development, neurogenesis and pathway selection of the 
neuronal populations that innervate these target tissues.  Earlier studies have 
demonstrated that the cells of the otocyst, which is a precursor of all inner ear 
sensory organs, including the sensory HC and their underlying supporting cells 
(SC) and of the neurons that innervate the HC, secretes a factor called ODF 
during early stage inner ear development (Ard et al., 1985, Lefebvre et al., 1990, 
Bianchi and Cohan, 1991, 1993).   The ODF secreted by the otocyst mediates 
directional neurite outgrowth and survival of SAG neurons; the SAG contains 
precursors of both SG neurons and VG neurons (Barald and Kelley, 2004).   
We have recently demonstrated that the bioactive components of ODF 
include MIF, and MIF functions as an essential molecular neurotrophin in normal 
inner ear development (Gerlach-Bank, Ebisu et al., in preparation, Chapter 2).  
We have detected the expression of MIF both in the developing otocyst and in 
adult SC of the cochlea and that of CD74 both in developing SAG and 
postnatal/adult SG neurons in mammals (Gerlach-Bank, Ebisu et al., in 
preparation, Chapter 2) and its homologues iclp1 and 2 in the developing 
zebrafish SAG (Shen et al, in preparation).  Moreover, MIF knock-out (KO) mice 




the cochlea with concomitant loss of SGNs in this region of the cochlea (Gerlach-
Bank, Ebisu et al., in preparation, Chapter 2).  Based on these observations and 
data, we also anticipated an essential role for the MIF receptor, CD74 in inner 
ear neuronal development.      
Thus, in the current study, we asked whether CD74 could be 
demonstrated to play a role in inner ear SAG neurite outgrowth and survival.  In 
cultured SAG bioassays, we demonstrated that CD74 siRNA significantly 
suppressed ODF-mediated SAG neurite outgrowth by almost 70% compared to 
the CD74 missense siRNA control (average scores of 1.0 compared to 3.11, 
respectively) as shown in Figures A.3-A and B.  We also demonstrated that 
CD74 siRNA significantly reduced ODF-induced SAG neuronal survival by 
almost 80% compared to the CD74 missense siRNA control (average percentage 
of cell survival = 5.1% compared to 24.6%) as shown in Figures A.3-C and D. 
Nevertheless, suppression of CD74 expression alone failed to completely 
inhibit ODF-induced SAG neurite outgrowth and survival, suggesting that there 
may be additional receptor(s) for MIF that play a role in mediating neurite 
outgrowth and survival and/or the different factor(s) in ODF may have the same 
effect as MIF in promoting SAG neurite outgrowth and survival.   
A recent study has identified two additional functional receptors for MIF, 
CXC chemokine receptors named CXCR2 and CXCR4 (Bernhagen et al., 2007).  
According to these authors, MIF acts as a noncognate ligand for these receptors 




(Bernhagen et al., 2007, Schober et al., 2008, Beswick and Reyes, 2009) and 
CXCL12 for CXCR4 (Schober et al., 2008).  CXCR2 is commonly expressed on 
macrophages and functions in recruiting leukocytes to sites of infection 
(Bernhagen et al., 2007, Beswick and Reyes, 2009).  Besides its expression in 
the immune system, CXCR2 expression has been found in the nervous system 
(Horuk et al., 1997, Giovannelli et al., 1998, Luan et al., 2001, Valles et al., 2006).  
Developmental studies have shown that CXCR2 is expressed throughout the 
mouse brain during early development (Luan et al., 2001) and CXCR2-/- mice 
exhibited reduced numbers of cells in the oligodendrocyte lineage, myelination, 
and white matter in the vertebrate CNS (Padovani-Claudio et al., 2006).  CXCR4 
is a G-protein coupled receptor for stromal cell-derived factor-1 (SDF-1/CXCL12) 
(Ganju et al., 1998, Vera et al., 2008), which is functionally expressed on the cell 
surface of various types of cancer cells, and also plays a role in cell proliferation 
and migration of these cells (Burger and Kipps, 2006).  In the developing mouse 
CNS, CXCR4 expression is detected as early as E8.5 and its expression is also 
found in adulthood (McGrath et al., 1999, Tissir et al., 2004, Lieberam et al., 
2005).  Abnormal development of the cerebellum (Zou et al., 1998), the 
hippocampal dentate gyrus (Lu et al., 2002) and uncontrolled initial motor axon 
trajectories (Lieberam et al., 2005) have also been reported in CXCR4 KO mice.  
These results suggest the importance of CXCR2 and CXCR4 in the development 
and/or maintenance of the CNS, and prompt us to speculate that they also may 
be involved in inner ear neuronal development.  We will examine the possible 




embryonic SAG and postnatal/adult SG neurons both in the mouse and the chick.  
If we detect their expression in SAG/SG, we will then examine their role in inner 
ear neuronal development and maintenance by functionally blocking their 
expression using similar siRNA strategies to those described in this report.  In the 
present study, we examined only the role of CD74 and that only during 
embryonic stages.  As previously reported and mentioned above, the expression 
of CD74 was detected in the postnatal/adult SGNs as well (Gerlach-Bank, Ebisu 
et al., in preparation, Chapter 2).  Thus, its role in postnatal/adult SGNs needs to 
be determined in similar functional assays.  We have identified a quartet of 
bioactive cytokine components in ODF by performing proteomic assays and 
cytokine array studies (Gerlach-Bank, Ebisu et al., in preparation; Ebisu et al, in 
preparation), including MIF (Gerlach-Bank, Ebisu et al., in preparation, Chapter 
2) and MCP-1 (Bianchi et al., 2005).  The remaining identified factors and their 
receptors also need to be examined for their possible role(s) in neurite extension 
and neuron survival in the inner ear.     
In the present study, we also showed that MIF protein is expressed as 
early as E9.5 in the developing inner ear in mice, since the IMO cell line 
IMO2B1DT was derived from this stage of the developing Immortomouse.  
Additionally, we demonstrated that mouse MIF siRNA successfully reduced its 
expression in IMO cells.  This helps to validate IMO cells as a valid source of 
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